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Abstract 
 
Background: Hypertension (HTN) is a complex, multifactorial, quantitative trait under polygenic 
control that affects more than one billion people globally. Despite advances in our understanding 
of the pathophysiology of HTN and the implementation of more effective treatment and prevention 
strategies, HTN remains one of the world’s great public health problems.  The accepted inference 
from genome-wide association studies (GWAS) is that the genetic code lays the foundation for 
transcriptomic changes and in turn physiological change. On the other side of the coin, 
environmental factors (smoking, diet, chemical exposure) can in turn affect DNA itself in genes 
relevant to blood pressure (BP). Variation in epigenetic forms of modification may thus explain 
additional phenotypic variation in BP and provide new clues to the physiological processes 
influencing its regulation. DNA methylation is one of these epigenetic mechanisms responsible 
for changes to gene expression, activated by interaction with environmental triggers. DNA 
methylation is a reversible epigenetic modifier of specific dinucleotide sites called CpGs, which 
consists of a transfer of a methyl group derived from S-adenosyl-L-methionine to position five of 
a cytosine ring, forming 5mC. Pathophysiologically, the kidney is known as the key organ of BP 
regulation and one of the most important contributors to HTN. According to the hypothesis put 
forward by Guyton, over 40 years ago, the control of BP in the steady-state and longer-term is 
critically dependent on renal mechanisms. In fact, almost all monogenic forms of HTN are driven 
by rare mutations in genes involved in salt handling in the distal nephron. It is therefore crucial to 
understand kidney DNA methylation changes that may drive gene expression in kidney and lead 
to HTN.  
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Hypothesis:  The central hypothesis underpinning this PhD thesis is that alterations in kidney 
specific DNA methylation plays a fundamental role in modulating gene expression changes 
involved in the regulation of BP and pathophysiology of EH.  
 
Aims:  This PhD thesis focuses on characterising the role of DNA methylation in the hypertensive 
kidney using array and RNA-sequencing methods. Three major aims are addressed: 
 
• Aim 1: To characterise blood and kidney global DNA methylation dynamics and its 
functional role in the hypertensive population (Chapter 3). 
 
• Aim 2: To determine the role of genome-wide, loci specific DNA methylation in the 
hypertensive human kidney (Chapter 4).  
 
• Aim 3: To understand the relationship between DNA methylation and differential 
expression of genes associated with BP and HTN in the human kidney (Chapter 5). 
 
Results:  In Aim 1 global DNA methylation changes were characterised in peripheral blood 
leukocyte and kidney DNA of the hypertensive (HT) population using he ELISA method. We 
found no association between HTN diagnosis and global methylation percentage in either 
peripheral blood leukocytes or kidney DNA. However, a negative correlation was found between 
global methylation and diastolic blood pressure (DBP), yet this relationship was not evident after 
adjustment for the effect of antihypertensive medication. Furthermore, we investigated the 
sensitivity of ELISA-based global methylation detection by calculating the percentage of global 
methylation in kidney using array based methods; the results were similar, demonstrating no 
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association between HTN diagnosis and median kidney methylation β-value or M-value. Similar 
findings were evident for systolic blood pressure (SBP). Interestingly, for β-values, a linear 
relationship between median global methylation percentage and DBP was established but this 
finding was not transferable for M-values.  
 
In Aim 2 we examined a total of 94 human kidneys to investigate loci specific methylation patterns 
of HTN on the renal genome. Our methylation analysis identified one HTN-associated CpG site, 
three SBP-associated CpG sites and 19 DBP-associated CpG sites; including four CpG sites 
previously identified in large genome-wide, peripheral blood studies of HTN. We discover novel 
differential methylation in CpGs not previously associated with BP in the human kidney; among 
these are sites involved in pathways regulating transport of glucose, organic acids and amine 
compounds; circadian rhythm; neural development; transport of monocarboxylates; peptidase 
activity; transcriptional regulation; insulin signaling; cell cycle progression; metabolism; G-
coupled protein receptor (GCPR) signalling; nuclear receptors in lipid metabolism and toxicity 
and RNA processing.  We also conduct a replication analysis of BP-associated, methylated CpG 
sites in the human kidney and pre-existing GWAS findings in blood. Four kidney loci overlap with 
blood-based GWAS CpG sites, suggesting that loci specific methylation studies may have cross-
tissue applicability.  
 
In Aim 3 we examined 180 human kidneys to uncover genetic signatures of HTN in the renal 
transcriptome. The transcriptome analysis of 180 kidneys revealed 14 HTN-associated genes, 1 
gene associated with DBP and 6 genes associated with DBP; including those involved in smooth 
muscle response to BP fluctuation and BP response to salt intake in salt sensitive humans. 
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Furthermore, as DNA methylation is a known regulator of gene expression we investigated 
whether differential DNA methylation in proximity to HTN-associated renal genes correlated to 
their renal expression. We identify that DNA methylation and renal gene expression are tightly 
linked in the regulation of pathways that modulate vascular function, cellular communication, 
inflammation and sodium regulation. In particular, we identify a close relationship between renal 
DNA methylation and expression FAM50B, PC and report a strong connection with this 
relationship to chronic BP elevation. 
 
Conclusion: This PhD Thesis provides novel evidence for implication of renal DNA methylation 
in HTN pathogenesis and a tightly linked relationship between DNA methylation and expression 
of genes associated with HTN and BP. Together, this PhD Thesis provides new insights into the 
role of renal DNA methylation in BP modulation. This Thesis provides a new framework for the 
epigenetic regulation of transcription in the human kidney and points towards DNA methylation 
as a key modulator of renal BP-associated gene expression.  
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Chapter 1. A review of the literature 
1.0  Abstract 
Essential hypertension (EH) is a complex, polygenic condition with no single causative agent. 
Despite advances in our understanding of the pathophysiology of EH, HTN remains one of the 
world’s leading public health problems. Furthermore, there is increasing evidence that epigenetic 
modifications are as important as genetic predisposition in the development of EH. Indeed, a 
complex and interactive genetic and environmental system exists to determine an individual’s risk 
of EH. Epigenetics refers to all heritable changes to the regulation of gene expression as well as 
chromatin remodelling, without involvement of nucleotide sequence changes. Epigenetic 
modification is recognized as an essential process in biology, but is now being investigated for its 
role in the development of specific pathologic conditions, including EH. Epigenetic research will 
provide insights into the pathogenesis of BP regulation that cannot be explained by classic 
Mendelian inheritance. This review concentrates on epigenetic modifications to DNA structure, 
including the influence of non-coding RNAs (ncRNA) on HTN development. 
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1.1  Blood pressure 
BP refers to the force per unit area that is exerted on a vessel by the contained blood, which is 
expressed in millimeters of mercury (mmHg). Unless otherwise stated BP refers to the systemic 
arterial BP in the largest arteries near to the heart. Pressure gradients – the differences in BP within 
the vascular system – provide the driving force that ensures blood circulates from areas of high 
pressure to those of low. Systemically, any fluid driven by a pump through a circuit of closed 
channels operates under pressure, where the fluid nearest to the pump experiences the greatest 
exerted pressure [1]. Fundamentally the pumping actions of the heart generates blood flow, and 
pressure is generated when the flow is opposed by resistance. Therefore, systemic BP is highest in 
the aorta and declines throughout the pathway, where it reaches 2-6 mmHg in the right atrium [1]. 
The largest drop in pressure exists in the arterioles, which offer the most resistance to BP. 
Regardless of the strength of the pressure gradient, blood will continue to flow until it circulates 
in its entirety, back to the heart [1].  
 
1.2  Blood pressure regulation 
BP is primarily regulated by the autonomic nervous system, vasculature or the kidney. The 
autonomic nervous system is a collection of afferent and efferent neurons that link the central 
nervous system with visceral effectors [2]. The two arms of the autonomic nervous system, the 
sympathetic and the parasympathetic, consist of parallel and differentially regulated pathways that 
are made up of cholinergic neurons (preganglionic neurons). These peripheral ganglia and 
associated networks contain motor neurons that control smooth muscle and other visceral targets. 
The sympathetic ganglia control cardiovascular targets [2]. Although BP fluctuates substantially 
with various activities, the 24-hour control of BP is tightly regulated. Abnormalities to the control 
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of BP can emerge from the autonomic nervous system, in baroreceptors, chemoreceptors, renal 
afferents or the central circuitry [2]. The neural control of BP operates via parasympathetic neurons 
that innervate the heart and three main classes of sympathetic efferent neurons (baroreceptive, 
thermosensitive and glucosensitive cardiovascular) which innervate blood vessels in the heart, 
kidneys and the adrenal medulla. It is this large group of efferent neurons that has a dominant role 
in the regulation of long and short term BP control, where the activity of these efferent neurons at 
rest is the biggest determinant of long-term BP control. Resting activity is determined by a core 
network of neurons that reside in the rostral ventrolateral medulla, the spinal cord, the 
hypothalamus and the nucleus of the solitary tract [2].  
 
The endothelium is an integral component of the vascular wall and is a major regulator of BP [3]. 
Vasodilator factors such as nitric oxide, prostacyclin and endothelium-derived hyperpolarising 
factors are released by the endothelium which drive vascular control of BP [3]. Decreases in 
endothelial produced vasodilators reduce vascular relaxation and as a consequence increases 
vascular resistance and BP. Vasoconstrictors such as thromboxane, angiotensin II and endothelin 
are also produced by the endothelium. Of these, one of the most potent vasoconstrictors is 
endothelin, where studies identify endothelin receptor subtypes and isoforms in the kidney and 
blood vessels affect sodium balance and vascular function [4-6].  
 
The kidney plays a central role in the regulation of arterial BP, where renal control of extracellular 
volume and renal perfusion pressure are closely involved in maintaining the arterial circulation 
and BP [7]. Renal artery perfusion pressure is a primary regulator of sodium excretion, a process 
labelled natriuresis, and directly influences activity of various vasoactive systems such as the 
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renin-angiotensin-aldosterone system (RAAS) [7]. According to theories by Guyton and 
colleagues, many factors affect renal control of body fluid volume, and thereby arterial pressure. 
These include nervous effects acting on the kidney, hormonal factors affecting the kidney and the 
pathology of the kidney. Regardless of the underlying cause, all long term arterial BP regulation 
must involve the system that regulates body fluid volume in some way. Therefore, long term 
arterial pressure regulation must involve a balance between intake and output of water and salt and 
almost always involves the kidneys [8].  One of the primary systems that regulate fluid balance 
and BP is the RAAS. When renal blood flow is reduced, the kidneys convert prorenin to renin 
which is secreted directly into circulation [9]. The circulating plasma renin then facilitates the 
conversion of angiotensinogen (released by the liver) to angiotensin I, which is further converted 
to angiotensin II by angiotensin converting enzyme (ACE) found in the lungs. Angiotensin II is 
one of the primary vasoconstriction peptides, which results in the narrowing of blood vessels and 
ultimately an increase in BP [9]. Presence of angiotensin II also prompts the release of aldosterone 
from the adrenal glands where it initiates increased blood uptake of sodium and water in the renal 
tubules. To maintain electrolyte homeostasis, potassium is excreted during this process and the 
volume of extracellular fluid increases, further increasing BP. One of the most studied causes to 
abnormally high or chronically high BP is dysregulation to the RAAS [10]. To date, the RAAS is 
one of the most targeted systems for pharmaceutical intervention of high BP, HTN and renal 
failure. 
 
1.3  Hypertension 
HTN affects more than one billion people globally and is a major risk factor for stroke, chronic 
kidney disease, and myocardial infarction  [11]. Despite advances in our understanding of the 
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pathophysiology of HTN and the implementation of more effective treatment and prevention 
strategies, HTN remains one of the world’s great public health problems [12]. The public health 
impact created by HTN is due to its contribution to cardiovascular disease (CVD) events, such as 
heart attack, congestive heart failure, peripheral vascular disease, and stroke [13]. Furthermore, 
there is increasing evidence that epigenetic modifications are as important as genetic 
predisposition in the development of HTN. Indeed, a complex and interactive genetic and 
environmental system exists to determine an individual’s risk of HTN (Figure 1.1).  
 
1.4  Essential hypertension 
EH, also referred to as primary or idiopathic, is defined as high BP in which a secondary cause, 
such as renal disease, renal failure, aldosteronism, other causes of secondary HTN or Mendelian 
(monogenic) forms are not present [14]. Human EH is a complex, multifactorial, quantitative trait 
under polygenic control [15] and is estimated to be responsible for a larger proportion of the global 
disease burden and premature death than any other disease risk factor [16]. EH accounts for more 
than 90% of all HTN cases; where the heterogeneous disorder may have multiple causal factors 
that lead to chronically elevated BP [14]. In industrialised countries, an individual’s risk of 
developing EH (BP≥ 140/90 mmHg) during their lifetime exceeds 90% [17].  
 
BP is a highly variable quantitative trait, with a strong positive and continuous correlation to the 
risk of CVD, renal disease, and mortality, even in the normotensive (NT) range [18]. EH is 
diagnosed in adults when the average of two or more SBP readings, on multiple subsequent 
occasions consistently reach  ≥140 mmHg, or when the average of two or more DBP readings, on 
multiple subsequent occasions consistently reach  ≥ 90 mmHg [19]. In the aging population (> 50 
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years), SBP of more than 140 mmHg is identified as a more prominent CVD risk factor than DBP; 
notwithstanding, the risk of CVD begins at 115/75 mmHg, and doubles with each increment of 
20/10 mmHg [19].  
 
 
Figure 1.1   Influences on phenotype manifestation. Development of polygenic conditions 
such as EH depend on a complex but interactive genetic and environmental system. 
 
The single best prevention of HTN-associated cardiovascular complications is the reduction of BP. 
All antihypertensive medications lower BP (by definition), however differences between 
medications exist with respect to reduction of target-organ disease and prevention of major 
cardiovascular events (stroke, myocardial infarction, renal failure). To ensure the best BP control 
and reduce HTN-associated risk, most patients receive two or more drug types and concomitant 
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statin treatment [17]. Despite the availability of medications and our understanding of the disease 
pathophysiology, HTN and its risk factors remain uncontrolled in most patients.  
 
1.5  Etiological factors in essential hypertension 
Although there is no single identifiable causative agent recognised for EH; a number of factors 
increase BP, including genetics [20] obesity [21], insulin resistance [22], high alcohol intake [23], 
high salt intake [24], aging [25],  sedentary lifestyle [26], stress [27], low dietary potassium [28], 
and low dietary calcium [29]. Further, many of these factors are additive, such as obesity and 
alcohol intake [14].  There are many gene loci that have been identified as contributors to EH [20, 
30]. These were discovered via a plethora of studies that compare allele frequencies of 
polymorphisms in candidate genes between the HT and NT populations and linkage studies that 
involve pedigrees affected by rare monogenic forms of HTN [31]. This research uncovered large 
advances in the genetic understanding of EH and in identification of 13 single gene mutations that 
are responsible for various forms of familial HTN  [31, 32]. More recently, genome-wide scans 
have become the standard tool for analysis of complex human traits, as it allows for detection of 
novel susceptibility genes that candidate approaches inevitably miss [31]. The genetic influence 
on BP is often expressed in terms of heritability, i.e. the fraction of the total interindividual 
variance attributable to genes. This index requires comparison of BP between pairs of subjects 
showing different familial connections and therefore differing degrees of genetic similarly; as such 
studies involving extended families, twins and adoptees were conducted in an attempt to isolate 
environmental influences [31].  Many pitfalls surround studies of heritability, but the range 
reported in the literature is 30-60% for BP [33]; with high likelihood of shared responsibility of 
several causal genes.  
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The genetic component of EH is tightly linked with environmental influences, such as salt intake, 
lack of exercise and weight gain, to produce the disease phenotype [34]. Numerous HTN-
associated genetic variants have been uncovered by GWAS [35, 36] which has resulted in 
publication of genes annotated to HTN in the human phenotype ontology database (HPO) [37]. 
The discovery of genetic variation responsible for elevated BP is important to allow better 
treatment and management of HTN. Whereas, recognition of additional environmental 
contributors will allow for nonpharmacological prevention and education. More importantly, there 
are interactions between genetic and environmental factors, that influence specific phenotypes 
such as sympathetic nerve activity, RAAS, and endothelial factors [38]. These intermediary 
phenotypes determine vascular resistance, cardiac output and, as a consequence, BP.  Recognition 
of genetic variants that contribute to EH is complicated by the multifactorial nature of the disease.  
Cardiac output and peripheral resistance, the two core phenotypes that determine BP, are regulated 
by intermediary phenotypes, for example the autonomic nervous system, hormones (vasopressor/ 
vasodepressor), cardiovascular system structure, body fluid volume and renal function [39]; 
thereby highlighting the number of genes that could participate in the development of HTN. A 
major challenge of HTN research is to identify the underlying mechanisms unencumbered by 
compounding secondary effects. Furthermore, a major hinderance to the advancement of genetic 
research in HTN lies in the fact that numerous interacting QTLs can influence the sample 
phenotype and that multiple QTLs are involved in the overall BP status [40]. Added to the 
polygenic complexity are inherent limitations, such as phenotyping variability, genetic 
heterogeneity, sampling bias and the availability of effector tissues, and the disparity in model 
assumption and environmental complications. Moreover, conclusions made on human EH are 
10 | P a g e  
 
based on correlative results as no experimental manipulations are permissible, making cause-effect 
relationships difficult to determine in human studies [40].  
 
1.6  The kidney and essential hypertension 
Disruptions to renal function is closely associated with HTN; where kidney disease provokes HTN 
and, on the other  hand, HTN aggravates renal dysfunction [41]. Furthermore, almost all of the 
monogenic forms of HTN affect sites in the kidney that handle salt excretion and transport [7]. 
The kidney makes a major hemodynamic contribution to EH and has long been implicated in the 
pathogenesis of the disease. The notion that EH could be due to alterations to renal genetics stems 
from the results of renal transplantation in spontaneously hypertensive rats (SHR) [42, 43]. It was 
discovered that a renal graft from a HT rat raises the BP of the NT recipient, while grafting a NT 
donor kidney into a HT recipient caused a fall in BP. Hence Dahl’s famous pronouncement “blood 
pressure travels with the kidney”. This suggests that some renal abnormalities predispose to HTN. 
More recently, it was shown that nephron numbers are reduced in established EH [44]. In those 
with identified renal dysfunction, the kidney raises BP via several mechanisms. For example, the 
pressure-natriuresis relationship is shifted to the right, that is, sodium excretion requires high renal 
perfusion pressures [41]. Further, inappropriate activation of the RAAS, increased sympathetic 
tone  (independent of glomerular filtration rate), impaired endothelial vasodilation and alteration 
in pulse pressure profile all contribute to the known  renal involvement in EH pathogenesis [41].  
 
1.7  Epigenetics 
Epigenetics refers to all heritable changes to the regulation of gene activity, without changes to the 
DNA sequence itself [45]. In other words, “epigenetics” refers to analysis of the human genome 
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from the perspective of chromatin and chromosomes, as well as to the quintessential issue of the 
DNA sequence. Epigenetic modifications can be provoked by a variety of factors, including 
environmental influences during foetal and childhood development, chemical exposure, aging, 
dietary habits, and the use of recreational drugs and some prescription medications [46].  
 
The launch of international initiatives, the Human Epigenome Project [47], which first released 
data in 2003, and the International Human Epigenome Consortium [48] formed in 2010, attest to 
the rapid expansion of interest in epigenetics. Epigenetic inheritance is an essential mechanism 
that enables the stable propagation of gene activity states from one generation of cells to the next 
[49]; it is helping to resolve puzzling aspects of heredity, while explaining how the same genome 
can give rise to apparently contrasting phenotypic traits [50]. Chromatin consists of nucleosomes: 
DNA strands wrapped around histones. Several distinct biochemical processes can epigenetically 
modify both DNA and histones (Figure 1.2) [46]. These include RNA-based mechanisms mediated 
by small non-coding microRNAs [51] (Figure 1.2, Figure 1.3) post-translational histone 
modifications (Figure 1.2, Figure 1.4), and DNA methylation (Figure 1.2, Figure 1.5). Epigenetic 
modification is recognised as essential in biological processes and in recent years there has been 
studies investigating its role in the development of specific pathologic conditions. Research into 
epigenetic mechanisms will provide insights into the pathogenesis of BP regulation that cannot be 
explained by classic Mendelian inheritance.  
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Figure 1.2  Impact of epigenetic modifications. DNA wrapped around nucleosomes are made 
up of four pairs of histone proteins. Histone proteins are prone to epigenetic 
modification, primarily acetylation and methylation but also phosphorylation, 
sumoylation, and biotinylation. These modifications change the formation of 
chromatin to either an open (active) or closed (inactive) state, thereby altering their 
transcriptional activity. DNA methylation changes the structure of DNA itself, 
allowing active transcription or silencing of genes. The outcome of DNA 
methylation is dependent on the location of the methylated site. miRNAs primarily 
target the 3’ UTR of mRNA (although 5’ targeting is possible). This negatively 
regulates the quantity of the encoded protein produced via degradation of mRNA 
molecules or by post-transcriptional regulation of mRNA stability. 
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1.7.1   Non-coding RNAs and hypertension 
 
Non-coding RNAs (ncRNA) are implicated in several epigenetic processes, notably small RNAs 
that can influence histone modifications and cytosine methylation which are connected with gene 
expression regulation [52]. NcRNA modification can produce effects analogous to classical DNA 
or histone epigenetic mechanisms described earlier, or can induce HTN via separate, distinct 
processes. Essentially, epigenetics allow the same genome to show alternative phenotypes based 
on different epigenetic influences. Some of the most complicated and researched epigenetic 
phenomena including X-chromosome inactivation, parental imprinting and paramutation have an 
RNA contribution, either directly or indirectly [52]. While most ncRNAs have no identified 
function yet, it is conceivable that all are participants in epigenetic mechanisms which are yet to 
be clearly defined. NcRNAs have a strong influence on the “central dogma” of biology. The past 
view that all DNA was transcribed into RNA and then translated into protein has now been updated 
to include the fundamental role of ncRNAs on the regulation protein levels. Recently, several small 
and mid-sized ncRNAs have been described and are known to have a role in the regulation of 
transcription, post-transcription and translation. Small ncRNAs include PIWI-interacting RNAs 
(piRNAs), transcription initiation RNAs, and microRNAs (miRNAs) [53, 54]. Mid-size ncRNAs 
include small nucleolar RNAs, promoter upstream transcripts, transcription-start-site associated 
RNAs (TSS-associated), and promoter-associated small RNAs. Long ncRNAs (lncRNAs) are 
most commonly associated with a reduction in transcription but may also have a role in the 
regulation of miRNA levels [54]. Here we deliver a summary of some key miRNAs involved in 
HTN as well as a review of lncRNAs. 
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Figure 1.3  MicroRNA biogenesis. MiRNA biogenesis involves down-regulation of gene 
transcription via target mRNA degradation or by mRNA translation blockage. 
RISC: RNA-induced silencing complex. 
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Table 1.1  Summary of key non-coding RNA findings that influence hypertension 
 
Reference Tissue Type/ Sample Size Findings 
 
Goyal, et al. 
[55] 
Rat: Tissues: brain; 20 maternal 
low protein pups, 17 control 
pups 
mmu-miR-27a and mmu-miR-27b 
regulate ACE1 and was upregulated (3.3- 
and 8.8-fold respectively) in MLP rat; 
mmu-mir-330 regulates angiotensin II 
type 2 receptor (AT2) and was 
downregulated 3.5-fold in MLP rat. 
 
Sethupathy, 
et al. [56] 
Human: Fibroblasts from 
monozygotic twin; n = 2 
Has-miR-155 binds to 3’UTR of AGR1 
mRNA “A” allele causing a reduction in 
AGTR1 mRNA, reducing the pressor 
effect in response to angiotensin II. 
 
Cheng, et 
al. [57] 
Human: Endothelial cells from 
pre-eclamptic placentas 
Has-miR-155 up-regulated in 
preeclampsia placentas, indicating 
involvement in regulation of AGTR1. 
Marques, et 
al. [58] 
Human: Tissue: kidney; Sample 
1: 42 mixed sex, Polish 
individuals of mixed HTN 
status; Sample 2: 22 male only, 
mixed HTN status. All samples 
untreated for HTN 
Has-miR-181a & has-miR-663 is able to 
bind 3’UTR of renin mRNA, found to be 
under-expressed in EH. These miRNA 
able to regulate renin mRNA directly, 
explaining overexpression of renin in EH 
kidney. 
 
Wang, et al. 
[59] 
Mouse: Tissue: Mesenteric 
arterioles; 16 male C57Bl/5 
mice; 16 sham mouse control 
siRNA targeting p22phox mRNA 
demonstrated inhibition of contractile 
response from angiotensin II, 
consequently lowering BP. 
Cabili, et al. 
[60] 
Human: Tissue: 24 various and 
cells lines; 24 human samples 
lincRNAs may promote the transcription 
of their neighbouring coding genes, 
including those implicated in EH and BP 
regulation. 
Annilo, et 
al.  [61] 
Human and Mouse: various 
tissues and cell lines; n = not 
disclosed 
Seven BP candidate genes ADD3, NPPA, 
ATP1A1, NPR2, CYP17A1,ACSM3 and 
SLC14A2 were connected with cis-
lncRNA transcripts. 
MLP, maternal low protein; EH, essential hypertension; mRNA, messenger RNA; miRNA, micro 
RNA; lincRNA, long non-coding RNA; HTN, hypertension; siRNA, silencing RNA; BP, blood 
pressure 
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MiRNAs are the most commonly studied small ncRNA; currently there is no research available 
investigating the involvement of the other types of small and mid-sized ncRNAs in EH. There are 
more than 1800 miRNAs in the genome, each approximately 22 nucleotides in length [62]. 
miRNAs down-regulate protein-coding genes by binding to target sequences in the 3’ (5’ targeting 
is uncommon but possible) untranslated region of a target mRNA, resulting in mRNA degradation 
or repression of mRNA translation [63] (Figure 1.3). Evidence suggests a single miRNA can 
regulate numerous mRNAs, so it is plausible that miRNAs are causative agents for complex 
deletions [63]. miRNAs are increasingly implicated as regulators of cardiovascular system [64], 
including modulation of arterial pressure [65] (Table 1.1). 
 
In regards to the RAAS-regulated genes, it appears that miRNAs may also have a role modulating 
ACE mRNA transcription [66]. MiRNA has-miR-155 was found by Sethupathy et al [56] to target 
the polymorphic sequence located in the 3’UTR of AGTR1 mRNA. This site has a Mendelian C 
(minor) and an A (major) allele. The minor-C allele is associated with EH [56]. Has-miR-155 
binds most effectively to the A allele, leading to a reduction in AGTR1 mRNA in EH individuals 
who inherit this allele. Individuals with the C allele did not have reduced AGTR1 mRNA and 
exhibited a greater pressor effect in response to angiotensin II [56]. Has-miR-155 is also found to 
be up-regulated in preeclampsia placentas; it regulates AGTR1 expression in umbilical vein 
endothelial cells [57]. A recent GWAS documented expression of mRNAs and miRNAs in kidneys 
from untreated EH individuals, which were removed as a consequence of renal cancer [58]. Two 
miRNAs (has-miR-181a and has-miR-663) with the ability to bind to the 3’UTR of renin mRNA 
were found to be under-expressed in EH. These miRNAs were able to regulate the expression of a 
reporter gene and renin-mRNA itself, which explains over-expression of renin mRNA seen in EH 
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kidney [58]. Disruptor of telemetric silencing – 1 (DOT1) causes hypermethylation of H3 [67], 
small interfering RNAs (siRNA) have been shown to have an opposite effect by silencing the 
expression of the DOT1 Gene [68]. Furthermore, siRNAs have been observed to have a role in 
modulating the RAAS system [68]. Angiotensin II was shown to induce a contractile response in 
smooth muscle cells extracted from mice overexpressing p22phox, a subunit of NADPH oxidase 
responsible for activating NADPH oxidase and generating superoxide anions in atherosclerotic 
plaques in human blood vessels [69]. siRNA targeting p22phox inhibits the contractile response 
from angiotensin II, lowering BP [59]. 
 
Large intergenic non-coding RNAs (lincRNAs) have been identified as both a modulator of health 
development [70-72] and disease states [73], and may regulate the expression of neighboring genes 
and distant loci [74]. LincRNAs are more tissue specific than protein-coding genes [60], 
suggesting they have selective functions in different tissues. Cabili et al [60] described the 
annotation and tissue-specific expression of all lincRNAs. Their gene ontology analyses were 
based on lincRNA expression in different tissues [60]. The protein-coding genes located close to 
lincRNA loci included genes previously associated with EH and BP regulation, for example, those 
encoding corticotropin-releasing hormone [60], suggesting many lincRNAs have an enhancer-like 
function that promotes transcription of their neighboring coding genes [75].  
 
Long non-coding RNAs (lncRNAs), a heterogeneous group of non-coding transcripts longer than 
200 nucleotides, regulate their targets by influencing epigenetic control, mRNA processing, 
translation or chromatin structure. LncRNAs have been implicated in several biological processes, 
including transcriptional regulation by epigenetic mechanisms [74]. An exemplary representation 
18 | P a g e  
 
is X-chromosome inactivation present in the female genome of mammals which involves the 
inactivation of one copy of a female sexual chromosome by DNA methylation. This process is 
coordinated by the X-inactive specific transcript (XIST) and the XIST antisense transcript (TSIX) 
ncRNAs, very long ncRNAs whose expression can be regulated by epigenetic mechanisms such 
as DNA methylation [52]. LncRNAs have a potential to influence CVD, stroke, BP and HTN. 
Seven BP candidate genes ADD3, NPPA, ATP1A1, NPR2, CYP17A1, ACSM3, and SLC14A2 
were connected with cis-lncRNA transcripts [61]. Of these, the lncRNA NPPA-AS was selected 
for further investigation which revealed NPPA-AS has a demonstrated influence on the splicing 
of the natriuretic peptide precursor A (NPPA) gene (present in cardiac hypertrophy and heart 
failure) and, therefore, has potential CVD involvement [61]. 
 
1.7.2   Histone modification and hypertension 
 
DNA is packaged into the dynamic protein structure of chromatin, whose basic unit is the 
nucleosome. A nucleosome comprises of two copies each of the histone proteins H2A, H2B, H3, 
and H4 [76]. Post-translational modifications regulate gene expression by controlling the dynamics 
of chromatin. Modifications occurring at residues in histone tails include acetylation and 
methylation (Figure 1.4) as well as phosphorylation, sumoylation, and biotinylation [76]. 
Epigenetic histone modification occurs when the N-terminal tail is subjected to a variety of post-
translational modifications [46]. Up to 60 possible modifications can occur. Specifically, the 
nucleotide lysine can be modified by methylation, acetylation, ubiquitylation, or sumoylation, 
whereas arginine can only be modified by methylation, and serine and threonine are modified only 
by phosphorylation [46]. While each histone modification pattern has a unique impact on the 
corresponding nucleosome, generally, the outcomes are similar: histone acetylation promotes gene 
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transcription while deacetylation represses transcription; histone lysine methylation in position 79 
inhibits while histone arginine methylation activates gene transcription; histone lysine 
hypermethylation or mono-methylation at position 9 can have opposing effects—respectively 
silencing or activating the target gene [77] (Table 1.2). 
 
 
Figure 1.4  Histone modification. Post-translational changes in the form of histone 
modifications influence gene expression by controlling chromatin dynamics. 
Methylation is commonly associated with gene silencing and can directly interfere 
with the binding of transcription factors. Histone tail acetylation can increase the 
access of transcription factors to DNA by transforming condensed chromatin into 
a more relaxed structure. 
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Table 1.2  Summary of histone modification findings in relation to hypertension 
 
Reference Tissue Type/ Sample Size Findings 
Han et al. 
[78] 
Rat: Tissue: Aorta, renal artery; 
SHR and WKY 
Up-regulated histone modifier H3K27me3 
in renal artery of SHR correlated with HTN 
improvement after resveratrol intake. 
 
Fish, et al. 
[79] 
 
Human: Umbilical vein 
endothelial cells 
Endothelial cell nucleosomes 
corresponding to eNOS enriched in various 
histones relevant to eNOS expression. 
 
Lee et al. 
[80] 
Rat: Tissue: adrenal gland, aorta, 
heart, kidney, liver, and lung. 
SHR and WKY 
 
Higher expression of Ace1 mRNA & 
protein in SHR. Ace1 promoter enriched 
with H3Ac and H3K4me3 in SHR. 
Cho, et al. 
[21] 
Rat: Tissue: Mesenteric artery, 
aorta; SD and Sham rat. 
Nkcc1 up-regulated in SD rat. Acetylated 
histone H3 up-regulated, trimethylated 
histone H3 down-regulated. 
Duart, et 
al. [22 
Human: Peripheral blood; First 
sample: 206 mixed sex, NT; 
Second sample: 730 mixed sex, 
HTN and NT. 
 
DOT1L strongly associated with increased 
BP in Caucasians. Possibly via mediation of 
hypermethylation of H3. 
Mu, et al. 
[23] 
Mouse: Tissue: Kidney; 
norepinephrine infused-C57 
BL/6j, Adrb1 knockout and 
Adrb2 knockout mice. 
WNK4 down-regulation caused increased 
H3 & H4 acetylation, leading to 
overexpression of NCC and therefore 
promoting HTN onset. 
 
eNOS, endothelial nitric oxide synthase; SD, Sprague–Dawley rat; DOT1L, DOT1-like histone 
H3K79 methyltransferase; NCC, sodium chloride co-transporter; WNK4, with-no-lysine kinase 4. 
HTN, hypertension; SHR: spontaneously hypertensive rat, WKY: Wistar Kyoto rat; Ace1; 
angiotensin converting enzyme receptor 1; BP; blood pressure; NKCC1: Na+-K+-2Cl_ 
cotransporter 1; ACE: angiotensin converting enzyme 
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Histone modification affecting arterial pressure levels has been documented in a variety of human 
and animal tissues, including vascular smooth muscle. Vascular oxidative stress can contribute to 
endothelial dysfunction—a hallmark of HTN—and the development of HTN. A study by Bhatt et 
al [81] documented the beneficial effects of resveratrol on endothelial function in the SHR. A later 
study of the mechanisms behind this effect was conducted by Han et al [78]. Epigenetic 
modifications, in the form of up-regulated H3K27me3 expression was observed in the renal artery 
of a salt-sensitive HTN model of the Wistar rat [78], possibly correlating with the improvement 
observed in HTN status but this was not clear. Endothelial nitric oxide synthase (eNOS) is 
primarily responsible for the production of nitric oxide in the vascular endothelium, and plays a 
key role in the regulation of vascular tone [78]. eNOS activity is thought to be down-regulated in 
CVD. Fish et al [79] found that eNOS expression appears to be controlled by cell-specific histone 
modifications. It was also demonstrated that the nucleosomes of endothelial cells corresponding 
to the eNOS core promoter were enriched in lysine 9 of histone H3 and lysine 12 acetylation of 
histone H4, and of di- and tri-methylation of lysine 4 of histone H3. Fish et al [79] observed that 
all of these epigenetic histone modifications were significantly important for the expression of 
eNOS [79]. 
 
The study by Riviere et al [82] noting the modulation of sACE by CpG methylation also 
documented the involvement of histone deacetylases in the same process. Later findings of Lee et 
al [80] further validated these observations. Riviere et al [82] also found that tissues from SHRs 
exhibit higher expression levels of Ace1 mRNA and protein than those of WKY controls. They 
found the Ace1 promoter regions of the SHR tissues were more enriched with H3Ac and 
H3K4me3, and concluded that Ace1 is locally up-regulated in SHR tissues via histone code 
modifications [80]. 
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In line with observations by Lee et al  [83], Cho et al [84] found that levels of the membrane 
transporter Nkcc1 mRNA and protein in the aortas of Sprague–Dawley (SD) rats were significantly 
increased after administration of an angiotensin II infusion. Cho et al [84] found that acetylated 
histone H3 (an activating histone), was significantly increased together with greatly decreased 
trimethylated histone H3 (a deactivating histone) [84], suggesting that both histone modification 
and/or DNA demethylation have a role in the epigenetic up-regulation of Nkcc1 during HTN 
development. 
 
DOT 1 (mentioned earlier) is a methyl-transferase, which enhances methylation of lysine 79 
residue of histone H3 (H3K79) [46]. DOT1-mediated hypermethylation of H3 disrupts silencing 
of genes associated with maintaining telomere length during DNA repair, located in the telomeric 
regions of chromosomes [85]. This disruption correlates with a decrease in connective tissue 
growth factor transcription, increased intracellular cAMP and alterations in the adaption of blood 
vessels to stressors-associated with HTN [85]. In Caucasians, DOT1-like histone H3K79 
methyltransferase (DOT1L) is strongly associated with increased BP response to 
hydrochlorothiazide [67]. 
 
Activation of the renal sympathetic nervous system has long been thought to play a crucial role in 
the development of salt-reactive HTN  [86]. Over activity of renal sympathetic pathways can 
promote the activation of several mechanisms which lead to increased sodium retention, including 
stimulation of renin release, reduced renal blood flow, and increased sodium reabsorption in the 
loop of Henle  [87, 88]. Serine-threonine kinases have a key role in renal tubular sodium 
reabsorption; specifically, the with-no-lysine (WNK) family of serine-threonine kinases [89]. In 
NT mice, a low-sodium diet decreases expression of renal WNK4, whereas a high sodium diet 
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increases its expression [90, 91]. Renal sympathetic activity can also promote sodium reabsorption 
via activation of the β2 adrenergic receptor (β2AR) leading to cyclic AMP (cAMP) production, 
and increased activity of renal epithelium sodium channels (ENaC) [92]. WNK4 signalling targets 
ENaC, and may also mediate the prohypertensive effects of renal sympathetic over activity. In 
addition to the classical cAMP pathway, cAMP modulates gene transcription via inhibition histone 
deacetylase-8 activity leading to increased histone acetylation [93, 94]. Mu et al [95] found that 
salt loading triggers β-adrenergic-mediated down-regulation of renal WNK4, increases salt 
retention, and consequently leads to the development of salt sensitive HTN. WNK4 was recently 
found to be negatively regulated by the glucocorticoid receptor [65]. Mu et al [95] also noted that 
the underlying mechanism down-regulating renal WNK4 is cAMP dependent modulation of 
histone acetylation, which consequently increased histone H3 and H4 acetylation. Acetylation of 
H3 and H4 seems to favour binding of the glucocorticoid receptor to a WNK4 promoter region 
that contains a negative glucocorticoid-responsive element  [95]. Mu et al found WNK4 expression 
was inhibited via these pathways leading to overexpression of the sodium chloride co-transporter 
(NCC) and the onset of HTN [95]. 
 
1.7.3   DNA Methylation and hypertension 
Epigenetic DNA modification (methylation) occurs when a methyl group derived from S-
adenosyl-L-methionine is bound to position 5 of the cytosine ring, forming 5mC [96] (Figure 1.5). 
DNA methylation is tightly regulated by DNA methyltransferases (DNMTs), specifically 
DNMT1, DNMT3A and DNMT3B [97]. Methylation of the newly synthesized DNA strand during 
replication is orchestrated by DNMT1 [97]. This ensures transfer of specific methylation patterns, 
known as marks, during cell division [97]. Alternatively, DNMT3A and DNMT3B modulate de 
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novo DNA methylation [97]. Collectively, these DNMTs are responsible for the maintenance and 
regulation of methylation and are essential for normal development [98, 99]. Methylation occurs 
at various locations throughout the genome, at sites called CpGs. Most commonly, methylation 
resulting in a functional change in gene expression occurs in locations called CpG islands [46]. 
CpG islands are short sequences of DNA with a high linear frequency of 5’-CpG-3’ sequences. 
The “p” denotes the phosphoesteric bond linking the cytosine and the guanine nucleotides [77]. 
CpG islands are often located in promoter regions and approximately 40% of genes contain CpG 
islands in the end 5’ region (promoter, untranslated region, and exon1). The rest of the genome 
(intergenic and intronic regions) is considered CpG poor [96]. In healthy somatic cells, up to 90% 
of CpG dinucleotide sites are methylated, except for those located in the promoter region, which 
appear to be somewhat protected from such modification [96]. Non-CpG island DNA methylation 
has also been reported to influence protein-DNA interactions, gene expression and chromatin 
structure, and stability [100]. Functionally, DNA methylation suppresses gene transcription, so 
DNA hypermethylation typically results in gene silencing [46].  
 
Different degrees of DNA methylation have been correlated with variable onset, timing, and 
severity of EH (Table 1.3). Global genomic DNA methylation can be quantified by measuring the 
amount of 5mC present in a DNA sample. Smolarek et al [101] found a correlation between 
decreased levels of 5mC in peripheral blood with an increase in EH grade severity. The 
concentration of 5mC was calculated as a ratio of spot intensities and a significant deficit in 5mC 
was observed in healthy controls, relative to levels found in the two severity grades of EH. The 
mean level of 5mC was 1.80 ± 0.69 in healthy controls and 1.14 ± 0.48 in all HT subjects 
(specifically, 1.29 ± 0.50 grade 1, 0.99 ± 0.42 grade 2), indicating that global DNA methylation 
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levels decrease as the severity of EH increases. However in this study, the percentage of 5mC was 
expressed as a coefficient “R” value, and the method for calculating “R” was not disclosed. 
 
 
 
Figure 1.5 Epigenetic DNA methylation. DNA methylation involves the binding of a 
methyl group to the 5’ carbon of cytosine ring. This primarily occurs at CpG 
islands and results in inhibition of gene transcription, particularly if it occurs 
in the gene promoter region. It may also promote transcription if it is located 
at gene exons sites. DNA methylation is an essential biological process 
which is linked with several epigenetic phenomena including X-
chromosome inactivation, genomic imprinting and repetitive element 
repression. 
 
The most robust data on the involvement of methylation in BP regulation comes from the study 
by Kato et al [102]. Kato and colleagues performed a genome-wide association and replication 
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study and identified genetic variants at 12 new loci that correlated with BP modulation in 320,251 
individuals of East Asian, European, and South Asian ancestry [102]. An investigation of the 
relationship between the sentinel BP single nucleotide polymorphisms (SNPs) with local DNA 
methylation in 1904 South Asians (peripheral blood; Illumina Human Methylation 450 Bead Chip 
array (Erasmus Medical Centre, Rotterdam, The Netherlands)) revealed a two-fold enrichment 
between sequence variation and DNA methylation. Twenty-eight of the 35 sentinel SNPs were 
associated with one or more methylation markers [102], suggesting that DNA methylation may lie 
on the regulatory pathway linking sequence variation BP. Genes associated with the 12 newly 
identified SNP loci include those involved with vascular smooth muscle (IGFBP3, KCNK3, 
PDE3A, PRDM6) and renal function (ARHGAP24, OSR1, SLC22A7, TBX2) [102]. Investigation 
of cross-tissue patterns of DNA methylation at the leading CpG sites associated with sentinel SNPs 
showed that DNA methylation in the blood was closely correlated with methylation patterns of 
various tissues (liver, muscle, subcutaneous and visceral fat).  
 
 
A more recent, large scale study by Richard et al [103] discovered that heritable methylation sites, 
independent of known genetic variants, explain an additional 1.4% and 2.0% of the inter-individual 
variation in SBP and DBP respectively. Although these studies provide tantalising evidence for 
the role of methylation all were conducted in the easily accessible leukocyte DNA.  Since DNA 
methylation patterns are highly variable across different tissues [36], utilisation of peripheral blood 
for non-blood based diseases and phenotypes has not been validated and further research is needed 
to investigate this correlation with a HT affector organ, such as the kidney. 
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Initial DNA methylation research centered on correlating EH with the global level of 5mC [101], 
but more recent studies have focused on the methylation of specific DNA sequences. The 
hydroxysteroid dehydrogenase 11 β2 enzyme (HSD11B2) converts cortisol to cortisone, which is 
found in circulatory concentrations up to 1000 times higher than aldosterone (the primary 
mineralocorticoid hormone and sodium (Na) transport modulator of the RAAS [46]. Cortisol and 
aldosterone bind mineralocorticoid receptors with equal affinity, but due to the difference in 
concentration of the hormones, cortisol has a larger role in sodium reabsorption by the kidneys 
and, in consequence, plays a larger role in fluid-related arterial pressure [46]. HSD11B2-mediated 
degradation of cortisol to cortisone is disrupted when the promoter region of the HSD11B2 gene 
is hypermethylated [104, 105]. The resulting imbalance in the active metabolites of cortisol and 
cortisone, tetrahydrocortisol (THF), and tetrahydocortisone (THE), respectively, promotes the 
onset of HTN [104, 105], in accord with the findings by Friso et al. [106]. Friso et al. [106] also 
found that HSD11B2 promoter methylation was associated with EH, with parallel disruptions to 
the THF/THE ratio. 
 
Due to the well-known involvement of the RAAS on arterial pressure regulation, any changes in 
the activation status of RAAS-regulated genes have a pronounced effect on an individual’s 
potential to develop HTN. This effect has been extensively tested in animal models of HTN 
[66].Hypomethylation of the promoter regions of the angiotensin II type 1b receptor gene in the 
adrenal glands of the maternal low protein (MLP) rat promoted HTN through an exaggerated 
response to salt [66]. The same effect was seen in a second study, where maternal protein 
deficiency during pregnancy induced hypomethylation of the promoter regions of RAAS-
responsive genes, such as angiotensin converting enzyme (ACE), causing predisposition to HTN 
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in offspring as well as cognitive deficits [55]. The human PRCP gene encodes a lysosomal 
prolylcarboxypeptidase protein, which is implicated in cleavage of c-terminal amino acids linked 
to proline in peptides such as angiotensin II and III [92]. Methylation profiling conducted on young 
African males revealed that the PRCP gene was hypomethylated in EH subjects [107]. Similarly, 
when expression patterns of the angiotensin 1a receptor (Atgr1a) were analysed in both SHR and 
its NT control, the WKY, expression of Atgr1a was significantly increased by week 20 in the SHR. 
Bisulfite sequencing revealed that the Atgr1a promoter from endothelial cells in the aorta and 
mesenteric arteries of the SHR rats became progressively hypomethylated with age compared to 
their WKY counterparts [108], suggesting heightened Atgr1a expression in the SHR was related 
to the hypomethylation of the Atgr1a promoter and may have a role in the maintenance of high 
BP. Somatic ACE (sACE) converts angiotensin I to the active form, angiotensin II and is, 
therefore, a key regulator of BP [82]. Bisulfite sequencing conducted on cultured endothelial cells 
and WKYs revealed that hypermethylation was associated with transcriptional repression of 
sACE, indicating possible epigenetic involvement of sACE modulation in HT  [82]. 
 
Membrane transporters such as Na+-K+-2Cl- cotransporter 1 (NKCC1), participate directly with 
fluid and electrolyte loss and therefore arterial pressure regulation [83]. NKCC1, expressed by the 
Sic2a2 gene, mediates the transport of sodium, potassium and chloride into and out of the cells 
[46]. Changes in ion fluxes have been implicated in EH, particularly an augmented, passive influx 
Na+, K+, Rb+, and Cl- in HT vascular smooth muscle cells [83]. Hypomethylation of the Sic2a2 
gene promoter in the SHR aorta and heart, result in increased expression of NKCC1 and is 
positively correlated with HTN [83]. Methyl CpG binding protein 2 methylates the norepinephrine 
transporter gene, silencing its expression [46]. Hypermethylation of the norepinephrine transporter 
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gene, which transports norepinephrine and dopamine from the synaptic gap back to the pre-
synaptic neuron, has been shown to lead to increased transport responsiveness, resulting in EH 
[109]. Furthermore, phenyl-ethanolamine N-methyltransferase (PNMT), which can act similarly 
to methyl CpG binding protein 2, has been shown to exacerbate the decrease in norepinephrine 
uptake, thereby enhancing the local and systemic catecholaminergic effect [109]. 
 
Table 1.3 Summary of methylation findings in relation to hypertension and cardiovascular 
pathology  
Reference Tissue Type/ Sample Size Findings 
 
Smolarek, 
et al. [101] 
Human: Peripheral blood; 60 
with EH; 30 controls 
Mean 5mC amount in DNA significantly 
decreased as HTN severity increased. 
 
Kato, et al. 
[20] 
 
Blood, muscle, liver, fat; 
320,251 individuals of East 
Asian, European and South 
Asian ancestry 
 
Discovered to be correlated with BP 
modulation. Two-fold enrichment discovered 
between DNA methylation and sentinel BP 
SNPs, providing evidence for DNA methylation 
role in BP regulation. 
 
Richard et 
al. [103] 
Human: Peripheral blood, 
17,010 individuals of 
European, African 
American, and Hispanic 
ancestry 
The replicated methylation sites are heritable 
and independent of known BP genetic variants, 
explaining an additional 1.4% and 2.0% of the 
interindividual variation in SBP and DBP, 
respectively. 
 
Friso, et 
al. [21] 
Human: Peripheral blood; 25 
with EH; 32 with prednisone 
therapy 
 
HSD11B2 gene promoter methylation 
associated with EH onset via disruption to 
THF/THE ratio. 
 
Goyal, et 
al. [22 
Rat: Tissues: brain; 20 MLP 
pups, 17 control pups 
Hypomethylation of RAAS system genes such 
as ACE resulting in HTN in offspring. 
Wang, et 
al. [23] 
Human: Peripheral blood; 8 
EH; 8 control 
PRCP gene hypomethylated in EH, linked to 
disruption in cleavage of angiotensin II and III 
Pei, et al. 
[24] 
Tissue: aorta; 6 SHR; 6 
WKY control 
 
Atgr1a gene progressively hypomethylated as 
SHR age progressed. Indicating increased 
expression of Atgr1a in aging SHR 
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Riviere, et 
al. [25] 
Rat: Cultured endothelial 
cells from WKY 
 
Hypermethylation associated with 
transcriptional repression of sACE, indicating a 
role for epigenetics in sACE modulation during 
HTN. 
Lee, et al. 
[26] 
Rat: Tissues: aorta, heart; 
SHR and WKY 
 
Hypomethylation of Sic2a2 gene lead to 
increased expression of NKCC1 which 
was positively correlated with HTN. 
 
Kim et al. 
[110] 
Human: PBL;  286; 129 
male, 157 female 
Elevated PBL DNA methylation is positively 
associated to CVD prevalence/ predisposing 
conditions. 
 
Lund et al. 
[111] 
Human: monocyte cell line 
Mice: PBMC; PBL; aorta  
Altered DNA methylation present in aorta and 
PBMC of apolipoprotein E mutant mice. 
Atherogenic lipoproteins promote global 
hypermethylation in human monocyte cell line.  
 
Bellizzi et 
al. [112] 
 
Human: 37; PBL Loss of global DNA methylation levels and 
frailty occurs in aging. 
Castro et 
al [113] 
Human: plasma; 17 vascular 
disease, 15 controls 
DNA methylation status significantly correlated 
with plasma tHcy and AdoHcy. 
 
Stenvinkel 
et al. [114] 
Human: 191; 37 CKD stage 
3 & 4; 98 CKD stage 5; 20 
haemodialysis patients; 36 
healthy controls 
 
Global DNA hypermethylation is associated 
with inflammation and increased mortality in 
CKD 
 
Zhao et al. 
[115] 
Human: PBL; 84 
monozygotic twins 
Global hypermethylation associated with 
insulin resistance. 
 
EH: essential hypertension; MLP: maternal low protein; HTN: Hypertension; SHR: spontaneously 
hypertensive rat, WKY: Wistar Kyoto rat; 5mC: 5-methyl-cytosine; ACE: angiotensin converting 
enzyme; RAAS: renin-angiotensin-aldosterone system; sACE: somatic ACE; SNPs: single 
nucleotide polymorphisms; NKCC1: Na+-K+-2Cl_ cotransporter 1; BP: blood pressure 
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1.8    Conclusions 
We are entering a new era of understanding how the genome interacts with the environment to 
affect disease pathogenesis. There is now emerging evidence that epigenetic, as well as genetic, 
factors are key players in regulating and maintaining BP, and strong evidence for a complex 
interaction of genetic and environmental factors that influence the risk of HTN in each individual 
(Figure 1.2). Many epigenetic studies are, however, limited by the fact that only blood is studied 
rather than the effector tissues. The utility of blood methylation status in epigenetic research is yet 
to be determined. Furthermore, the polygenic complexity of HTN and the limited knowledge on 
some epigenetic modifiers makes it more challenging to decipher the exact mechanisms involved. 
Further studies of the epigenetic modulators in humans will be needed to elucidate the exact 
mechanisms involved and to determine more effective therapeutic applications. 
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1.9   Hypothesis and Aims  
 
What we know  The critical concept that can be derived from the current literature review is 
that we are entering a new era of understanding how the genome interacts with the environment to 
affect disease pathogenesis. There is now emerging evidence that epigenetic, as well as genetic, 
factors are key players in regulating and maintaining BP, and strong evidence for a complex 
interaction of genetic and environmental factors that influence the risk of HTN in each individual. 
The vast majority of epigenetic studies are limited through the use of peripheral blood for non-
blood based pathologies, rather than the effector tissues. The applicability of blood as a surrogate 
tissue for the methylation status in other tissues is yet to be determined. Furthermore, the polygenic 
complexity of HTN and the limited knowledge on the role of tissue specific DNA methylation 
makes it more challenging to decipher the exact mechanisms involved.  
 
What we do not know  As one of the most important and stable epigenetic marks, DNA 
methylation has emerged as a powerful regulator of developmental processes but its role in EH 
remains elusive. Moreover, a broader conceptual framework for understanding how DNA 
methylation influences BP in a key affector organ of HTN is lacking.  
 
Hypothesis The central hypothesis underpinning this PhD thesis is that alterations in kidney 
specific DNA methylation plays a fundamental role in modulating gene expression changes 
involved the regulation of BP and the pathogenesis of EH. 
 
Aims:  To test the hypothesis, this PhD thesis focuses on characterizing the role of DNA 
methylation in the HT kidney using array and RNA-sequencing methods (Figure 1.6): 
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Aim 1: To characterize global DNA methylation dynamics and its functional role in the 
hypertensive population (Chapter 3).  
 
Aim 2: To determine the role of genome-wide, loci specific DNA methylation in the hypertensive 
human kidney and investigate associations between our renal findings and previous studies 
conducted in blood (Chapter 4). 
 
Aim 3: To understand the relationship between DNA methylation and differential expression of 
genes associated to BP and HTN in the human kidney and investigate existing overlap between 
our kidney findings and previous blood based GWAS (Chapter 5).  
 
To address the abovementioned aims, a number of classic molecular biology techniques, as well 
as contemporary next-generation sequencing approaches have been employed. These molecular 
techniques, as well as the human population they are applied to, are described in detail in the 
following General Methods chapter (Chapter 2).  
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Figure 1.6  Study design flow chart for PhD project. This PhD thesis investigates the role of kidney specific DNA methylation in 
the modulation of gene expression in genes involved in HTN. Furthermore, we investigate the overlap between HTN-
associated kidney methylation and expression and large GWAS datasets available from human blood.  
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Chapter 2. General methods 
 
 
 
 
 
 
 
 
 
 
“Do not go where the path may lead, go instead where there is 
no path and leave a trail” 
 
~ Ralph Waldo Emerson 
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Chapter 2. General methods 
 
2.1   Participants  
All studies have been approved by the University of Manchester Human Bioethical Committee. 
All TRANScriptome of renaL humAn TissuE (TRANSLATE) study individuals gave written 
informed consent for participation. The studies adhered to the Declaration of Helsinki.  
 
All analyses conducted in this PhD utilised peripheral blood and kidney samples collected from 
participants of the TRANSLATE study. TRANSLATE is a unique resource of 265, white 
European patients who underwent elective unilateral nephrectomy due to sporadic non-invasive 
renal cancer in one of three nephrology-urology centres: Silesian Renal Tissue Bank [116, 117], 
TRANSLATE P (recruitment conducted in Western Poland) and TRANSLATE Z (recruitment 
conducted in Southern Poland) [118]. The study recruited adults (aged >18 years) with no personal 
history of nephropathy. 
 
All participants of the TRANSLATE study underwent detailed clinical phenotyping, which 
consisted of documentation of clinical history (via coded questionnaire), basic anthropometry as 
well as triplicate measures of BP by mercury sphygmomanometer. HTN diagnosis was assigned 
to individuals who had elevated BP greater than >140/90 mmHg on at least two separate occasions, 
and/or were taking antihypertensive medications [117].  
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2.2   Sample collection  
Renal samples, consisting of approximately 1 cm3 of kidney tissue (both medulla and cortex), were 
collected from the contralateral healthy (unaffected by cancer) pole of the kidney immediately post 
nephrectomy. This method was previously employed in other studies as a means of securing 
“control” tissue for gene expressional analyses [119]. Histological sections were also taken at this 
time to confirm cancer and tissue margins. These samples were immediately transferred to either 
RNA later (Ambion, Austin, Tex) or dry tubes and preserved at -70°C before renal DNA and RNA 
extractions [116-118].  
 
Kidney DNA was extracted from 94 homogenised renal tissue samples using Qiagen purification 
kits for total DNA (Qiagen). Leukocyte DNA was extracted from 75 peripheral blood using 
QIAamp DNA mini blood extractions kit (Qiagen). Kidney RNA was extracted from 180 using 
the RNeasy kit (Qiagen). The various sample sizes were chosen based on the plate sequencing size 
(ELISA anlaysis), the 450K methylation chip size (methylation analysis) and the availability of 
the appropriate renal samples with matching clinical phenodata to reduce confounders (all 
samples).  
 
2.2.1  Effects of coexistant cancer on the renal transcriptome 
The potential effect of coexistent cancer on the transcriptome of the TRANSLATE “healthy” renal 
tissue was comprehensively discussed by Marques et al [120], where the global expression profiles 
of three different cohorts was compared. The three groups contained either healthy tissue from 
nephrectomy due to cancer, noncancerous kidney tissue, or clear cell renal carcinoma tissue. These 
sections were analysed using hierarchical clustering analysis and RNA-sequencing. Results from 
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this study showed tight clustering of global expression patterns between healthy tissue from 
nephrectomy and subjects who did not have cancer. Highlighting that it was unlikely that the 
transcriptome program in cells within neoplastically unaffected apparently healthy renal tissue 
were largely influenced by the presence of cancer in other parts of the kidney [120].  
 
2.3  Global kidney and leukocyte DNA methylation detection 
In Chapter 3 the global methylation analysis utilised 75 human peripheral blood leukocyte samples 
(Chapter 3: Table 3.3 and Table 3.4) and 94 human kidney samples (Chapter 3: Table 3.5 and 3.6) 
from the TRANSLATE study, respectively. Of the 75 peripheral blood leukocyte samples, 28 were 
a subset from the same participants that provided renal tissue. Kidney and leukocyte DNA (100ng) 
underwent global DNA methylation analysis using the 5mC ELISA kit (Zymo Research, USA). 
Where 100ng of DNA from each sample (at 10ng/µL) was added to a PCR tube before adding 
90µL of 5mC coating buffer to make a final volume of 100µL. The DNA was then denatured at 
98°C for five minutes, transferred immediately to ice for ten minutes, samples were transferred to 
5mC ELISA 96 well plate, covered, and then incubated at 37ºC for one hour. During the blocking 
stage, each well was washed three times with 200µL of 5mC ELISA buffer, before a final addition 
of 200µL of 5mC ELISA buffer was added and the plate was incubated at 37°C for 30 minutes. 
During the antibody addition stage, the buffer was discarded from the wells and 100µL of prepared 
antibody mix (Chapter 3: Table 3.2) was added to each well before incubation at 37ºC for one 
hour. During the colour development stage, the buffer was discarded from the wells, and the wells 
were washed in triplicate with 200 µL of 5mC buffer. HRP developer (100µL) was added to each 
well and allowed to develop for 60 minutes at room temperature. All samples were measured in 
duplicate and calibrated against 0%-100% methylated controls with a standard curve. Absorbance 
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was measured at 450 nm using the Multiskan FC Microplate Photometer (Thermo Scientific, 
Australia) and average global DNA methylation was calculated using the formula generated from 
the standard curve. Global methylation in the kidney was further investigated using the data 
generated from the Infinium HumanMethylation 450K BeadChip (Illumina) (method 2.4) by the 
calculating the mean of all CpG site beta-values between the HT and NT samples.  
 
2.4  Genome-wide, loci specific DNA methylation analysis  
2.4.1  Detection of differentially methylated CpG sites 
In Chapter 4 the genome-wide, loci specific DNA methylation analysis was conducted using 94 
human kidney samples (Chapter 4: Table 4.6 and 4.7) from the TRANSLATE study. The subset 
of TRANSLATE human renal DNA to be utilised in this section was chosen to ensure a balanced, 
yet sufficient, representation of hypertensive patients, both medicated and non-medicated. 
Furthermore, age and gender were balanced between the normotensive and hypertensive 
populations as much as possible with no histological signs of nephrosclerosis. Genome-wide 
kidney DNA methylation was investigated using the Infinium HumanMethylation 450K BeadChip 
(Illumina) with assistance from the Australian Genome Research Facility (Perth, Australia). Where 
1000ng of kidney DNA underwent quality analysis using resolution on a 0.8% agarose gen and 
Nanodrop assessment. From this, 750ng of high quality kidney DNA underwent bisulphite 
conversion with the use of the Zymo EZ DNA Methylation Kit (Zymo Research, USA). Bisuphite 
converted kidney DNA (4uL, at 50ng/mL) was then hybridised with the Infinium 
HumanMethylation450 BeadChip (Illumina). The 450K BeadChip uses two types of Illumina 
chemistry to provide a comprehensive DNA methylation status of over 485,000 CpG sites 
spanning 99.9% of Refseq genes (with an average of 17 CpG sites per gene region distributed 
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across the promoter, 5’ untranslated region, first exon, gene body and 3’ untranslated region). 
Apart from a vast majority of CpG islands (covered in 96%), the array provides coverage for island 
shores and the regions flanking them.  The arrays were then processed through Illumina iScan to 
deliver rapid, high resolution imaging of the methylation arrays. DNA methylation is represented 
as a β-value (0-1) which corresponds to the percentage of methylation at a given CpG site (0%-
100%, respectively). Data was imported into and analysed using the bioinformatics software, 
Partek (Genome Suite, version 6.6, Singapore) as well as the statistical computing software, R 
(RStudio, GNU General Public License).  
 
2.4.2  Methylation data pre-processing  
For every CpG site interrogated via the 450K array, the intensity of the scanned signal is used to 
calculate a methylated and non-methylated measurement. The raw IDAT files hold this intensity 
information which was extracted from the Illumina iScan. These files also contain a detection P-
value for every probe, which indicated how well the signal intensity was interpreted (small P 
values correlating with good probe performance).  
 
2.4.2.1  Methylation data preprocessing computational analysis 
No probes with a high detection P-value (P = ≥0.5) were detected. Probes located on sex 
chromosomes were removed as the data set contains both males and females, as well as cross 
reactive probes which target repetitive sequences or co-hybridize to alternative sequences that are 
highly homologous to the intended targets and therefore risk generating spurious signals [121]. 
These cross-reactive probes were removed to reduce the risk of invalid conclusion and lack of 
validation in downstream analysis. Similarly, sites that overlapped with SNPs located within a 
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probe or within ten base pairs of a probe were excluded, a total of 418,581 probes remained for 
analysis.  
 
2.4.3   Methylation data normalisation 
The Illumina 450K array contains two probe types. Type I probes originate from the 450K 
predecessor, the 27K array and contain two probes in the same colour channel to measure 
methylated and unmethylated intensities [122]. Type II probes were designed differently, and use 
one probe and two different colour channels to make the same measurement [122]. The two 
different probe types generate different signals. Therefore, to avoid probe type specific false 
positives, identify technical variation, and increase the chances of detecting DNA methylation 
changes caused by HTN, raw β-values underwent intra-array normalisation. 
 
2.4.3.1  Methylation data normalisation computational analysis 
Raw β-values underwent intra-array normalisation using the Dasen method (Figure 2.1) 
implemented through the Bioconductor wateRmelon package (version 3.6) [123]. The Dasen 
method also performs between-array normalisation, where the background difference between 
type I and type II probes for both methylated and unmethylated signal intensities are adjusted prior 
to quantile normalisation so that chips ran at different time points are comparable The β-value is 
then generated from the adjusted signal intensities using the equation 1.  
Equation 1: β = methylated probe intensity / methylated probe intensity + unmethylated probe 
intensity. 
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Figure 2.1  Inter-array normalisation using the Dasen method. To avoid probe type specific 
false positives, identify technical variation, and increase the changes of detecting 
DNA methylation changes caused by HTN, raw β-values underwent intra-array 
normalisation using the Dasen method implemented through the Bioconductor 
wateRmelon package (version 3.6). 
 
 
All β-values were log-transformed into M-values (Figure 2.2) using the logit function (log2 (β/ (1-
β))). M-values are a more valid alternative for detecting DNA methylation changes, as they 
eliminate the heteroscedasticity of higher-and lower-end β-value [124]. The M-value is calculated 
as the log2 ratio of the intensity of the methylated probe versus the unmethylated probe (see 
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equation 2). It should also be noted that logit transformation further reduced type I/ type II probe 
bias [124]. Two samples were excluded from further analyses due to identification mislabeling 
(Figure 2.3) 
Equation 2: 
 !" 	= 	%&'( ) *+,(./,123456,7)9:*+,(./,;<123456,7)9:= 
 
Figure 2.2  Principal components plot demonstrating normalisation of log transformed β-
values to M-values. All β-values were log-transformed into M-values using the 
logit function (log2 (β/ (1-β))). M-values are a more valid alternative for detecting 
DNA methylation changes, as they eliminate the heteroscedasticity of higher-and 
lower-end β-value [124]. The M-value is calculated as the log2 ratio of the intensity 
of the methylated probe versus the unmethylated probe. Logit transformation 
further reduced type I/ type II probe bias [124].  
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2.4.4  Methylation data statistical analysis 
Differentially methylated, individual, CpG sites and islands in the HT and NT kidney were 
determined using regression (RStudio, GNU General Public License), with adjustment made for 
the antecedent covariates age, BMI, smoker status and gender. Two samples [PKPOZ2, PKPOZ3] 
were excluded from the analysis due to mismatched labelling (Figure 2.3).  
 
 
Figure 2.3 Principal components plot demonstrating mismatched gender labels. Kidney 
DNA methylation samples clustered by gender to display mismatched labelling on 
samples PKPOZ2 and PKPOZ3. These two samples were removed from both the 
global (Chapter 3) and the loci specific methylation analysis (Chapter 4).   
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2.5  RNA-sequencing analysis 
2.5.1  Identification of hypertension-associated renal signatures 	
In Chapter 5, RNA was extracted from the kidney tissue of 180 participants of the TRANSLATE 
study (Chapter 5: Table 5.1 and 5.2) and preserved in RNAlater (Ambion, Austin, Texas). A total 
of 1µg of kidney RNA was extracted from all kidneys and subjected to Illumina Tru-Seq RNA 
Sample Preparation protocol. Briefly, oligo-dT attached magnetic beads are used to purify the 
poly-A containing mRNA molecules. Following purification, the mRNA is fragmented using 
divalent cations under elevated temperature. The cleaved RNA fragments are then copied into first 
strand cDNA using reverse transcriptase and random primers and second strand cDNA using DNA 
Polymerase I and RNase H. The cDNA fragments the undergo end repair processing, have the 
addition of a single ‘A’ base, and then ligation of the adapters. The products are then purified and 
enriched with PCR to create the final cDNA library. Kidney samples were then sequenced with 
75-bp paired end reads on an Illumina HiSeq 4000. All generated raw reads were stored in FASTQ 
format. The base call and read quality were evaluated using FASTQC. The input library 
complexity was assessed using RNA-SeQC. The pre-processing of reads for adapter trimming was 
conducted by Trimmomatic. The reads were then pseudo-aligned to the GRCh38 Ensembl 
transcriptome reference (Ensembl release 83); and expression was quantified in transcripts per 
million (TPM) at a transcript level using Kallisto. Transcript expression values were then summed 
to give gene-level quantification. 
 
2.5.2   RNA-sequencing pre-processing 
The generated raw reads from RNA-sequencing were stored in FASTQ format, where the base call 
and read quality were evaluated using FASTQC. Input library complexity was assessed using 
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RNA-SeQC and pre-processing of reads for adapter trimming was conducted using Trimmomatic. 
The reads were then pseudo-aligned to the GRCh38 Ensembl transcriptome reference (Ensembl 
release 83; and expression was quantified in transcripts per million (TPM) at a transcript level 
using Kallisto; a RNA-quantification program that is two orders of magnitude faster than previous 
approaches and achieves similar accuracy [125].  
 
2.5.2.1  RNA-sequencing preprocessing computational analysis 
Kallisto removes unnecessary computational technicality from RNA-sequencing analysis by 
pseudo-aligning reads to a reference, producing a list of transcripts that are compatible with each 
read while avoiding alignment of single bases. Transcript expression values were then summed to 
give gene-level quantification. Outlier samples were removed based on a statistic described in 
Wright et al [126] or based on pairwise correlation between samples, where samples were excluded 
if their median correlation was below 0.75. Samples without matching genotype data were also 
excluded. Only genes located on autosomal chromosomes were considered for downstream 
analyses. A threshold of genes expression was set at TPM>0.1 in at least 50% of samples and 
minimal read counts ≥6. A gene was also removed if its interquartile range equaled zero. Only 
genes that passed all of the above RNA-seq quality control filers were selected for downstream 
analyses.  
 
2.5.3   RNA-sequencing data normalisation 
2.5.3.1  RNA-sequencing preprocessing computational analysis 
Prior to any statistical analyses, gene-level TPM values were normalised (Figure 2.4 A-C). First, 
log2 of TPM values were normalised across samples using robust quantile normalisation with an 
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offset of one. The quantiles normalised gene expression values were transformed using rank-based 
inverse normal transformation. Outlying observations were set to missing using residuals from 
robust linear regression and were then imputed using linear regression. To account for hidden 
variation in RNA-seq data due to technical processing (such as batch effects or sample processing 
in pre-sequencing stage), we used probabilistic estimation of expression residuals (PEER) method 
[127] and estimated 30 hidden factors for TRANSLATE Study. The numbers of hidden factors 
were chosen based on sample sizes of each dataset as recommended in GTEx eQTL analysis [128]. 
The estimated hidden factors were used as covariates in all downstream regression analyses where 
appropriate. 
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Figure 2.4 Principal components plot of TRANSLATE normalisation process. A) PCA plot of TRANSLATE sample RNA-
sequencing raw TPM reads demonstrates clustering by batch using the first two principal components. B) PCA plot of 
TRABSLATE sample RNA-sequencing quantile normalised data showing clustering by batch using the first two 
principal components. Batch 3 was removed from the analysis due to small sizing, and sample ID KID 18 was removed 
due to probable sample contamination. C) PCA plot of TRANSLATE sample residuals demonstrates that PEER has 
removed the batch effects and clustering is no longer visible by batch number; plotted using the first two principal 
components.   
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Chapter 3.  Global leukocyte and kidney 
DNA methylation in essential 
hypertension 
 
 
 
 
 
 
 
 
 
“Somewhere something incredible is waiting to be known” 
 
~ Carl Sagan 
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Chapter 3. Global leukocyte and kidney DNA 
methylation in essential hypertension 
 
3.0  Abstract 
It is evident that a combination of lifestyle factors and genetic predisposition contribute to the 
development of EH. However, relatively little is known about the mechanisms by which global 
DNA methylation influences BP. The purpose of this section of my PhD is to investigate the 
relationship between EH and global methylation levels in leukocyte and kidney DNA. We found 
no relationship between HTN diagnosis and global methylation percentage in either peripheral 
blood leukocyte or kidney DNA. However, a negative correlation was found between global 
methylation percentage in the kidney and DBP. This relationship was not evident after adjustment 
for the use of antihypertensive medication. Our array-based calculation of global methylation 
found no association between HTN diagnosis/ BP values, and median kidney methylation beta-
value or m-value. This conflicting information highlights the need for a more sensitive 5mC 
detection method than the ELISA assay.   Finally, to validate peripheral blood as a surrogate tissue 
for methylation findings in the kidney, we investigated the correlation between 5mC percentage 
in both leukocyte and kidney DNA. No correlation was evident, suggesting that blood may not 
provide a reliable alternative to HTN related human tissue that is more difficult to obtain, such as 
the kidney.  
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3.1  Introduction 
Global methylation refers to the measure of genome-wide cytosine methylation, expressed as a 
percentage [129]. However this term has been used interchangeably, and perhaps inappropriately, 
to describe measurement of cytosine methylation of repetitive elements or of multiple gene regions 
[129]. The role of DNA methylation in cancer has been extensively discussed [130-141]. The key 
findings state broadly that tumour development is associated with increased DNA methylation at 
CpG islands, loss-of-imprinting, and epigenetic remodelling of repeat elements, particularly loss 
of DNA methylation at satellite DNA [142, 143]. Studies reporting the association between global 
DNA methylation and the etiology of complex, non-cancerous diseases are more prevalent in the 
last decade (Table 3.1). Interestingly, recent data shows an association between global DNA 
methylation and the severity of CVD [110], atherosclerotic lesions [111, 144], frailty in the elderly 
[112], plasma homocysteine levels [113], chronic kidney disease [114], insulin resistance [115], 
coronary artery disease [145] and HTN [146].  
 
Studies reporting on global methylation in the HT population are scarce, highlighting the need for 
further research in this area. However, the small portion of information available, suggests that 
global methylation percentage in humans decreases as the severity of HTN increases [101]. 
Furthermore, global DNA methylation in the kidney has not been investigated. Implication of the 
kidney in HTN can be dated back almost 200 years [147, 148], but it wasn’t until 1972 that Guyton 
and Colleagues developed a mature hypothesis suggesting that the kidney governs the level of BP 
by regulating extracellular fluid volume, which Guyton called pressure-natriuresis [8]. The 
hypothesis by Guyton and Colleagues further stated that any modification of the pressure-
natriuresis response can result in chronic elevation of intra-arterial pressure via an equilibrium 
shift between salt and water [8]. Cross transplantation studies conducted in the 1970s further 
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highlighted the key role of intrinsic functions of the kidney in the pathogenesis of HTN [42, 149, 
150].  Studies by Dahl et al [149, 150] discovered that transplantation of a from a Dahl HT (salt 
sensitive) kidney into a NT (salt resistant) rat induced HTN in the recipient. Contrastingly, 
reciprocal transplantation of a kidney from a NT rat into a Dahl HT rat abolishes HTN. These 
findings were also investigated in the SHR and the Milan HT rat with comparable findings  [42, 
151].  This was followed by a human study in 1982 [152], where six patients with EH received 
kidney transplants from NT donors. At a 4.5 year follow-up, all patients were NT and had evidence 
of reversal of HT damage to the heart and retinal vessels [152]. It is predicted that these effects are 
a consequence of epigenetic modifications. 
 
Although the design of GWAS and epigenome-wide association studies appear to be similar, the 
dynamic nature of epigenomics presents challenges for successful study design that are not 
encountered in GWAS. Among these challenges is the selection and collection of the most 
appropriate tissue to be investigated, since epigenetic landscapes are tissue-specific and genomic 
context dependent [153]. For epigenome-wide association studies, availability of human target 
tissue is problematic. Therefore, surrogate tissues are often used, and peripheral blood is the most 
common.  However, the utilisation of peripheral blood for the majority of epigenome research 
presents a question to the applicability of blood for non-blood based diseases and phenotypes. In 
this chapter we hypothesised that blood is a quality surrogate tissue for methylation patterns in the 
kidney. Therefore, the aim of this section of my PhD is to determine if global DNA methylation 
in the kidney is correlated to HTN diagnosis. Further, can peripheral blood leukocytes provide a 
surrogate for cross-tissue patterns of DNA methylation in the HT kidney? Lastly, the existing 
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methods for measurement of 5mC are unreliable, therefore we aim to investigate the use of array-
based methods for the calculation of global 5mC percentage. 
 
Table 3.1  Summary of global methylation findings 
Reference Tissue Type/ Sample Size Findings 
 
 
Kim et al. 
[110] 
 
Human: PBL;  286; 129 male, 
157 female 
 
Elevated PBL DNA methylation is positively 
associated to CVD prevalence/ predisposing 
conditions. 
 
Lund et al. 
[111] 
Human: monocyte cell line 
Mice: PBMC; PBL; aorta  
Altered DNA methylation present in aorta and 
PBMC of apolipoprotein E mutant mice. 
Atherogenic lipoproteins promote global 
hypermethylation in human monocyte cell line.  
 
Bellizzi et 
al. [112] 
 
Human: 37; PBLs Loss of global DNA methylation levels and 
frailty occurs in aging. 
Castro et 
al. [113] 
Human: plasma; 17 vascular 
disease, 15 controls 
DNA methylation status significantly correlated 
with plasma tHcy and AdoHcy. 
 
Stenvinkel 
et al. [114] 
Human: 191; 37 CKD stage 3 & 
4; 98 CKD stage 5; 20 
haemodialysis patients; 36 
healthy controls 
 
Global DNA hypermethylation is associated with 
inflammation and increased mortality in CKD 
 
Zhao et al. 
[115] 
Human: PBL; 84 monozygotic 
twins 
Global hypermethylation associated with insulin 
resistance. 
 
Sharma et 
al. [145] 
Human PBL; 287; 137 CAD 
patients, 150 controls 
 
Global DNA methylation significantly increased 
in CAD patients. 
 
Smolarek 
et al. [101]  
Human: Peripheral blood; 60 
with EH; 30 controls 
Mean 5mC amount in DNA significantly 
decreased as HTN severity increased. 
 
PBL, peripheral blood leukocytes; PBMC, peripheral blood monocytes; AdoHcy, S-
adenosylhomocysteine; tHcy, total homocysteine; HTN, hypertension; CAD, coronary artery 
disease; CKD, chronic kidney disease 
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3.2   Methods 
3.2.1   Participants and sample collection  
For recruitment details of TRANSLATE study participants refer to Chapter 2. Renal samples, 
consisting of approximately 1 cm3 of kidney tissue, were collected from the healthy (unaffected 
by cancer) pole of the kidney immediately post nephrectomy. These samples were immediately 
transferred to either RNA later (Ambion, Austin, Tex) or dry tubes and preserved at -70°C before 
renal DNA and RNA extractions [116-118].  
 
Kidney DNA was extracted from 96 homogenised renal tissue samples using Qiagen purification 
kits for total DNA (Qiagen). Leukocyte DNA was extracted from peripheral blood using QIAamp 
DNA mini blood extractions kit (Qiagen). Histological processing of the kidney tissue was also 
conducted at this time.   
 
3.2.2  Global kidney and leukocyte DNA methylation detection 
For the global methylation analyses we utilised 75 human peripheral blood leukocyte samples 
(Table 3.3 and Table 3.4) and 94 human kidney samples (Table 3.5 and 3.6) from the 
TRANSLATE study, respectively. Of the 75 peripheral blood leukocyte samples, 28 were a subset 
from the same participants that provided renal tissue. Kidney and leukocyte DNA (100ng) 
underwent global DNA methylation analysis using the 5mC ELISA kit (Zymo Research, USA). 
Where 100ng of DNA from each sample (at 10ng/µL) was added to a PCR tube before adding 
90µL of 5mC coating buffer to make a final volume of 100µL. The DNA was then denatured at 
98°C for five minutes, transferred immediately to ice for ten minutes, samples were transferred to 
5mC ELISA 96 well plate, covered, and then incubated at 37ºC for one hour. During the blocking 
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stage, each well was washed three times with 200µL of 5mC ELISA buffer, before a final addition 
of 200µL of 5mC ELISA buffer was added and the plate was incubated at 37°C for 30 minutes. 
During the antibody addition stage, the buffer was discarded from the wells and 100µL of prepared 
antibody mix (Table 3.2) was added to each well before incubation at 37ºC for one hour. During 
the colour development stage, the buffer was discarded from the wells, and the wells were washed 
in triplicate with 200µLof 5mC buffer. HRP developer (100µL) was added to each well and 
allowed to develop for 60 minutes at room temperature.  
 
Table 3.2          Antibody solution preparation for 5mC ELISA protocol 
 
 Dilution Volume (µl) Example (18 wells) 
5mC ELISA Buffer N/A (# wells + 2) 100 2,000 µl 
Anti-5-Methylcytosine 1:2,000 Buffer Vol. / 2,000 1 µl 
Secondary Antibody 1:1,000 Buffer Vol. / 1,000 2 µl 
Antibody solution preparation for 5mC ELISA protocol. Prepared antibody mix for detection of 
5mC in peripheral blood and kidney samples.  
 
All samples were measured in duplicate and calibrated against 0%-100% methylated controls 
(provided pre-made with the Zymo ELISA kit) with a standard curve. Absorbance was measured 
at 450 nm using the Multiskan FC Microplate Photometer (Thermo Scientific, Australia) and 
average global DNA methylation was calculated using the formula generated from the standard 
curve.  
 
56 | P a g e  
 
Global methylation in the kidney was further investigated using the data generated from the 
Infinium HumanMethylation 450K BeadChip (Illumina) (Chapter 2: method 2.4) by the 
calculating the mean of all CpG site beta-values between the HT and NT samples.  
3.2.3  Global methylation - statistical analysis 
An analysis of variance (ANOVA) was used to determine the relationship between global 
methylation of the kidney/ leukocyte DNA and HTN (IBM SPSS for Windows: version 21), with 
adjustment made for the antecedent covariates gender, age, and BMI. Five samples [PKPOZ3, 
PKPOZ2, PKPOZ67, PKPOZ71, and PKPOZ82] were excluded from the kidney analysis due to 
miss labelling of samples or miscalculated global 5mC. Similarly, four samples [KID6, PKZAB68, 
PKZAB11, and KID46] were excluded from the leukocyte DNA analysis due to missing 
phenodata. Further, a Pearson’s correlation analysis was used to determine any relationship 
between global methylation of the kidney/ leukocyte DNA and BP (IBM SPSS for Windows: 
version 21). A Pearson’s correlation analysis was also utilised to determine if peripheral blood 
leukocytes provide a surrogate for cross-tissue patterns of methylation in the kidney (IBM SPSS 
for Windows: version 21).   
 
3.2.4 Genome-wide, loci specific DNA methylation analysis – array 
based calculation of global methylation 
Genome-wide kidney DNA methylation was investigated using the Infinium HumanMethylation 
450K BeadChip (Illumina) according to the manufacturer’s guidelines with assistance from the 
Australian Genome Research Facility (Perth, Australia). For a description of this methodology see 
Chapter 2 methods.   
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3.2.4.1  Array based calculation of global methylation – statistical analysis 
To further validate the global kidney DNA findings, the median beta-value and m-value for all 
samples included in the 450K methylation array were calculated using R software. Linear 
regression was used to investigate the relationship between median global beta-value/ m-value and 
HTN diagnosis. This data was also adjusted for the effects from age, BMI, smoker status and 
gender. Two samples [PKPOZ2, PKPOZ3] (Chapter 2: Figure 2.3) were excluded from the 
analysis due to mismatched labelling.   
3.3  Results 
 
3.3.1  ELISA-based global DNA methylation 5mC percentage in 
peripheral blood leukocytes 
A total of 75 peripheral blood leukocyte samples from TRANSLATE study were included in the 
global methylation analysis. The clinical characteristics of the leukocyte sample participants are 
outlined in Table 3.3 and Table 3.4. We used ELISA-based chemistry (Zymo Research, Integrated 
Sciences, NSW) to investigate the relationship between EH and mean global 5mC percentage in 
peripheral blood leukocytes. After adjusting for the ELISA plate, HT leukocyte 5mC percentage 
was not significantly different to the mean 5mC percentage in the NT leukocyte controls (P=.383) 
(Figure 3.1). Further, no correlation was evident between leukocyte global DNA methylation 
percentage and unadjusted SBP (r=0.06, P=.825) and unadjusted DBP (r=0.10, P=.478) (Figure 
3.2), or adjusted SBP (r=0.07, P=.724) and adjusted DBP (r=0.14, P=.279) (Figure 3.3). 
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Table 3.3          Leukocyte sample numeric variables – global methylation 
Variables Mean ± SD Median (IQR) N 
Age (years) 63.2 ± 12.8  62.5 (58.0-70.8) 75 
Body mass index (BMI) 27.9 ± 5.1 27.7 (25.3-30.4) 75 
SBP (mmHg) 133.8 ± 15.0 133.3 (126.7-141.7) 75 
DBP (mmHg) 78.2 ± 10.0 78.3 (73.3-83.3) 75 
Waist circumference (cm) 95.7 ± 16.0 96.0 (88.0-104.0) 73 {2} 
Adjusted SBP (mmHg) 143.0 ± 20.8 143.3 (133.3-154.1) 75 
Adjusted DBP (mmHg) 74.3 ± 11.7 83.3 (78.3-90.0) 75 
Creatinine µmol/L 82.2 ± 21.9 76.9 (67.4-89.3) 75 
Serum sodium mmol/L 140.6 ± 3.0 141.0 (139.3-142.3) 73 {2} 
Serum potassium mmol/L 4.5 ± 0.6 4.5 (4.2-4.7) 72 {3} 
Glucose mmol/L 6.0 ± 0.9 5.6 (5.1-6.0)  59 {16} 
Four samples excluded due to missing phenodata: KID 46, KID 6, PKZAB 11, PKZAB 68; {x}, 
excluded/ unknown 
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Table 3.4          Leukocyte sample categorical variables – global methylation 
Variable N 
Hypertension % Yes 52 (70%) 
Sex (M) 44 (59%) 
Diabetes (Y) 14 (19%) 
Smoker status 72 {2} 
           Current smoker 3 (4%) 
           Ex-smoker 34 (47%) 
           Non-smoker 35 (49%) 
Chronic Kidney Disease (Y) 2 (3%) 
Coronary Artery Disease (Y)  15 (20%) 
Peripheral Artery Disease (Y) 4 (5%) {2] 
Antihypertension medication (Y) 45 (61%) 
Lipid lowering treatment (Y) 17 (24%) {2} 
Alcohol consumption  72 {2} 
         Drinker 42 (58%) 
         Excessive drinker 0 (0%) 
         Teetotal 30 (42%) 
Paternal history of Hypertension  (Y) 7 (10%) {2} 
Maternal history of Hypertension (Y) 18 (25%) {2} 
( x %), percentage of the total analysed population; { x }, excluded/ unknown.  Four samples 
excluded due to missing phenodata: KID 46, KID 6, PKZAB 11, PKZAB 68 
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Figure 3.1 Global methylation percentage - normotensive and hypertensive peripheral 
blood leukocytes. HT leukocyte 5mC percentage is not significantly different to 
the NT leukocyte control P=.383.  
 
Figure 3.2 Global methylation percentage – unadjusted blood pressure: peripheral blood 
leukocytes.  Global methylation percentage showed no correlation to unadjusted 
(for medication effects) SBP (r=0.06, P=.825) or unadjusted DBP (r=0.10, P=.478). 
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Figure 3.3  Global methylation percentage – adjusted blood pressure: peripheral blood 
leukocytes.  Global methylation percentage showed no correlation to adjusted SBP 
(r=0.07, P=.724) or adjusted DBP (r=0.14, P=.279). BP is adjusted (+15mmHg 
systolic, +10mmHg diastolic) to account for the effects of antihypertensive 
medication.  
 
3.3.2 ELISA-based global DNA methylation 5mC percentage in the 
kidney 
Ninety-four renal samples from the TRANSLATE study were included in the ELISA-based global 
methylation analysis in the human kidney. The clinical characteristics of the renal sample 
participants are outlined in Table 3.5 and Table 3.6. After adjustment, the HT kidney 5mC 
percentage was not significantly different to the mean 5mC percentage in the NT kidney controls 
(P=.245) (Figure 3.4).  However, a negative correlation was found in the kidney for unadjusted 
DBP (r=-0.23, P=.037), but not unadjusted SBP (r=-0.11, P=.374) (Figure 3.5). The significant 
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negative correlation for was not preserved when BP values were adjusted for the effect of 
antihypertensive medication (+15 mmHg systolic, +10 mmHg diastolic) for both SBP (r=-0.08, 
P=.265) and DBP (r=-0.17, P=.068) (Figure 3.6).   
 
Table 3.5          Kidney methylation sample numeric variables – global methylation  
Variables Mean ± SD Median (IQR) N 
Age (years) 63.2 ± 13.8 63.0 (56.0-69.8) 94 
Body mass index (BMI) 28.4 ± 5.9 28.1 (24.9-30.8) 94 
Systolic blood pressure (mmHg) 140.5 ± 20.3 141.0 (130.0-150.3) 93 {1} 
Diastolic blood pressure (mmHg) 86.1 ± 12.0 86.7 (80.0-92.0) 93 {1} 
Waist circumference (cm) 97.24 ± 13.5 96.0 (91.50-105.0) 92 {2} 
Adjusted systolic blood pressure (mmHg) 149.6 ± 26.7 150.3 (135.0-161.7) 93 {1} 
Adjusted diastolic blood pressure (mmHg) 92.1 ± 18.4 91.0 (83.3-101.7) 93 {1} 
Creatinine µmol/L 89.4 ± 31.4 86.3 (71.1-102.5) 94 
Serum sodium mmol/L 139.8 ± 3.7 140.0 (138.0-141.7) 92 {2} 
Serum potassium mmol/L 4.4 ± 0.7 4.3 (4.0-4.7) 91 {3} 
Glucose mmol/L 6.0 ± 0.8 5.8 (5.5-6.3) 82 {12} 
Two samples excluded due to mismatched phenodata: PKPOZ 2, PKPOZ 3; {x}, excluded/ 
unknown 
 
 
 
 
 
Table 3.6         Kidney methylation sample categorical variables – global methylation 
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Variable N 
Hypertension % Yes 69 (73%) 
Sex (M) 64 (68%) 
Diabetes (Y) 17 (18%) 
Smoker status 93 {1} 
           Current smoker 12 (13%) 
           Ex-smoker 42 (45%) 
           Non-smoker 39 (41%) 
Chronic Kidney Disease (Y) 1 (1%) 
Coronary Artery Disease (Y)  18 (19%) 
Peripheral Artery Disease (Y) 5 (5%) {2} 
Antihypertension medication (Y) 56 (60%) 
Lipid lowering treatment (Y) 13 (14%) {2} 
Alcohol consumption  92 {2} 
         Drinker 64 (68%) 
         Excessive drinker 0 (0%) 
         Teetotal 28 (30%) 
Paternal history of Hypertension  (Y) 15 (16%) {1} 
Maternal history of Hypertension (Y) 24 (26%) {1} 
( x %), percentage of the total analysed population; { x }, excluded/ unknown  
Two samples excluded due to mismatched phenodata: PKPOZ 2, PKPOZ 3 
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Figure 3.4  Global methylation percentage - normotensive and hypertensive kidney. After 
adjustment for the effects of antecedent covariates (age, BMI, gender), the HT 
kidney 5mC percentage was not significantly different to the mean 5mC percentage 
in the NT kidney controls (P=.245). 
 
Figure 3.5  Global methylation percentage – unadjusted blood pressure: kidney. A 
negative correlation trend is evident for unadjusted (for medication effects) SBP 
(r=-0.11, P=.374) however significance level was not reached. Unadjusted DBP 
showed a significant negative correlation (r=-0.23, P=.037).  
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Figure 3.6   Global methylation percentage – adjusted blood pressure: kidney. 
Significance level was not reached for the negative correlation trend for 5mC 
percentage and SBP (r=-0.08, P=.265) and DBP (r=-0.17, P=.068). These BP 
values are adjusted for the effects of antihypertensive medication (+15mmHg 
systolic, +10mmHg diastolic).  
 
3.3.3 Methylation array-based global DNA methylation calculation in 
the kidney 
Inconsistent findings from previous studies of global methylation has highlighted the need for a 
more a reliable 5mC measurement method. To date, calculation of global methylation has not been 
obtained using array based methylation data.  Therefore, to validate the ELISA-based kidney DNA 
methylation 5mC percentage findings, the median beta-value and M-value for all kidney samples 
was calculated from data obtained from the Infinium HumanMethylation450 array. No association 
between HTN diagnosis and median kidney methylation beta-value (P=.850) or M-value (P=.510) 
was evident. Similar findings were evident for SBP beta-value (P=.074) and M-value (P=.798), 
adjusted SBP beta-value (P=.199) and M-value (P=.778). Interestingly, for beta-values, a linear 
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relationship between median global methylation percentage and DBP was established (P=.002), 
however this finding was not transferable for M-values (P=.459). These results were consistent 
when adjusted BP values were used; adjusted-SBP (beta-value P=.218, M-value P=.703), DBP 
values (beta-value P=.023, M-value P=.573). It should be noted that all array-based analyses were 
adjusted for antecedent covariates, BMI, age, smoker status and gender. 
 
3.3.4 Comparative of peripheral blood and kidney DNA methylation 
5mC percentage  
Patterns of DNA methylation are highly variable across tissue types. To date, majority of studies 
of methylation in HTN has been conducted on tissues other than the kidney. To assess the 
applicability of peripheral blood methylation findings to those of the kidney, we investigated the 
correlation between global DNA methylation 5mC percentages of the two tissue types, where both 
blood and kidney DNA was available for the same participant (Table 3.7, Table 3.8). No significant 
correlation was evident between leukocyte and kidney global DNA methylation 5mC percentage 
(r=0.11, P=.244) (Figure 3.7).  
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Table 3.7 Matching leukocyte and kidney samples used for tissue correlation analyses – 
numeric variables of interest 
 
Variables Mean ± SD Median (IQR) N 
Age (years) 63.9 ± 11.5 63.5 (58.5-73.0) 28 
Body mass index (BMI) 28.2 ± 4.2 28.1 (25.5-30.2) 28 
Systolic blood pressure (mmHg) 130.4 ± 25.2 132.3 (125.0-142.3) 28 
Diastolic blood pressure (mmHg) 80.5 ± 7.9 80.0 (76.0-86.7) 28 
Adjusted systolic blood pressure (mmHg) 143.9 ± 10.3 141.9 (135.0-153.1) 28 
Adjusted diastolic blood pressure (mmHg) 86.2 ± 7.6 86.7 (80.0-90.2) 28 
 
 
 
 
 
 
 
 
Table 3.8         Matching leukocyte and kidney samples used for tissue correlation analyses - 
categorical variables of interest 
Variable N 
Hypertension % Yes 22 (79%) 
Sex (M) 20 (71%) 
Diabetes (Y) 10 (36%) 
Antihypertension medication (Y) 17 (61%) 
( x %), percentage of the total analysed population 
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Figure 3.7  Global methylation percentage - leukocyte and kidney. No correlation is evident 
for between leukocyte and kidney 5mC percentage (r=0.11, P=.244). Suggesting 
that blood may not be a good surrogate tissue for kidney based methylation analyses 
findings. 
 
3.4   Discussion 
3.4.1 Global methylation and hypertension diagnosis 
It is evident that a combination of lifestyle factors and genetic predisposition contribute to the 
development of EH. The purpose of this section of my PhD is to investigate the relationship 
between global methylation as a surrogate of epigenetic changes in leukocyte and kidney DNA 
and EH. Unlike previous research findings which report a correlation between global DNA 
methylation and disease, our findings suggest no relationship between HTN diagnosis and global 
methylation percentage in both peripheral blood leukocytes and kidney DNA. However, as HTN 
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is tightly linked with both age [154] and BMI [155], it is likely that associations were lost when 
we adjusted for these covariates. Where the relationship between HT and increasing age can exist 
without weight gain [154] and  overweight and obesity can infer an increased risk of EH in children 
as young as 6-8 years old [155]. The difficulty with investigating global DNA methylation 
percentage in EH is discovering correlations that are not due to the effects of age and BMI. 
 
3.4.2   Global methylation and blood pressure 
Unlike the multidimensional nature of EH, the relationship between global DNA methylation and 
BP, as a singular phenotypical measurement, is more extensively investigated. We found a 
negative correlation between increasing global methylation percentage in the kidney and DBP 
reading, however this correlation was not preserved when DBP values were adjusted for the effect 
of anti-hypertensive medication. This is similar to findings by Smokarek [101] who concluded that 
the global methylation percentage decreased as BP increases. However, there is conflicting 
evidence about global DNA methylation and BP. A study by  Kim et al [110] found that elevated, 
not decreased, DNA methylation was positively correlated to CVD and its complications.  This 
conflicting information highlights the need for a more sensitive 5mC detection method.  
 
3.4.3 Array-based calculation of global methylation 
In this study, we investigate the sensitivity of 5mC detection using the ELISA method by 
comparing the ELSA results with those calculated using an array-based method. In most cases, 
ELISA manufacturer’s claim that the ELISA kit possesses a discriminating power of 1:1000 when 
comparing methylated to unmethylated DNA. However, only large changes in DNA methylation 
(~1.5-2 fold) can be resolved by this method due to the high level of inter- and intra-assay 
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variability [156]. ELISA based assays are typically prone to high variability (based on quality of 
the monoclonal antibody and effectivity of wash steps); thus, they are only suitable for the rough 
estimation of DNA methylation. However, they are quick and easy to perform and provide a cheap 
method for identification of large changes in global DNA methylation. Futhermore, the Zymo 5mC 
ELISA kit is unable to discriminate between 5mC and 5-hydroxymethylcytosine (5hmC) 
detection. This is of significant consequence as functionally, the production of 5hmC seems to 
promote gene expression during active demethylation [157]. Our array-based calculation of global 
methylation found no association between HTN diagnosis and median kidney methylation beta-
value or m-value. Similar findings were evident for SBP and adjusted SBP. A correlation was 
found for DBP, however when the more stringent, m-value was utilised, this relationship was not 
evident.  
 
3.4.4 Peripheral blood methylation as a surrogate for methylation in kidney 
Epigenome-wide studies of HTN focus on modification markers in peripheral blood, since in most 
cases, the target tissue is not accessible from a significant number of live individuals. However, 
DNA methylation can show tissue-specific patterns, which highlights the need for validation of 
the suitability of peripheral blood findings as an investigative tool of DNA methylation in the HT 
population. We compare the blood findings to the kidney as an essential link between the kidney 
and BP control has long been established. Previous cross-transplantation studies have supported a 
key role for intrinsic functions of the kidney in the pathogenesis of HTN [149, 150]. In this study, 
we investigate kidney and leukocyte global methylation patterns in HT participants, where both 
tissue types were available, to determine if methylation patterns in blood closely correlate to 
methylation patterns in the kidney. Our results show no significant correlation between global 
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methylation patterns in the kidney and peripheral blood, suggesting that blood may not be a good 
template for measuring global DNA modification mechanisms in the kidney. These findings are 
in contrast to those of Kato et al [102] who found that blood methylation patterns closely relates 
to those of liver and adipose; however the findings by Kato refer to loci specific methylation, not 
global methylation analysis. Our findings can partly be explained by findings by Reinius et al 
[158], who demonstrated that global CpG methylation between various whole blood cell lines 
differed by up to 22%, indicating that whole blood methylation results may be unintelligible. This 
is of particular importance to our study as the homogenised kidney samples contained a variety of 
different cell types, and therefore the overall methylation percentage may be unreliable.  
 
3.5   Conclusion and future direction   
Our findings demonstrate that in the kidney, but not peripheral blood leukocyte, global DNA 
methylation is correlated to DBP. However no relationship is evident for HTN diagnosis, 
regardless of the tissue type. Furthermore, peripheral blood and kidney global DNA methylation 
patterns are not correlated in both the HT and NT samples, indicating that blood may not be a good 
surrogate tissue for kidney global methylation studies. Furthermore, interpretation of methylation 
profiles where multiple cell types are investigated should be done so with great caution, and 
differences resulting from varying proportions of cell types should be considered. Collectively, 
these findings highlight the importance of further research on the involvement of loci specific 
kidney DNA methylation in EH. In the following chapter, the involvement of genome-wide, loci 
specific DNA methylation in HTN are examined to further understand the mechanisms driving 
chronic BP elevation in humans.  
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Chapter 4. Genome-wide loci specific 
DNA methylation in essential 
hypertension 
 
 
 
 
 
 
 
 
 
“Science is a beautiful gift to humanity, we should not distort 
it” 
 
~ A. P. J Abdul Kalam 
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Chapter 4. Genome-wide loci specific DNA 
methylation in essential hypertension 
4.0  Abstract 
Gene-specific DNA methylation involving several biological pathways related to the pathogenesis 
of HTN has been discovered. However these studies relied on either, a small number of samples 
or used only peripheral blood tissue. This section of my PhD contributes to the knowledge of the 
polygenic form of HTN by highlighting the mechanism responsible for altered gene expression in 
the kidney and provides several new insights into HTN-related DNA methylation changes in the 
human kidney. Firstly, we identify individual CpG sites where differential methylation is 
associated with either HTN diagnosis, or SBP and DBP. We discover novel differential 
methylation in CpGs not previously associated to BP in the human kidney, among these are sites 
involved in pathways regulating transport of glucose, organic acids and amine compounds; 
circadian rhythm; neural development; transport of monocarboxylates; peptidase activity; 
transcriptional regulation; insulin signalling; cell cycle progression; metabolism; GCPR 
signalling; nuclear receptors in lipid metabolism and toxicity; and RNA processing. Second, we 
identify differentially methylated CpG islands that are associated with either HTN diagnosis or 
well as SBP and DBP. Among these are differentially methylated islands located in the NTRK2, 
SLC12A7 and SLC17A7 gene regions, all which have been previously implicated in BP-related 
studies. In finality, we conduct a correlation analysis of BP-associated, methylated CpG sites in 
the kidney and pre-existing GWAS findings of BP-associated loci in blood. We found four loci 
that overlap in the human kidney and in blood methylation studies, including CXXC5, CDK6, 
PPP2R5A and ANKRD11; highlighting the cross-tissue applicability of our findings.  
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4.1  Introduction 
In Chapter 3, global DNA methylation was found to be a possible modulator of DBP in the kidney. 
However, a direct relationship between global DNA methylation and HTN was not evident. 
Further, the methods for detecting global methylation require more refining. In this section of my 
thesis, I investigate the role of epigenome-wide, loci specific DNA methylation in the kidney, as 
a potential driver of BP change in the HT population. Studies identifying multiple genetic loci 
(Table 4.1), each with a small contribution to the common polygenic form of HTN, have been 
uncovered by GWAS in very large number of subjects [102, 103]. The accepted inference from 
GWAS is that the genetic code lays the foundation for transcriptomic changes and in turn 
physiological changes. On the other side of the coin, environmental factors (smoking, diet, 
chemical exposure) [159] can in turn affect DNA itself [34] in genes relevant to BP. Variation in 
epigenetic forms of modification may thus explain additional phenotypic variation in BP and 
provide new clues to the physiological processes influencing its regulation. DNA methylation is 
one of these epigenetic mechanisms responsible for changes to gene expression, activated by 
interaction with environmental triggers [102, 160].  
 
The most robust study on the involvement of loci specific DNA methylation in BP regulation 
comes from a 2017 GWAS [102]. This study identified genetic variants at 12 new loci that 
correlated to BP modulation. An investigation of the relationship between the sentinel BP single 
nucleotide polymorphisms (SNPs) with local DNA methylation in 1,904 South Asians (peripheral 
blood; Illumina Human Methylation 450 Bead Chip array (Erasmus Medical Centre, Rotterdam, 
The Netherlands) revealed a two-fold enrichment between sequence variation and DNA 
methylation. Twenty-eight of the 35 sentinel SNPs were associated with one or more methylation 
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markers [102], suggesting that DNA methylation may lie on the regulatory pathway linking 
sequence variation and BP. Genes associated with the 12 newly identified SNP loci include those 
involved with vascular smooth muscle (IGFBP3, KCNK3, PDE3A, PRDM6) and renal function 
(ARHGAP24, OSR1, SLC22A7, TBX2) [102].  
 
A more recent, large scale GWAS by Richard et al [103] discovered that heritable methylation 
sites, independent of known genetic variants, explain an additional 1.4% and 2.0% of the inter-
individual variation in SBP and DBP respectively. Although these studies provide tantalising 
evidence for the role of methylation all were conducted in the easily accessible leukocyte DNA.  
Since DNA methylation patterns are highly variable across different tissues [36], utilisation of 
peripheral blood for non-blood based diseases and phenotypes has not been validated.   
 
Pathophysiologically, the kidney is known as the key organ of BP regulation and one of the most 
important contributors to HTN. According to the hypothesis put forward by Guyton, over 40 years 
ago [161, 162], the control of BP in the steady-state and longer-term is critically dependent on 
renal mechanisms. In fact, almost all monogenic forms of HTN are driven by rare mutations in 
genes involved in salt handling in the distal nephron. It is therefore crucial to understand kidney 
DNA methylation changes that may drive gene expression in kidney and lead to HTN. 
Furthermore, as DNA methylation patterns display tissue specificity, it is important to characterise 
DNA methylation changes in the kidney itself. Recent genome-wide approaches have discovered 
that some CpG islands have distinct methylation patterns in various tissues, with the most dramatic 
changes evident in germ cells and somatic tissues [163-165]. Few studies have addressed this in 
human somatic tissues, and to date no studies have investigated kidney DNA methylation patterns 
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associated with HTN. In this chapter we hypothesised that genome-wide, locus specific DNA 
methylation is the fundamental link driving chronic BP elevation in the human kidney.  Therefore, 
here we conducted a genome-wide analysis of DNA methylation changes in the human kidney to 
identify epigenetic signatures of HTN using the largest collection of apparently healthy human 
renal tissue.  
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Table 4.1 Summary of genome-wide methylation findings in relation to hypertension 
Reference Tissue Type/ Sample Size 
 
Findings 
Kato, et 
al. [20] 
Blood, muscle, liver, fat; 
320,251 individuals of East 
Asian, European and South 
Asian ancestry 
Discovered to be correlated with BP modulation. 
Two-fold enrichment discovered between DNA 
methylation and sentinel BP SNPs, providing 
evidence for DNA methylation role in BP 
regulation. 
 
Richard et 
al. [103] 
 
Human: Peripheral blood, 
17,010 individuals of 
European, African American, 
and Hispanic ancestry 
 
The replicated methylation sites are heritable and 
independent of known BP genetic variants, 
explaining an additional 1.4% and 2.0% of the 
interindividual variation in SBP and DBP, 
respectively. 
 
Friso, et 
al. [21] 
 
Human: Peripheral blood; 25 
with EH; 32 with prednisone 
therapy 
 
HSD11B2 gene promoter methylation associated 
with EH onset via disruption to THF/The ratio. 
Goyal, et 
al. [22 
Rat: Tissues: brain; 20 MLP 
pups, 17 control pups 
Hypomethylation of RAAS system genes such as 
ACE resulting in HTN in offspring. 
Wang, et 
al. [23] 
Human: Peripheral blood; 8 
EH; 8 control 
PRCP gene hypomethylated in EH, linked to 
disruption in cleavage of angiotensin II and III 
Pei, et al. 
[24] 
Tissue: aorta; 6 SHR; 6 WKY 
control 
 
Atgr1a gene progressively hypomethylated as 
SHR age progressed. Indicating increased 
expression of Atgr1a in aging SHR. 
 
Riviere, et 
al. [25] 
Rat: Cultured endothelial cells 
from WKY 
 
Hypermethylation associated with transcriptional 
repression of sACE, indicating a role for 
epigenetics in sACE modulation during HTN. 
Lee, et al. 
[26] 
Rat: Tissues: aorta, heart; SHR 
and WKY 
 
Hypomethylation of Sic2a2 gene lead to 
increased expression of NKCC1 which was 
positively correlated with HTN. 
 
EH: essential hypertension; MLP: maternal low protein; HTN: Hypertension; SHR: spontaneously 
hypertensive rat, WKY: Wistar Kyoto rat; 5mC: 5-methyl-cytosine; ACE: angiotensin converting 
enzyme; RAAS: renin-angiotensin-aldosterone system; sACE: somatic ACE; SNPs: single 
nucleotide polymorphisms; NKCC1: Na+-K+-2Cl_ cotransporter 1; BP: blood pressure. 
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4.2  Methods 
4.2.1   Participants and sample collection 
The genome-wide, loci specific methylation analysis utilised 94 human kidney samples (Table 4.2 
and Table 4.3) from the TRANSLATE study. All participants of the TRANSLATE study 
underwent detailed clinical phenotyping which consisted of documentation of clinical history (via 
coded questionnaire), basic anthropometry as well as triplicate measures of BP by mercury 
sphygmomanometer. HTN diagnosis was assigned to individuals who had elevated BP greater than 
>140/90 mmHg on at least two separate occasions, and/or were taking antihypertensive 
medications [117]. The subset of TRANSLATE human renal DNA to be utilised in this section 
was chosen to ensure a balanced, yet sufficient, representation of hypertensive patients, both 
medicated and non-medicated. Furthermore, age and gender were balanced between the 
normotensive and hypertensive populations as much as possible with no histological signs of 
nephrosclerosis. 
 
Renal samples, consisting of approximately 1 cm3 of kidney tissue, were collected from the healthy 
(unaffected by cancer) pole of the kidney immediately post nephrectomy. Kidney DNA was 
extracted from 96 homogenised renal tissue samples using Qiagen purification kits for total DNA 
(Qiagen). Leukocyte DNA was extracted from peripheral blood using QIAamp DNA mini blood 
extractions kit (Qiagen).  
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4.2.2  Genome-wide, loci specific DNA methylation analysis  
4.2.2.1   Detection of differentially methylated CpG sites 
Genome-wide kidney DNA methylation was investigated using the Infinium HumanMethylation 
450K BeadChip (Illumina) with assistance from the Australian Genome Research Facility (Perth, 
Australia). Where 1000ng of kidney DNA underwent quality analysis using resolution on a 0.8% 
agarose gel and Nanodrop assessment. From this, 750ng of high quality kidney DNA underwent 
bisulphite conversion with the use of the Zymo EZ DNA Methylation Kit (Zymo Research, USA). 
Bisuphite converted kidney DNA (4uL, at 50ng/mL) was then hybridised with the Infinium 
HumanMethylation450 BeadChip (Illumina). The 450K BeadChip uses two types of Illumina 
chemistry to provide a comprehensive DNA methylation status of over 485,000 CpG sites 
spanning 99.9% of Refseq genes (with an average of 17 CpG sites per gene region distributed 
across the promoter, 5’ untranslated region, first exon, gene body and 3’ untranslated region). 
Apart from a vast majority of CpG islands (covered in 96%), the array provides coverage for island 
shores and the regions flanking them.  The arrays were then processed through Illumina iScan to 
deliver rapid, high resolution imaging of the methylation arrays. DNA methylation is represented 
as a β-value (0-1) which corresponds to the percentage of methylation at a given CpG site (0%-
100%, respectively).  
 
4.2.2.2  Methylation data pre-processing  
For every CpG site interrogated via the 450K array, the intensity of the scanned signal is used to 
calculate a methylated and non-methylated measurement. The raw IDAT files hold this intensity 
information which was extracted from the Illumina iScan. These files also contain a detection P-
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value for every probe, which indicated how well the signal intensity was interpreted (small P 
values correlating with good probe performance).  
 
4.2.2.2.1  Methylation data preprocessing computational analysis 
No probes with a high detection P-value (P = ≥0.5) were detected. Probes located on sex 
chromosomes were removed as the data set contains both males and females, as well as cross 
reactive probes which target repetitive sequences or co-hybridize to alternative sequences that are 
highly homologous to the intended targets and therefore risk generating spurious signals [121]. 
These cross-reactive probes were removed to reduce the risk of invalid conclusion and lack of 
validation in downstream analysis. Similarly, sites that overlapped with SNPs located within a 
probe or within ten base pairs of a probe were excluded, a total of 418,581 CPG probes remained 
for analysis.  
 
4.2.2.3  Methylation data normalisation 
The Illumina 450K array contains two probe types. Type I probes originate from the 450K 
predecessor, the 27K array and contain two probes in the same colour channel to measure 
methylated and unmethylated intensities [122]. Type II probes were designed differently, and use 
one probe and two different colour channels to make the same measurement [122]. The two 
different probe types generate different signals. Therefore, to avoid probe type specific false 
positives, identify technical variation, and increase the chances of detecting DNA methylation 
changes caused by HTN, raw β-values underwent intra-array normalisation. 
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4.2.2.3.1  Methylation data normalisation computational analysis 
Raw β-values underwent intra-array normalisation using the Dasen method implemented through 
the Bioconductor wateRmelon package (version 3.6) [123]. The Dasen method also performs 
between-array normalisation, where the background difference between type I and type II probes 
for both methylated and unmethylated signal intensities are adjusted prior to quantile normalisation 
so that chips ran at different time points are comparable The β-value is then generated from the 
adjusted signal intensities using the equation 1.  
Equation 1:  
β = methylated probe intensity / methylated probe intensity + unmethylated probe intensity. 
All β-values were log-transformed into M-values using the logit function (log2(β/(1-β))). M-values 
are a more valid alternative for detecting DNA methylation changes, as they eliminate the 
heteroscedasticity of higher-and lower-end β-value [124]. The M-value is calculated as the log2 
ratio of the intensity of the methylated probe versus the unmethylated probe (see equation 2). It 
should also be noted that logit transformation further reduced type I/ type II probe bias [124].  
 
Equation 2: 
 !" 	= 	%&'( ) *+,(./,123456,7)9:*+,(./,;<123456,7)9:= 
 
4.2.2.4  Methylation data statistical analysis 
Differentially methylated individual CpG sites and islands in the HT and NT kidney were 
determined using regression (RStudio, GNU General Public License), with adjustment made for 
the antecedent covariates age, BMI, smoker status and gender. Two samples [PKPOZ2, PKPOZ3] 
were excluded from the analysis due to mismatched labelling (Chapter 2, Figure 2.1).  
82 | P a g e  
 
4.3   Results 
4.3.1  Genome-wide methylation analysis in the hypertensive kidney – 
CpG sites 
We used 94 renal samples from the TRANSLATE study (Table 4.2 and Table 4.3) to investigate 
the association of EH diagnosis and its co-existent phenotypic traits with DNA methylation at 
418,581 CpGs interrogated with the Illumina HumanMethylation450 BeadChip. Methylation 
levels at one CpG site (SLC17A7) was associated with HTN diagnosis at an adjusted P-value of 
<.05; three CpG sites (FUBP1, SLC16A4 and PAPLN) were associated with SBP (adjusted P-value 
<.05); 19 CpGs (FUBP1, ZNF526, BBX, PKNOX2, SCG2, PCNXL3, C15orf23, PSMB9, TRIM41, 
TALDO1, REEP3, FRG1, VDR, VARS, SPTB, PHTF1, RIOK3, ZFYVE19, DCP2) were associated 
with DBP (adjusted P-value <.02). Associations of these 23 CpGs (Table 4.4) were adjusted for 
known confounders to HTN and high BP, being body mass index, smoking status, age and gender. 
Full names and biological characterisation of these genes are available in Table 4.5. 
 
4.3.2  Genome-wide methylation analysis in the hypertensive kidney – 
CpG islands 
We also investigated the association of differentially methylated CpG islands with HTN diagnosis 
and its co-existent phenotypic traits (Table 4.6). Two CpG islands were associated with HTN 
diagnosis, located in the HCCA2 (P = 1.44E-05) and SLC17A7 (P = 1.46E-05) gene. One 
differentially methylated CpG island was associated with SBP, located in ILF2 (adjusted P<.03). 
Lastly, 11 CpG islands were associated with DBP (adjusted P<.01), covering the ZNF224, 
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ZMPSTE24, PIGF/ CRIPT, BCL6B, FUZ, SLC12A7, KIAA0664, NTRK2, SLC45A4 and COG3 
genes. Individual CpG sites located within islands are outlined in Table 4.7.   
 
 
Table 4.2 Kidney methylation sample numeric variables – loci specific, genome-wide 
methylation 
 
Variables Mean ± SD Median (IQR) N 
Age (years) 63.2 ± 13.8 63.0 (56.0-69.8) 94 
Body mass index (BMI) 28.4 ± 5.9 28.1 (24.9-30.8) 94 
Systolic blood pressure (mmHg) 140.5 ± 20.3 141.0 (130.0-150.3) 93 {1} 
Diastolic blood pressure (mmHg) 86.1 ± 12.0 86.7 (80.0-92.0) 93 {1} 
Waist circumference (cm) 97.24 ± 13.5 96.0 (91.50-105.0) 92 {2} 
Adjusted systolic blood pressure (mmHg) 149.6 ± 26.7 150.3 (135.0-161.7) 93 {1} 
Adjusted diastolic blood pressure (mmHg) 92.1 ± 18.4 91.0 (83.3-101.7) 93 {1} 
Creatinine µmol/L 89.4 ± 31.4 86.3 (71.1-102.5) 94 
Serum sodium mmol/L 139.8 ± 3.7 140.0 (138.0-141.7) 92 {2} 
Serum potassium mmol/L 4.4 ± 0.7 4.3 (4.0-4.7) 91 {3} 
Glucose mmol/L 6.0 ± 0.8 5.8 (5.5-6.3) 82 {12} 
Two samples excluded due to mismatched phenodata: PKPOZ 2, PKPOZ 3; {x}, excluded/ 
unknown  
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Table 4.3        Kidney methylation sample categorical variables - loci specific, genome-wide 
methylation 
Variable N 
Hypertension % Yes 69 (73%) 
Sex (M) 64 (68%) 
Diabetes (Y) 17 (18%) 
Smoker status 93 {1} 
           Current smoker 12 (13%) 
           Ex-smoker 42 (45%) 
           Non-smoker 39 (41%) 
Chronic Kidney Disease (Y) 1 (1%) 
Coronary Artery Disease (Y)  18 (19%) 
Peripheral Artery Disease (Y) 5 (5%) {2} 
Antihypertension medication (Y) 56 (60%) 
Lipid lowering treatment (Y) 13 (14%) {2} 
Alcohol consumption  92 {2} 
         Drinker 64 (68%) 
         Excessive drinker 0 (0%) 
         Teetotal 28 (30%) 
Paternal history of Hypertension  (Y) 15 (16%) {1} 
Maternal history of Hypertension (Y) 24 (26%) {1} 
( x %), percentage of the total analysed population; { x }, excluded/ unknown  
Two samples excluded due to mismatched phenodata: PKPOZ 2, PKPOZ 3 
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Table 4.4       23 CpG sites associated with essential hypertension and BP 
 
 
CpG probe 
name 
 
Chr 
 
Position 
 
Gene 
Location 
relative to 
gene 
Location 
relative to 
CpG 
island 
 
β 
 
Fold 
change 
 
Adj P-
Value 
 
 
P-Value 
 
 
Associated 
phenotype 
cg23409374 19 49934742 SLC17A7 Body Island 4.812 0.700 <.05 8.24E-08 HTN 
cg08228724 1 78444087 FUBP1 Body N-Shore 6.098 1.008 <.05 7.21E-08 SBP 
cg17749509 1 110934279 SLC16A4 TSS1500 Open Sea 5.265 0.992 <.05 1.68E-07 SBP 
cg10300255 14 73706367 PAPLN 5’UTR Island 4.661 1.007 <.05 3.11E-07 SBP 
cg08228724 1 78444087 FUBP1 Body N_Shore 5.776 1.014 <.02 1.69E-07 DBP 
cg23324123 19 42730293 ZNF526 Body Island 5.559 0.991 <.02 2.10E-07 DBP 
cg15208284 3 107242730 BBX 5'UTR Island 5.205 1.009 <.02 3.02E-07 DBP 
cg22956116 11 125034643 PKNOX2 5'UTR N_Shore 5.051 1.010 <.02 3.53E-07 DBP 
cg20101489 2 224467074 SCG2 5'UTR OpenSea 5.045 1.015 <.02 3.55E-07 DBP 
cg07707380 11 65396146 PCNXL3 Body OpenSea 4.965 0.993 <.02 3.86E-07 DBP 
cg01301233 15 40675452 C15orf23 Body Island 4.865 1.009 <.02 4.27E-07 DBP 
cg16501436 6 32821039 PSMB9; TAP1 
TSS1500; 
1stExon 
Island 4.862 1.008 <.02 4.28E-07 DBP 
cg13228972 5 180651008 TRIM41 1stExon Island 4.739 1.008 <.02 4.85E-07 DBP 
cg09351035 11 748060 TALDO1 Body S_Shore 4.729 1.009 <.02 4.91E-07 DBP 
cg01109287 10 65281299 REEP3 5'UTR Island 4.666 1.010 <.02 5.23E-07 DBP 
cg01543582 4 190862539 FRG1 Body S_Shore 4.629 1.009 <.02 5.43E-07 DBP 
cg23654431 12 48298967 VDR TSS200 Island 4.384 1.009 <.02 6.98E-07 DBP 
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cg21368481 6 31747210 VARS Body OpenSea 4.291 0.992 <.02 7.68E-07 DBP 
cg26210003 14 65290110 SPTB TSS1500 OpenSea 4.260 1.007 <.02 7.92E-07 DBP 
cg00419759 1 114301964 PHTF1 TSS200 Island 4.260 1.008 <.02 7.93E-07 DBP 
cg00306421 18 21033656 RIOK3 Body Island 4.249 1.009 <.02 8.01E-07 DBP 
cg15059511 15 41099719 
ZFYVE19; 
DNAJC17 
5'UTR; 
TSS200 
Island 4.248 1.009 <.02 8.02E-07 DBP 
cg18179833 5 112312951 DCP2 Body Island 4.247 1.009 <.02 8.03E-07 DBP 
Position is Hg19. β – coefficient from linear regression models. Abbreviations: Chr, chromosome; CpG, cytosine-phosphate-guanine; 
TSS1500, 1500 base pair to the transcription start site; 5’UTR, 5-prime untranslated region; body, body of gene; HTN, hypertension 
diagnosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; Island, located within a CpG island; OpenSea, not associated 
with any CpG islands (lone CpG site); N_Shore, north shore of CpG island (<2kbp from island); S_Shore, south shore of CpG island 
(<2kbp from island) 
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Table 4.5        Full names and biological characterisation of genes associated with the 23 differentially methylated CpG sites in hypertension BP  
Gene 
symbol Chr 
Gene 
biotype  Gene description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological 
process (GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
SLC17A7 19 protein coding 
Solute Carrier 
Family 17 
Member 7 
No 
L-glutamate 
transmembrane 
transporter activity, 
inorganic phosphate 
transmembrane 
transporter activity, 
extracellularly glutamate-
gated chloride channel 
activity, symporter 
activity, sodium: 
inorganic phosphate 
symporter activity 
neural retina 
development, 
transport, ion 
transport, sodium 
ion transport, 
phosphate ion 
transport 
integral 
component of 
plasma 
membrane, 
membrane, 
synaptic 
vesicle, cell 
junction 
Glutamate 
transport 
FUBP1 1 Protein coding 
Far Upstream 
Element Binding 
Protein 1 
No 
DNA binding, single-
stranded DNA binding, 
DNA binding 
transcription factor 
activity, RNA binding, 
protein binding 
transcription, 
DNA-templated, 
regulation of 
transcription, 
DNA-templated, 
transcription by 
RNA polymerase 
II, positive 
regulation of gene 
expression 
 
Nucleus, 
nucleoplasm 
biology and 
pathology of 
oligodendrocytes 
SLC16A4 1 Protein 
coding 
Solute Carrier 
Family 16 
Member 4 
Yes 
monocarboxylic acid 
transmembrane 
transporter activity, 
symporter activity 
monocarboxylic 
acid transport, 
transport 
integral 
component of 
plasma 
membrane 
catalyzes the 
transport of 
monocarboxylates 
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Gene 
symbol Chr 
Gene 
biotype  Gene description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological 
process (GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
PAPLN 14 Protein 
coding 
Papilin, 
Proteoglycan Like 
Sulfated 
Glycoprotein 
No 
serine-type 
endopeptidase inhibitor 
activity, peptidase 
activity, zinc ion binding, 
peptidase inhibitor 
activity 
proteolysis, 
negative 
regulation of 
peptidase activity, 
negative 
regulation of 
endopeptidase 
activity 
extracellular 
region 
nonenzymatic 
papilin influences 
cell 
rearrangements 
and modulates 
metalloproteinase
s during 
development, 
turnover, and 
repair 
FUBP1 1 As described above 
ZNF526 19 Protein 
coding 
Zinc Finger 
Protein 526, 
KIAA1951 
No DNA binding, metal ion binding 
transcription, 
DNA-templated nucleus 
transcriptional 
regulation 
BBX 3 Protein 
coding 
BBX, HMG-Box 
Containing No 
 DNA binding 
 
transcription, 
DNA-templated, 
regulation of 
transcription, 
DNA-templated, 
bone development 
nucleus, 
nucleoplasm, 
cytosol 
necessary for cell 
cycle progression 
from G1 to S 
phase 
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Gene 
symbol Chr 
Gene 
biotype  Gene description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological 
process (GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
PKNOX2 11 Protein 
coding 
PBX/Knotted 1 
Homeobox 2 No 
 
RNA polymerase II 
regulatory region 
sequence-specific DNA 
binding, DNA binding, 
actin monomer binding, 
sequence-specific DNA 
binding, actin filament 
binding 
regulation of 
transcription, 
DNA-templated, 
regulation of 
transcription by 
RNA polymerase 
II 
nucleus, 
nucleoplasm, 
cytoplasm, 
actin 
cytoskeleton, 
microtubule 
cytoskeleton 
sequence-specific 
DNA binding and 
actin monomer 
binding 
SCG2 2 Protein 
coding Secretogranin II No 
cytokine activity, protein 
binding, chemoattractant 
activity 
 
 
MAPK cascade, 
angiogenesis, 
negative 
regulation of 
endothelial cell 
proliferation, 
positive 
regulation of 
endothelial cell 
proliferation, 
inflammatory 
response 
 
extracellular 
region, 
extracellular 
space, 
endoplasmic 
reticulum 
lumen, 
secretory 
granule, 
dense core 
granule 
involved in 
chemotaxis of 
monocytes and 
endothelial cells 
and in regulation 
of endothelial cell 
proliferation 
PCNXL3 11 Protein 
coding 
Pecanex Homolog 
3 No - - 
integral 
component of 
membrane 
- 
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Gene 
symbol Chr 
Gene 
biotype  Gene description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological 
process (GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
C15orf23 15 Protein coding 
Kinetochore 
Localized 
Astrin/SPAG5 
Binding Protein 
No    protein binding 
 
mitotic sister 
chromatid 
segregation, cell 
cycle, spindle 
organization, 
chromosome 
segregation, cell 
division 
 
chromosome, 
centromeric 
region, 
kinetochore, 
condensed 
chromosome 
kinetochore, 
spindle pole,  
kinetochore-
microtubule 
interaction for 
faithful 
chromosome 
segregation 
PSMB9; 
TAP1 
6 Protein 
coding 
Proteasome 
Subunit Beta 9; 
 
Transporter 1, 
ATP Binding 
Cassette 
Subfamily B 
Member 
No 
 
endopeptidase activity, 
threonine-type 
endopeptidase activity, 
protein binding, 
peptidase activity, 
hydrolase activity; 
 
ATP binding, peptide 
transporter ATPase 
activity 
 
 
MAPK cascade, 
protein 
polyubiquitinatio
n, stimulatory C-
type lectin 
receptor signaling 
pathway, immune 
system processes; 
 
adaptive immune 
response 
 
proteasome 
complex, 
nucleus, 
nucleoplasm, 
cytoplasm, 
cytosol; 
 
mitochondrio
n, 
endoplasmic 
reticulum, 
endoplasmic 
reticulum 
membrane, 
microtubule 
organizing 
center, 
membrane 
 
 
tightly linked 
cluster of 
interferon-
inducible genes 
within the MHC 
with an essential 
role in antigen 
processing; 
 
translocates 
peptides from the 
cytosol to MHC 
class I molecules 
in the ER 
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Gene 
symbol Chr 
Gene 
biotype  Gene description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological 
process (GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
TRIM41 5 Protein coding 
Tripartite Motif 
Containing 41 No 
protein binding, zinc ion 
binding, transferase 
activity, identical protein 
binding, metal ion 
binding 
- 
intracellular, 
nucleus, 
nucleolus, 
cytoplasm, 
nuclear body 
- 
TALDO1 11 Protein coding Transaldolase 1 No 
 
sedoheptulose-7-
phosphate:D-
glyceraldehyde-3-
phosphate 
glyceronetransferase 
activity, protein binding, 
transferase activity, 
carbohydrate binding, 
monosaccharide binding 
 
carbohydrate 
metabolic 
process, xylulose 
biosynthetic 
process, fructose 
6-phosphate 
metabolic 
process, pentose-
phosphate shunt, 
pentose-
phosphate shunt, 
non-oxidative 
branch 
 
nucleus, 
nucleoplasm, 
cytoplasm, 
cytosol, 
intracellular 
membrane-
bounded 
organelle 
key enzyme of the 
pentose phosphate 
pathway 
REEP3 10 Protein coding 
Receptor 
Accessory Protein 
3 
No - 
 
nuclear envelope 
organization, cell 
cycle, mitotic 
nuclear envelope 
reassembly, cell 
division 
endoplasmic 
reticulum 
membrane, 
microtubule, 
membrane, 
integral 
component of 
membrane 
microtubule-
binding protein 
required to ensure 
proper cell 
division and 
nuclear envelope 
reassembly 
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Gene 
symbol 
Chr Gene 
biotype  Gene description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological 
process (GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
FRG1 4 Protein 
coding 
FSHD Region 
Gene 1 No 
RNA binding, actin 
binding, protein binding, 
actin filament binding 
 
mRNA splicing, 
via spliceosome, 
rRNA processing, 
mRNA 
processing, 
muscle organ 
development, 
RNA splicing 
nucleus, 
spliceosomal 
complex, 
nucleolus, 
cytoplasm, 
Cajal body 
over-expression 
leads to abnormal 
alternative 
splicing of 
specific pre-
mRNAs 
VDR 12 Protein coding 
Vitamin D 
Receptor No 
 
DNA binding, 
contributes to DNA 
binding transcription 
factor activity, steroid 
hormone receptor 
activity, nuclear receptor 
activity, protein binding 
 
negative 
regulation of 
transcription by 
RNA polymerase 
II, cell 
morphogenesis, 
skeletal system 
development, 
transcription, 
DNA-templated, 
regulation of 
transcription, 
DNA-templated 
 
nucleus, 
nucleoplasm, 
cytoplasm, 
receptor 
complex, 
RNA 
polymerase II 
transcription 
factor 
complex 
intracellular 
hormone receptor 
that specifically 
binds 
1,25(OH)2D3 and 
mediates its 
effects 
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Gene 
symbol 
Chr Gene 
biotype  Gene description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological 
process (GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
VARS 6 Protein coding 
Valyl-TRNA 
Synthetase No 
aminoacyl-tRNA editing 
activity, aminoacyl-
tRNA ligase activity, 
valine-tRNA ligase 
activity, protein binding, 
ATP binding 
 
Translation, 
tRNA 
aminoacylation 
for protein 
translation, valyl-
tRNA 
aminoacylation, 
regulation of 
translational 
fidelity, 
aminoacyl-tRNA 
metabolism 
involved in 
translational 
fidelity 
cytoplasm, 
mitochondrio
n, cytosol 
neurodevelopmen
tal disorder with 
microcephaly, 
seizures, and 
cortical atrophy 
SPTB 14 Protein coding 
Spectrin Beta, 
Erythrocytic No 
actin binding, Ras 
guanyl-nucleotide 
exchange factor activity, 
structural constituent of 
cytoskeleton, protein 
binding, ankyrin binding 
 
MAPK cascade, 
ER to Golgi 
vesicle-mediated 
transport, 
cytoskeleton 
organization, 
axon guidance, 
actin filament 
capping 
cytoplasm, 
Golgi 
apparatus, 
cytosol, 
cytoskeleton, 
cell cortex 
anemia, neonatal 
hemolytic, fatal 
and near-fatal, 
Elliptocytosis-3, 
Spherocytosis, 
type 2 
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Gene 
symbol 
Chr Gene 
biotype  Gene description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological 
process (GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
PHTF1 1 Protein coding 
Putative 
Homeodomain 
Transcription 
Factor 1 
No 
DNA binding, DNA 
binding transcription 
factor activity 
transcription, 
DNA-templated, 
regulation of 
transcription, 
DNA-templated 
nucleus, 
endoplasmic 
reticulum, 
cis-Golgi 
network, 
integral 
component of 
membrane 
transcriptional 
regulator that 
control a variety 
of cell fates 
RIOK3 18 Protein coding 
RIO Kinase 3 
 
SudD (Suppressor 
Of BimD6, 
Aspergillus 
Nidulans) 
Homolog 
No 
protein serine/threonine 
kinase activity, protein 
binding, ATP binding, 
kinase activity, 
transferase activity 
immune system 
process, rRNA 
processing, 
protein 
phosphorylation, 
chromosome 
segregation, 
phosphorylation 
 
cytoplasm, 
cytosol, 
preribosome, 
small subunit 
precursor 
- 
ZFYVE19; 
DNAJC17 
15 Protein 
coding 
Zinc Finger 
FYVE-Type 
Containing 19; 
 
DnaJ Heat Shock 
Protein Family 
(Hsp40) Member 
C17 
No 
protein binding, lipid 
binding, 
phosphatidylinositol-3-
phosphate binding, metal 
ion binding; 
 
nucleic acid binding, 
RNA binding 
cell cycle, 
abscission, 
negative 
regulation of 
cytokinesis, cell 
division; 
 
negative 
regulation of 
transcription by 
RNA polymerase 
II,   
cytoplasm, 
centrosome, 
microtubule 
organizing 
center, 
cytoskeleton, 
midbody; 
 
nucleus, 
cytoplasm 
Members of the 
HSP40 family, 
such as 
DNAJC17, are 
involved in 
transcriptional 
regulation 
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Gene 
symbol 
Chr Gene 
biotype  Gene description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological 
process (GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
DCP2 5 Protein 
coding 
Decapping 
MRNA 2 No 
RNA binding, 5-3 
exoribonuclease activity, 
protein binding, 
hydrolase activity, 
exoribonuclease activity, 
producing 5-
phosphomonoesters 
nuclear-
transcribed 
mRNA catabolic 
process, 
nonsense-
mediated decay 
deadenylation-
dependent 
decapping of 
nuclear-
transcribed 
mRNA, mRNA 
catabolic process, 
negative 
regulation of 
telomere 
maintenance via 
telomerase, 
regulation of 
mRNA stability 
P-body, 
nucleus, 
nucleoplasm, 
cytoplasm, 
cytosol 
key component of 
an mRNA-
decapping 
complex required 
for removal of the 
5-prime cap from 
mRNA prior to its 
degradation from 
the 5’UTR 
Position is Hg19. Abbreviations: Chr, chromosome; CpG, cytosine-phosphate-guanine; 5’UTR, 5-prime untranslated region; HTN, hypertension 
diagnosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; mRNA, messenger; DNA, deoxyribonucleic acid; rRNA, ribosomal RNA; ER, 
endoplasmic reticulum; tRNA, transfer RNA; HPA, human protein atlas; GO, gene ontology; MHC, major histocompatibility complex 
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Table 4.6       Differentially methylated renal CpG islands associated with hypertension and BP 
 
CpG island 
 
Chr 
 
UCSC gene 
name 
 
Contains 
CpGs in 
Enhancer 
 
β 
 
Fold 
change 
 
Adjusted 
P-Value 
 
 
P-Value 
 
 
Associated 
phenotype 
chr11:1715347-1715607 11 HCCA2 TRUE 2.912 0.800 <.20 1.44E-05 HTN 
chr19:49934316-49934868 19 SLC17A7 - 2.905 1.062 <.20 1.46E-05 HTN 
chr2:121492857-121495234 2 - - 2.605 1.002 <.03 1.07E-06 SBP 
chr19: 44598374-44598854 19 ZNF224 - 7.638 1.006 <.01 1.08E-08 DBP 
chr1:40723796-40724010 1 ZMPSTE24 - 3.356 1.006 <.01 8.42E-07 DBP 
chr2:46843650-46844332 2 PIGF/ CRIPT - 2.737 1.004 <.01 1.59E-06 DBP 
chr17:6925400-6927527 17 BCL6B TRUE 2.371 0.997 <.01 2.30E-06 DBP 
chr19:50316211-50316469 19 FUZ - 2.239 1.003 <.01 2.41E-06 DBP 
chr6:111279644-111280210 6 GTF3C6 - 2.293 1.000 <.01 2.50E-06 DBP 
chr5:1085140-1085847 5 SLC12A7 - 2.096 0.994 <.01 3.06E-06 DBP 
chr17:2600975-2601980 17 KIAA0664 - 1.824 0.997 <.01 4.04E-06 DBP 
chr9:87283178-87285704 9 NTRK2 - 1.814 1.004 <.01 4.08E-06 DBP 
chr8:142227937-142229160 8 SLC45A4 - 1.798 0.997 <.01 4.15E-06 DBP 
chr13:46038953-46039681 13 COG3 - 1.756 1.003 <.01 4.33E-06 DBP 
Position is Hg19. β – coefficient from linear regression models. Abbreviations: Chr, chromosome; CpG, cytosine-phosphateguanine; 
HTN, hypertension diagnosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; S_Shore, south shore of CpG island (<2kbp 
from island); N_north shore of CpG island (<2kbp from island); island, located within island; S_shelf, located <2kbp from island south 
shore; N_shelf, located <2kbp from island north shore. 
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Table 4.7 Individual CpG sites located within differentially methylated islands – associated with hypertension and blood pressure 
CpG island identification CpG site UCSC gene symbol UCSC gene name Chr Location of CpG relative to island Enhancer 
chr11:1715347-1715607 
cg01467630 HCCA2 
YY1 Associated 
Protein 1/ 
Hepatocellular 
Cancinoma-
Associated Protein 
2 
11 
N_Shore TRUE 
cg09004134 HCCA2 N_Shore  
cg11271329 HCCA2 Island TRUE 
cg16914552 HCCA2 N_Shore TRUE 
cg19749898 HCCA2 N_Shelf  
cg22755008 HCCA2 Island TRUE 
cg00490097 HCCA2; KRTAP5-6 S_Shelf  
cg05096964 HCCA2 N_Shore TRUE 
cg09750643 HCCA2; KRTAP5-6 S_Shelf  
cg26745757 HCCA2 Island TRUE 
       
Chr19:49934316-49934868 
cg02288564 SLC17A7 Solute Carrier 
Family 17 Member 
7 
19 
Island  
cg23409374 SLC17A7 Island  
cg03282345 SLC17A7 Island  
cg18150383 SLC17A7 N_Shore  
       
chr2:121492857-121495234 
cg04882233   
2 
Island  
cg05366156  Island  
cg07154861  Island  
cg08572016  Island  
cg12620942  Island  
cg13467765  Island  
cg14598373  Island  
cg24740509  Island  
cg25432992  Island  
cg02381820  Island  
cg03575764  Island  
cg09417299  Island  
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CpG island identification CpG site UCSC gene symbol UCSC gene name Chr Location of CpG 
relative to island 
Enhancer 
chr2:121492857-121495234 
cg09925014   
2 
Island  
cg13010161  N_Shelf  
cg14123232  Island  
cg18210026  Island  
cg20219891  S_Shore  
cg25371590  S_Shore  
cg26373051  N_Shore  
       
chr19:44598374-44598854 
cg10646633 ZNF224 
Zinc Finger Protein 
224 19 
Island  
cg23041193 ZNF224 Island  
cg25952543 ZNF224 N_Shore  
cg26489638 ZNF224 Island  
cg26649251 ZNF224 Island  
cg01508027 ZNF224 S_Shelf  
cg03238595 ZNF224 Island  
cg03486540 ZNF224 Island  
cg03600886 ZNF224 Island  
cg12477902 ZNF224 S_Shore  
cg18244544 ZNF224 N_Shore  
cg18728325 ZNF224 Island  
cg22012835 ZNF224 N_Shore  
cg23986727 ZNF224 N_Shore  
cg24206978 ZNF224 Island  
       
chr1:40723796-40724010 
 
cg03982820 ZMPSTE24 
Zinc 
Metalopeptidase 
STE24 
1 
Island  
cg09795680 ZMPSTE24 Island  
cg16044925 ZMPSTE24 Island  
cg16418374 ZMPSTE24 Island  
cg25275331 ZMPSTE24 Island  
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CpG island identification CpG site UCSC gene symbol UCSC gene name Chr Location of CpG 
relative to island 
Enhancer 
chr1:40723796-40724010 cg24615751 ZMPSTE24  1 Island  
       
chr2:46843650-46844332 
cg13172254 PIGF; CRIPT 
Phosphatidylinosito
l Glycan Anchor 
Biosynthesis Class 
F/ CXXC Repeat 
Containing 
Interactor Of PDZ3 
Domain 
B Cell 
CLL/Lymphoma 
6B 
2 
Island  
cg18454701  CRIPT; PIGF Island  
cg24868028  PIGF; CRIPT S_Shore  
cg25653703 PIGF; CRIPT  Island  
cg00441231 PIGF; CRIPT  Island  
cg01091258  PIGF; CRIPT S_Shore  
cg03971247 PIGF  N_Shelf  
cg05265562 CRIPT S_Shelf  
cg06654134 CRIPT; PIGF  S_Shore  
cg08813236 CRIPT; PIGF  Island  
cg17456231 PIGF; CRIPT  N_Shore  
cg21493583 PIGF; CRIPT  N_Shore  
cg25246012 CRIPT; PIGF S_Shore  
       
chr17:6925400-6927527 
cg03738253 BCL6B 
B Cell 
CLL/Lymphoma 
6B 
 Island  
cg06700146 BCL6B  Island  
cg10137837 BCL6B  Island  
cg21040575 MIR497; MIR195  N_Shelf  
cg23925513   N_Shore  
cg24720583 BCL6B  Island  
cg00641210 BCL6B  Island  
cg02329670 MIR497; MIR195  N_Shelf  
cg03693706 BCL6B  S_Shore  
cg04430582 MIR195; MIR497  N_Shelf  
cg05560728 BCL6B  N_Shore TRUE 
cg07073814 BCL6B  S_Shelf  
 
 
 
  
  
 
 
100 | P a g e  
 
CpG island identification CpG site UCSC gene symbol UCSC gene name Chr Location of CpG relative to island Enhancer 
 cg07139087 BCL6B   Island  
chr17:6925400-6927527 
cg08786079 BCL6B 
B Cell 
CLL/Lymphoma 
6B 
 S_Shelf  
cg10805819   N_Shore  
cg11263011 MIR195; MIR497  N_Shelf  
cg11353035 BCL6B  Island  
cg14392652 BCL6B  Island  
cg15165676 BCL6B  Island  
cg22975671 BCL6B  Island  
       
chr19:50316211-50316469 
cg11398523 FUZ 
Fuzzy Planar Cell 
Polarity Protein 
 
19 
Island  
cg19763319 FUZ Island  
cg21712019 FUZ Island  
cg22708738 FUZ Island  
cg23348158 FUZ S_Shore  
cg01139412 FUZ S_Shore  
cg02784848 FUZ S_Shore  
cg07452097 FUZ S_Shore  
cg08288330 FUZ N_Shore  
cg10166205 FUZ S_Shore  
cg10971790 FUZ Island  
cg23307385 FUZ S_Shore  
       
chr6:111279644-111280210 
 
cg00531924 GTF3C6  
General 
Transcription 
Factor IIIC Subunit 
6 
6 
Island  
cg00858015 GTF3C6 Island  
cg02930763  N_Shelf  
cg04140496 GTF3C6 N_Shore  
cg12072757 GTF3C6 Island  
cg18659022 GTF3C6  Island  
cg18873593 GTF3C6 Island  
cg00894869 GTF3C6 S_Shore  
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CpG island identification CpG site UCSC gene symbol UCSC gene name Chr Location of CpG 
relative to island 
Enhancer 
 
chr6:111279644-111280210 
 
cg02359132 GTF3C6 
General 
Transcription 
Factor IIIC Subunit 
6 
6 
N_Shore  
cg05449607 GTF3C6 N_Shore  
cg06234342 GTF3C6 N_Shore  
cg06351970 GTF3C6 Island  
cg14801546 GTF3C6 S_Shelf  
cg18710383 GTF3C6  Island  
cg25531478 GTF3C6 N_Shore  
cg26219797 GTF3C6 Island  
       
chr5:1085140-1085847 
cg04380229 SLC12A7 Solute Carrier 
Family 12  Member 
7 
5 
N_Shore  
cg12199905 SLC12A7 Island  
       
chr17:2600975-2601980 
cg08409553 KIAA0664 
Clustered 
Mitochondria 
Homolog 
 
17 
Island  
cg10479243 KIAA0664 N_Shore  
cg11990813 KIAA0664 S_Shore  
cg12035564 KIAA0664 N_Shore  
cg20306425 KIAA0664 N_Shore  
cg01132515 KIAA0664 Island  
cg05389310 KIAA0664 N_Shore  
cg12994911 KIAA0664 Island  
cg13051028 KIAA0664 Island  
cg16575427 KIAA0664 S_Shore  
cg20201957 KIAA0664 S_Shore  
cg20243898 KIAA0664 S_Shore  
cg21733020 KIAA0664 N_Shore  
       
chr9:87283178-87285704 
cg13723118 NTRK2 Neurotrophic 
Receptor Tyrosine 
Kinase 2 
9 
Island  
cg13965062 NTRK2 Island  
cg01009697 NTRK2 Island  
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CpG island identification CpG site UCSC gene symbol UCSC gene name Chr Location of CpG 
relative to island 
Enhancer 
 cg01292475 NTRK2   Island  
chr9:87283178-87285704 
cg03628748 NTRK2 
Neurotrophic 
Receptor Tyrosine 
Kinase 2 
9 
Island  
cg08470639 NTRK2 Island  
cg09539438 NTRK2 Island  
cg09926027 NTRK2 Island  
cg13504245 NTRK2 N_Shore  
cg22402007 NTRK2 N_Shore  
       
chr8:142227937-142229160 
cg10555010 SLC45A4 
Solute Carrier 
Family 45 Member 
4 
 
8 
N_Shore  
cg16341495 SLC45A4 Island  
cg18190534 SLC45A4 N_Shelf  
cg02607124 SLC45A4 N_Shore  
cg04685302 SLC45A4 Island  
cg06588735 SLC45A4 N_Shore  
cg13560841 SLC45A4 Island  
cg20080616 SLC45A4 N_Shore  
cg24855956 SLC45A4 N_Shelf  
cg26441120 SLC45A4 N_Shore  
       
chr13:46038953-46039681 
cg00603717 COG3 
Component Of 
Oligomeric Golgi 
Complex 3 
13 
Island  
cg05597554 COG3 Island  
cg24452930 COG3 Island  
cg02070564 COG3 Island  
cg07439474 COG3 Island  
cg07530947 COG3 S_Shelf  
cg09002231  N_Shelf  
cg10486909 COG3 N_Shore  
cg15201599 COG3 Island  
cg18379624 COG3 N_Shore  
cg18580551 COG3 S_Shore  
cg27523951 COG3 N_Shore  
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Table 4.7  Individuals CpG sites located within differentially methylated renal CpG islands associated with hypertension and blood 
pressure. Abbreviations: S_Shore, south shore of CpG island (<2kbp from island); N_north shore of CpG island (<2kbp from island); island, 
located within island; S_shelf, located <2kbp from island south shore; N_shelf, located <2kbp from island north shore.    
104 | P a g e  
 
4.3.3 Replication analysis of blood pressure-associated methylated CpG 
sites in the kidney and in blood 
We used data obtained from the kidney methylation array with matching BP methylation data obtained 
from a meta-analysis conducted in the blood of 17,010 individuals of mixed ancestry [103]. Of the 126 
CpG sites found by Richard et al [103], 4 overlap with loci that are differentially methylated in the 
kidney and associated with BP (Table 4.8). These include CXXC Finger Protein 5 (CXXC5), involved 
in chromatin regulation and acetylation; Cyclin Dependent Kinase 6 (CDK6), important for cell cycle 
progression; Protein Phosphatase 2 Regulatory Subunit B'Alpha (PPP2R5A), responsible for negative 
regulation of cell growth and division and have been implicated in dilated cardiomyopathy; and 
Ankyrin Repeat Domain 11 (ANKRD11), a histone modification regulator.  
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Table 4.8                 Peripheral blood replicated, blood pressure-associated, differentially methylated CpGs in the human kidney.   
UCSC 
gene 
symbol 
CpG 
number Chr Position 
β 
(CpG 
site) 
P-value Adj P-value  
CpG 
number Chr Position 
β 
(CpG 
site) 
P-
value 
Adj P-
value 
TRANSLATE kidney samples  Relative blood samples 
 
CXXC5 
 
cg00906476 
 
5 
 
139046200 
 
-0.414 
 
4.91E-05 
 
<.20 
 
 
cg22885332 
cg04104695 
 
5 
 
139034002 
139058749 
 
-0.414 
 
4.91E-05 
 
<.20 
CDK6 cg02689293 7 92464971 1.493 1.36E-05 <.05  
cg06688763 
cg15261712 
7 
922382017 
92238248 
1.493 1.36E-05 <.05 
PPP2R5A cg05346855 1 212460169 3.023 2.81E-06 <.05  cg12417775 1 212463238 3.023 2.81E-06 <.05 
ANKRD11 cg08130612 16 89350233 0.069 5.94E-05 <.05  cg05288253 16 89552259 0.069 5.94E-05 <.05 
Position is Hg19. β – coefficient from linear regression models. Abbreviations: Chr, chromosome; CpG, cytosine-phosphate-guanine; 
FDR, false discovery rate. 
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4.4   Discussion 
In Chapter 3 we investigate the association of global methylation with chronic BP elevation. Chapter 
4 focuses on the relationship between genome-wide, loci specific DNA methylation and chronic BP 
elevation. This section of my PhD contributes to the knowledge of the polygenic form of HTN by 
highlighting a potential mechanism responsible for altered gene expression in the kidney and provides 
several new insights into HTN-related DNA methylation changes in the human kidney.  
 
Gene-specific DNA methylation involving several biological pathways related to the pathogenesis of 
HTN has been discovered. These include altered methylation of the RAAS genes, AT1b [166, 167], 
AT1aR [108], ACE [55, 82, 168], ECE-1c [169] and ADD1 [170]; renal sodium retention system 
(RSRS) genes, HSD11B2 [106, 171, 172], NKCC1 [83, 84]; and sympathetic nervous system (SNS) 
genes, NET [109] and FABP3 [173]. Altered DNA methylation of the glucokinase gene, GCK, is also 
significantly associated with increased risk of onset of EH [174]. Genome-wide methylation analysis 
investigates methylation in all promoter and non-promoter CpGs. CpG sites associated with the SULF1, 
PRCP, NEUROG1, PITPNA, SLC26A10, CDC34, C9orf95, YWHAQ, SIRT7 and CLDN5 genes were 
discovered in a genome-wide investigation of peripheral blood leukocytes in eight young, HT, African 
males and eight age matched controls [107]. Similarly, CpGs associated with the FZD7M, LRP, 
TTBK1, USFP1, SYCE1, NDUSF8, ZNF540 and ABCG4 genes were discovered in a methylation 
microarray of six HT and four controls [175]. A recent study investigating methylation of BP loci, 
conducted in 4,513 European individuals identified four (TAF1B-YWHAQ, ZMIZ1, CPT1A, SLC1A5) 
CpG loci with a relationship to BP [103]. However, these studies relied on either a small number of 
samples or used only peripheral blood tissue.  
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4.4.1  Genome-wide methylation analysis in the hypertensive kidney – CpG 
sites 
Firstly, we identify CpG sites where differential methylation is strongly associated with HTN diagnosis 
as well as SBP and DBP. A large portion of these CpG sites have not been identified in BP related 
methylation investigations before, and many of them appear to lie in regions responsible for 
transcriptional regulation. Our analysis was focused primarily on the identification of the genome-wide 
HTN-associated differential DNA methylation in the kidney. Our findings highlight key changes to 
CpG sites located in pathways involving transport of glucose, organic acids and amine compounds; 
circadian rhythm; neural development; transport of monocarboxylates; peptidase activity; 
transcriptional regulation; insulin signalling; cell cycle progression; metabolism; GCPR signalling; 
nuclear receptors in lipid metabolism and toxicity; and RNA processing. 
 
4.4.2 Genome-wide methylation analysis in the hypertensive kidney – CpG 
islands 
Second, we identify differentially methylated CpG islands that are associated with HTN diagnosis as 
well as SBP and DBP. Of particular interest is the methylation of the CpG island located within the 
NTRK2 gene region. NTRK2 is a member of the neurotrophic tyrosine receptor kinase (NTRK) family 
with bias expression in the kidney, brain, gall bladder and adipose. Upon neurotrophin binding, NTRK2 
phosphorylates itself and members of the MAPK pathway, leading to cellular differentiation [176]. 
However, a study by Thameem et al [176] identified SNP variations within the NTRK2 gene exhibited 
associations with renal function. After adjustment for gender, age, diabetes, BP and BP medication, 
NTRK2 variants were identified as a possible regulator of eGFR.  
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Identification of genes responsible for cation-coupled Cl- transport occurred in the early 1990s, in the 
rectal gland of the shark Squalus acanthias [177] and the urinary bladder of the winter flounder 
Pseudopleuronectes americanus [178]. These fish expressed high activities of Na-K-2Cl and Na-Cl 
transporters respectively, which ultimately lead to their identification. Subsequently, the electroneutral 
cation-chloride-coupled cotransporter gene family (SLC12) was identified. This nine-member gene 
family encompasses two major branches, one includes two bumetanide-sensitive Na+-K+-2Cl-  
cotransporters and the thiazide sensitive Na+-Cl- cotransporter. In this branch, two genes (SLC12A1 
and SLC12A3) exhibit kidney-specific expression. The second branch contains four genes (SLC12A4-
7) which encode electroneutral K+-Cl- cotransporters [179]. These four genes are co-expressed in 
majority of tissues and have roles related to cell volume regulation, transepithelial salt transport, 
hearing and function of the peripheral nervous system [179]. Differential methylation related to DBP 
was found in the CpG island associated with the SLC12A7 gene in renal tissue.  Suggesting that 
methylation at this island has a significant role to play in the regulation of DBP.  
 
Numerous aspect of human physiology, such as temperature regulation, hormonal control, autonomic 
tone and metabolism are controlled by circadian rhythms, which are regulated by the suprachiasmatic 
nucleus [180]. Imbalance in the circadian system contributes to the development of disease, such as 
obesity, metabolic syndrome diabetes and CVD [181]. For CVD and HTN it is known that BP is 
influenced by circadian rhythms independent of sleep/wake and fasted/feeding cycles [182]. 
Futhermore, recent studies emphasise a role for peripheral clock genes in cellular processes that 
regulate BP. In the kidney PER1 is associated with regulation of renal epithelial sodium channels [183], 
while other clock genes have also been implicated in vascular endothelial function (Per2) [184] and 
thrombogenesis (BMAL1, CLOCK, and NPAS2) [185]. Solute Carrier Family 17 Member (SLC17A7) 
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encodes a protein that exhibits extracellular glutamate-gated chloride channel activity (VGLUT1). 
Differential methylation of the CpG island associated with the SLC17A7 gene region displayed 
associations with HTN diagnosis. This suggests a role for methylation in the human kidney in the 
regulation of circadian clock genes, potentially implicating methylation in the regulation of the 
suprachiasmatic nucleus.   
 
4.4.3 Replication analysis of blood pressure-associated methylated CpG 
sites in the kidney and in blood 
Four (located in CXXC5, CDK6, PPP2R5A and ANKRD11) of our HTN-related changes in loci-specific 
methylation were in line with blood-based methylation findings in previous studies, which highlights 
the cross-tissue applicability of our findings. At the molecular level the protein coded by CXXC5, also 
known as RINF, contains a zinc finger domain that is identical to that of TET1, TET3 and CXXC4; 
these are epigenetic modulators suggested to be involved in the erasure of DNA-methylation marks, as 
TET proteins are known to oxidise 5mC to 5hmC [186]. Expression of CDK6 is known to be 
upregulated in the spontaneously HT rat [187], similar to these findings CpG loci cg02689293 located 
in the 5’UTR if CDK6 was hypermethylated and overexpressed in the human kidney.  PP2R5A has a 
role in the regulation of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and is 
known to be involved in the pathophysiology of dilated cardiomyopathy type 1D.  Lastly, ANKRD11 
is a chromatin regulator which modulates histone acetylation. Although the actions of the ANKRD11 
gene are not yet understood, differential methylation in this gene region has been associated with renal 
fibrosis and chronic kidney disease  [188].  
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4.5  Conclusion and future direction   
Our findings identify kidney DNA methylation as a mechanism driving chronic BP elevation in 
humans. It has been demonstrated in Chapter 4 that DNA methylation in the kidney has a role in the 
regulation of all major pathways regulating the key modulators of BP (epithelial function, 
neurotransmitter uptake, and electrolyte balance). We recognise the limited size of our kidney 
methylation dataset. The power limitation is the most likely reason why our study uncovered limited 
associations between BP and HTN after stringent correction for multiple testing. Despite these 
constraints, our analysis is the first to identify differential kidney DNA methylation as a potential 
mechanism driving chronic BP elevation. As the first study of its’ kind, it is important to investigate 
the role of differential DNA methylation on the renal transcriptome. 
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Chapter 5.  Differential gene expression in 
essential hypertension 
 
 
 
 
 
 
 
“Dreams are often the most profound when they seem the most 
crazy” 
 
~Sigmund Freud 
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Chapter 5.  Differential gene expression in essential 
hypertension 
 
5.0  Abstract  
Elevated BP is a major risk factor for CVD with a significant genetic contribution. [12].  It is important 
to understand the epigenetic contribution to the manifestation of HTN as family studies indicate the BP 
level is determined in an individual by complex interactions between life course exposures and their 
genetic background  To date, over 900 genetic loci have been identified which have an association with 
BP variance [20]. Further, as the kidney is a key modulator of BP and recognised as the primary organ 
for BP control, it is crucial to investigate signatures of HTN in an effector organ.  In this chapter we 
hypothesised that DNA methylation induces lasting effects on renal HTN-related gene expression. 
Therefore, in this section of my PhD thesis we investigate kidney-specific, genome-wide transcriptional 
changes that are linked to HTN and the role DNA methylation has in the regulation of HTN-related 
genes. We identify that DNA methylation and renal gene expression are tightly linked in the regulation 
of pathways that modulate vascular function, cellular communication, inflammation and sodium 
regulation.  In particular we have identified a close relationship between renal DNA methylation and 
expression of FAM50B and PC and report a strong connection with this relationship to chronic BP 
elevation.  
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5.1  Introduction 
In chapter 4, genome-wide loci specific DNA methylation was identified as a key epigenetic modulator 
in the HT kidney. Further, HTN is linked to differential methylation at specific CpGs that are located 
in sites that govern chronic elevation in BP.  However, the effect of differential DNA methylation as a 
driver of transcriptional change in the HT kidney requires more defining. DNA methylation is known 
for its ability to induce long-lasting transcriptional repression, and elevated BP is a major risk factor 
for CVD with a significant genetic contribution. Family studies indicate the BP level is determined in 
an individual by complex interactions between life course exposures and their genetic background [12].  
HTN, as most human diseases, arises from a complex interaction between environmental and genetic 
factors. For BP, family and twin based studies have estimated the heritability range of elevated SBP to 
48% to 60% and elevated DBP to 34% to 67% [189-191]. Until 2011, genetic loci identified in BP 
GWAS accounted for less than 2.5% of the phenotypic variance [192], with more recent BP GWAS 
modestly increasing this estimate to approximately 3.5% [193-195]. In GWAS for HTN related 
phenotypes, interactions have successfully been identified for alcohol consumption [196], BMI [197], 
smoking status [198], education [199], and sodium intake [200], all which are considered modifiable 
through lifestyle alteration. These findings highlight the importance of investigation of genome-
environment interaction, as it may contribute to the knowledge gap that cannot be explained by 
heritability.  
 
Numerous GWAS have identified robust associations between genome loci and BP. The most 
comprehensive study, conducted in over one million individuals, identifies 901 gene loci that are 
associated with BP [20]. This study more than triple the number of loci for BP traits and contribute 
significantly to the missing heritability influencing BP level in the European population with extension 
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to other ancestries. However these findings explain only a small proportion of the estimated heritability 
of this complex phenotype. The marginal effects of variants modified by environmental factors may be 
missed by traditional marker-based analyses, therefore additional genetic factors may be detected 
through analysis of gene-environment interactions. Further, as the kidney is a key modulator of BP and 
recognised as the primary organ for BP control, it is crucial to investigate signatures of HTN in an 
effector organ.  In this chapter we hypothesised that DNA methylation induces lasting effects on renal 
HTN-related gene expression. Therefore, in this section of my PhD thesis we investigate kidney-
specific, genome-wide transcriptional changes that are linked to HTN and the role DNA methylation 
has in the modulation of these genes.  
 
5.2  RNA-Sequencing methods 
5.2.1   Participants and sample collection 
The genome-wide expression analysis utilised 180 human kidney samples (Table 5.1 and Table 5.2) 
from the TRANSLATE study. All participants of the TRANSLATE study underwent detailed clinical 
phenotyping which consisted of documentation of clinical history (via coded questionnaire), basic 
anthropometry as well as triplicate measures of BP by mercury sphygmomanometer. HTN diagnosis 
was assigned to individuals who had elevated BP greater than >140/90 mmHg on at least two separate 
occasions, and/or were taking antihypertensive medications [117].  
 
Renal samples, consisting of approximately 1 cm3 of kidney tissue, were collected from the healthy 
(unaffected by cancer) pole of the kidney immediately post nephrectomy. Kidney DNA was extracted 
from 96 homogenised renal tissue samples using Qiagen purification kits for total DNA (Qiagen). 
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Leukocyte DNA was extracted from peripheral blood using QIAamp DNA mini blood extractions kit 
(Qiagen).  
 
5.2.2 Identification of hypertension-associated renal signatures  
RNA was extracted from the kidney tissue of 180 participants of the TRANSLATE study and preserved 
in RNAlater (Ambion, Austin, Texas). A total of 1µg of kidney RNA was extracted from all kidneys 
and subjected to Illumina Tru-Seq RNA Sample Preparation protocol. Briefly, oligo-dT attached 
magnetic beads are used to purify the poly-A containing mRNA molecules. Following purification, the 
mRNA is fragmented using divalent cations under elevated temperature. The cleaved RNA fragments 
are then copied into first strand cDNA using reverse transcriptase and random primers and second 
strand cDNA using DNA Polymerase I and RNase H. The cDNA fragments the undergo end repair 
processing, have the addition of a single ‘A’ base, and then ligation of the adapters. The products are 
then purified and enriched with PCR to create the final cDNA library. Kidney samples were then 
sequenced with 75-bp paired end reads on an Illumina HiSeq 4000. All generated raw reads were stored 
in FASTQ format. The base call and read quality were evaluated using FASTQC. The input library 
complexity was assessed using RNA-SeQC. The pre-processing of reads for adapter trimming was 
conducted by Trimmomatic. The reads were then pseudo-aligned to the GRCh38 Ensembl 
transcriptome reference (Ensembl release 83); and expression was quantified in transcripts per million 
(TPM) at a transcript level using Kallisto. Transcript expression values were then summed to give gene-
level quantification. 
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5.2.3  RNA-sequencing pre-processing 
The generated raw reads from RNA-sequencing were stored in FASTQ format, where the base call and 
read quality were evaluated using FASTQC. Input library complexity was assessed using RNA-SeQC 
and pre-processing of reads for adapter trimming was conducted using Trimmomatic. The reads were 
then pseudo-aligned to the GRCh38 Ensembl transcriptome reference (Ensembl release 83; and 
expression was quantified in transcripts per million (TPM) at a transcript level using Kallisto; a RNA-
quantification program that is two orders of magnitude faster than previous approaches and achieves 
similar accuracy [125].  
 
5.2.3.1  RNA-sequencing preprocessing computational analysis 
Kallisto removes unnecessary computational technicality from RNA-sequencing analysis by pseudo-
aligning reads to a reference, producing a list of transcripts that are compatible with each read while 
avoiding alignment of single bases. Transcript expression values were then summed to give gene-level 
quantification. Outlier samples were removed based on a statistic described in Wright et al [126] or 
based on pairwise correlation between samples, where samples were excluded if their median 
correlation was below 0.75. Samples without matching genotype data were also excluded. Only genes 
located on autosomal chromosomes were considered for downstream analyses. A threshold of genes 
expression was set at TPM>0.1 in at least 50% of samples and minimal read counts ≥6. A gene was 
also removed if its interquartile range equaled zero. Only genes that passed all of the above RNA-seq 
quality control filers were selected for downstream analyses.  
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5.2.4   RNA-sequencing data normalisation 
5.2.4.1  RNA-sequencing preprocessing computational analysis 
Prior to any statistical analyses, gene-level TPM values were normalised (Figure 2.4 A-C). First, log2 
of TPM values were normalised across samples using robust quantile normalisation with an offset of 
one. The quantiles normalised gene expression values were transformed using rank-based inverse 
normal transformation. Outlying observations were set to missing using residuals from robust linear 
regression and were then imputed using linear regression. To account for hidden variation in RNA-seq 
data due to technical processing (such as batch effects or sample processing in pre-sequencing stage), 
we used probabilistic estimation of expression residuals (PEER) method [127] and estimated 30 hidden 
factors for TRANSLATE Study. The numbers of hidden factors were chosen based on sample sizes of 
each dataset as recommended in GTEx eQTL analysis [128]. The estimated hidden factors were used 
as covariates in all downstream regression analyses where appropriate. 
 
5.3   Results 
5.3.1   Differential gene expression in the hypertensive kidney 
We used 180 samples from the TRANSLATE study (Table 5.1 and Table 5.2) to investigate renal 
signature of HTN using RNA-seq. Expression of fourteen genes was associated with HTN diagnosis 
(P<.0001, FDR<.25) (Figure 5.1 a/b, Table 5.3). Eleven of them are protein-coding genes and three are 
classified as antisense RNA genes. Further, one antisense-RNA gene (Figure 5.2 a/b, Table 5.3) was 
associated with SBP (P=1.71E-06, FDR<.03), and remained so when adjusted for the effects of 
antihypertension medication. Lastly, six genes were associated with DBP (P<.0001) (Figure 5.3 a/b, 
Table 5.3), including four protein coding, a long non-coding RNA and one transcribed unprocessed 
pseudogene. The individual biological characteristics of the 21 differentially expressed genes are 
118 | P a g e  
 
shown in Table 5.4. 
 
Table 5.1                     Numeric variables for RNA-sequencing analysis in the human kidney 
 
Variables Mean ± SD Median (IQR) N 
Age (years) 61.3 ± 10.7 62 (55.0-68.3) 180 
Body mass index (BMI) 27.8 ± 5.3 26.9 (24.3-30.5) 180 
Systolic blood pressure (mmHg) 138.1 ± 14.0 138 (127.0-148.3) 165 {15} 
Diastolic blood pressure (mmHg) 83.3 ± 8.7 83.3 (78.3-90.0) 165 {15} 
Waist circumference (cm) 95.4 ± 15.9 96.0 (85.0-104.0) 145 {35} 
Adjusted systolic blood pressure (mmHg) 147.3 ± 17.6 148.3 (133.3-160.3) 165 {15} 
Adjusted diastolic blood pressure (mmHg) 89.5 ± 10.6 90.0 (81.7-98.3) 165 {15} 
Creatinine µmol/L 87.0 ± 25.6 83.7 (70.0-97.6) 180 
Serum sodium mmol/L 140.1 ± 2.9 140.0 (138.8-142.0) 132 {48} 
Serum potassium mmol/L 4.4 ± 0.4 4.4 (4.1-4.7) 131 {49} 
Glucose mmol/L 6.0 ± 1.7 5.7 (5.3-6.3) 143 {37} 
{ x }, excluded/ unknown  
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     Table 5.2             Categorical variable for RNA-sequencing analysis in the human kidney 
Variable N 
Hypertension % Yes 126 (70%) 
Sex (M) 99 (55%) 
Diabetes (Y) 32 (18%) 
Smoker status 161 {19} 
Current smoker 19 (12%) 
Ex-smoker 71 (44%) 
Non-smoker 71 (44%) 
Chronic Kidney Disease (Y) 1 (0.6%) 
Coronary Artery Disease (Y)  32 (18%) 
Peripheral Artery Disease (Y) 9 (6%) {35} 
Antihypertension medication (Y) 108 (60%) 
Lipid lowering treatment (Y) 29 (20%) {35} 
Alcohol consumption 157 {23} 
Drinker 96 (61%) 
Excessive drinker 1 (0.6% 
Teetotal 60 (38%) 
Paternal history of Hypertension  (Y) 19 (14%) {41} 
Maternal history of Hypertension (Y) 45 (32%) {38} 
( x %), percentage of the total analysed population; { x }, excluded/ unknown  
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Figure 5.1 A) Differentially expressed genes associated with hypertension diagnosis in the 
hypertensive kidney. Manhattan plot of genes differentially expressed genes associated with HTN 
diagnosis in the HT kidney. Of the fourteen genes (FDR<.25, P<.0001), 11 of them were protein-
coding genes and three were classified as antisense RNA genes. B) Volcano plot of differentially 
expressed genes associated with hypertension diagnosis in the hypertensive kidney. Of the 14 
genes discovered via differential gene expression analysis (FDR<.25, P<.0001), seven genes are 
overexpressed in the HT kidney and seven genes are underexpressed.   
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Figure 5.2 A) Differentially expressed genes associated with systolic blood pressure in the 
hypertensive kidney. Manhattan plot of genes differentially expressed genes associated with SBP in 
the HT kidney. One gene, AC007099.1 (FDR<.02, P<1.7E-06), is an antisense gene located on 
chromosome 2. B) Volcano plot of differentially expressed genes associated with systolic blood 
pressure in the hypertensive kidney. Antisense gene, AC007099.1, is underexpressed (FDR<.02, 
P<1.7E-06) and is associated with SBP in the HT kidney. 
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Figure 5.3  A) Differentially expressed genes associated with diastolic blood pressure in the 
hypertensive kidney. Manhattan plot of genes differentially expressed genes associated with DBP in 
the HT kidney. Of the six genes (FDR<.998, P<.001), four of them were protein-coding genes, one is 
classified as long non-coding and one is a pseudogene. B) Volcano plot of differentially expressed 
genes associated with diastolic blood pressure in the hypertensive kidney. Of the 6 genes 
discovered via differential gene expression analysis (FDR<.998, P<.001), 5 genes are overexpressed 
in the HT kidney and associated with DBP and one (PIP4K2A) is underexpressed.  
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Table 5.3         Differentially expressed renal genes associated with hypertension and blood pressure  
ENSMBL ID Chr Gene start Gene end Gene β St. error 
FDR 
 
P-Value 
 
Gene 
biotype 
Associated 
phenotype 
ENSG00000162604 1 62146718 62191095 TM2D1 0.504 0.108 <.01 8.06E-06 PC HTN 
ENSG00000267493 19 1267813 1270240 CIRBP-AS1 -0.657 0.144 <.01 1.08E-05 AS HTN 
ENSG00000259330 15 40617417 40618916 INAFM2 -0.300 0.070 <.15 3.58E-05 AS HTN 
ENSG00000173599 11 66615704 66725847 PC 0.196 0.047 <.20 6.32E-05 PC HTN 
ENSG00000149527 1 2357419 2436969 PLCH2 0.317 0.077 <.20 6.42E-05 PC HTN 
ENSG00000138375 2 217277137 217347776 SMARCAL1 -0.261 0.066 <.25 <.0001 PC HTN 
ENSG00000226419 1 113499037 113589677 SLC16A1-AS1 -0.266 0.068 <.25 <.0001 AS HTN 
ENSG00000174917 19 5678432 5680907 C19orf70 0.186 0.048 <.25 <.0001 PC HTN 
ENSG00000099977 22 24317830 24322660 DDT 0.252 0.065 <.25 <.0001 PC HTN 
ENSG00000163170 2 74362525 74375121 BOLA3 0.232 0.061 <.25 <.0001 PC HTN 
ENSG00000205683 14 73086004 73360824 DPF3 0.301 0.079 <.25 <.0001 PC HTN 
ENSG00000198431 12 104609557 104744083 TXNRD1 -0.245 0.065 <.25 <.0001 PC HTN 
ENSG00000132463 4 71681499 71705662 GRSF1 -0.305 0.081 <.25 <.0001 PC HTN 
ENSG00000145945 6 3849620 3851551 FAM50B -0.236 0.063 <.25 <.0001 PC HTN 
ENSG00000150867 2 75751194 75769832 AC007099.1 -0.013 0.002 <.02 <1.7E-06 AS SBP 
ENSG00000150867 10 22823778 230033484 PIP4K2A -0.019 0.005 0.998 9.52E-05 PC DBP 
ENSG00000143196 1 168664697 168698502 DPT 0.029 0.008 0.998 <.001 PC DBP 
ENSG00000176387 16 67464555 67471456 HSD11B2 0.019 0.005 0.998 <.001 PC DBP 
ENSG00000236882 5 95187936 95195837 LINC01554 0.026 0.007 0.998 <.001 lincRNA DBP 
ENSG00000167700 8 145734457 145736596 MFSD3 0.009 0.002 0.998 <.001 PC DBP 
ENSG00000180747 16 21458004 21531765 SMG1P3 0.012 0.003 0.998 <.001 Pseudo DBP 
Position is Hg19. β – coefficient from linear regression models. Abbreviations: Chr, chromosome; PC, protein coding; lincRNA, long 
non-coding RNA; pseudo, pseudogene; AS, antisense; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. 
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Table 5.4        Full names and biological characterisation of genes differentially expressed in the hypertensive kidney  
Gene 
symbol Chr 
Gene 
biotype 
Gene 
description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological process 
(GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
TM2D1 1 protein coding 
TM2 
domain 
containing 1 
N 
G-protein coupled 
receptor activity, 
beta-amyloid 
binding 
apoptotic process, G-
protein coupled 
receptor signaling 
pathway, apoptotic 
signaling pathway 
integral 
component of 
plasma 
membrane, 
membrane 
May participate 
in amyloid-beta-
induced 
apoptosis via its 
interaction with 
beta-APP42 
CIRBP-
AS1 19 antisense 
 
CIRBP 
Antisense 
RNA 1 
- - - - 
affiliated with 
the non-coding 
RNA class 
INAFM2 15 antisense InaF motif containing 2 - - - 
 
membrane, 
integral 
component of 
membrane 
affiliated with 
the lncRNA 
class 
PC 11 protein coding 
Pyruvate 
carboxylase N 
nucleotide binding, 
catalytic activity, 
biotin carboxylase 
activity, pyruvate 
carboxylase activity, 
protein binding, ATP 
binding, biotin 
binding, ligase 
activity 
pyruvate metabolic 
process, 
gluconeogenesis, lipid 
metabolic process, 
biotin metabolic 
process, metabolic 
process, negative 
regulation of gene 
expression, viral RNA 
genome packaging, 
positive regulation by 
host of viral release  
 
cytoplasm, 
mitochondrion, 
mitochondrial 
matrix, cytosol 
 
ligase activity 
and biotin 
carboxylase 
activity 
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Gene 
symbol Chr 
Gene 
biotype 
Gene 
description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological process 
(GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
PLCH2 1 protein coding 
Phospholipa
se C eta 2 N 
 
phosphatidylinositol 
phospholipase C 
activity, 
phospholipase C 
activity, signal 
transducer activity, 
calcium ion binding, 
phosphoric diester 
hydrolase activity, 
hydrolase activity, 
metal ion binding, 
calcium-dependent 
phospholipase C 
activity 
 
 
lipid metabolic 
process, signal 
transduction, 
biological_process, 
lipid catabolic 
process, intracellular 
signal transduction, 
inositol phosphate 
metabolic process, 
phosphatidylinositol 
metabolic process, 
phosphatidylinositol-
mediated signaling 
intracellular, 
cytoplasm, 
plasma 
membrane, 
membrane 
 
this 
phospholipase 
activity is very 
sensitive to 
calcium. May be 
important for 
formation and 
maintenance of 
the neuronal 
network in the 
postnatal brain 
SMARCAL
1 2 
protein 
coding 
SWI/SNF 
related, 
matrix 
associated, 
actin 
dependent 
regulator of 
chromatin, 
subfamily a 
like 1 
 
N 
nucleotide binding, 
helicase activity, 
protein binding, ATP 
binding 
DNA strand 
renaturation, DNA 
metabolic process, 
DNA repair, 
regulation of 
transcription from 
RNA polymerase II 
promoter 
nucleus, 
nucleoplasm, 
DNA 
replication 
factor A 
complex, site 
of double-
strand break 
May play an 
important role in 
DNA damage 
response by 
acting at stalled 
replication forks 
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Gene 
symbol Chr 
Gene 
biotype 
Gene 
description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological process 
(GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
SLC16A1-
AS1 1 antisense 
 
SLC16A1 
Antisense 
RNA 1 
- - - - 
affiliated with 
the non-coding 
RNA class 
C19orf70 19 protein coding 
Chromsome 
19 open 
reading 
frame 70 
N - cristae formation 
 
nucleoplasm, 
mitochondrion, 
mitochondrial 
inner 
membrane, 
membrane, 
integral 
component of 
membrane, 
mitochondrial 
crista junction, 
MICOS 
complex 
plays crucial 
roles in the 
maintenance of 
crista junctions, 
inner membrane 
architecture, and 
formation of 
contact sites to 
the outer 
membrane 
DDT 22 protein coding 
D-
dopachrome 
tautomerase 
N 
dopachrome 
isomerase activity, 
cytokine receptor 
binding, lyase 
activity, D-
dopachrome 
decarboxylase 
activity, 
phenylpyruvate 
tautomerase activity 
negative regulation of 
macrophage 
chemotaxis, positive 
regulation of tumor 
necrosis factor 
production, melanin 
biosynthetic process, 
positive regulation of 
inflammatory 
response, positive 
regulation of ERK1 
and ERK2 cascade 
extracellular 
space, 
cytoplasm, 
extracellular 
exosome 
Tautomerization 
of D-
dopachrome 
with 
decarboxylation 
to give 5,6-
dihydroxyindole 
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Gene 
symbol Chr 
Gene 
biotype 
Gene 
description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological process 
(GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
BOLA3 2 protein coding 
BolA 
family 
member 3 
N - - mitochondrion 
 
Acts as a 
mitochondrial 
iron-sulfur (Fe-
S) cluster 
assembly factor 
that facilitates 
(Fe-S) cluster 
insertion into a 
subset of 
mitochondrial 
proteins 
DPF3 14 protein coding 
Double 
PHD 
fingers 3 
N 
 
nucleic acid binding, 
zinc ion binding, 
metal ion binding 
 
transcription, DNA-
templated, regulation 
of transcription, DNA-
templated, nervous 
system developments, 
covalent chromatin 
modification 
 
nucleus, 
nucleoplasm, 
nBAF complex 
 
acts as a tissue-
specific anchor 
between histone 
acetylations and 
methylations 
and chromatin 
remodeling. It 
thereby 
probably plays 
an essential role 
in heart and 
skeletal muscle 
development 
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Gene 
symbol Chr 
Gene 
biotype 
Gene 
description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological process 
(GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
TXNRD1 12 protein coding 
Thioredoxin 
reductase 1 N 
 
thioredoxin-disulfide 
reductase activity 
protein binding 
electron carrier 
activity, protein 
disulfide 
oxidoreductase 
activity, 
oxidoreductase 
activity, 
oxidoreductase 
activity, acting on a 
sulfur group of 
donors, NAD(P) as 
acceptor, flavin 
adenine dinucleotide 
binding, 
methylselenol 
reductase activity, 
methylseleninic acid, 
eductase activity 
 
response to oxygen 
radical, mesoderm 
formation, selenium 
compound metabolic 
process, signal 
transduction, 
gastrulation, cell 
proliferation, 
nucleobase-containing 
small molecule 
interconversion, 
regulation of lipid 
metabolic process, 
electron transport 
chain, cellular 
response to oxidative 
stress, cell redox 
homeostasis, 
oxidation-reduction 
process, 
cellular oxidant 
detoxification 
 
fibrillar center 
cell, nucleus, 
nucleoplasm, 
cytoplasm, 
mitochondrion, 
cytosol, 
extracellular 
exosome 
oxidoreductase 
activity and 
flavin adenine 
dinucleotide 
binding 
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Gene 
symbol Chr 
Gene 
biotype 
Gene 
description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological process 
(GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
GRSF1 4 protein coding 
 
G-rich RNA 
sequence 
binding 
factor 1 
N 
 
nucleic acid binding, 
RNA binding, 
mRNA binding 
 
mRNA 
polyadenylation, RNA 
processing, mRNA 
processing, tRNA 
processing, 
anterior/posterior 
pattern specification, 
morphogenesis of 
embryonic epithelium 
 
cytoplasm, 
mitochondrion, 
ribonucleoprot
ein granule, 
mitochondrial 
nucleoid 
 
regulator of 
post-
transcriptional 
mitochondrial 
gene expression, 
required for 
assembly of the 
mitochondrial 
ribosome and 
for recruitment 
of mRNA and 
lncRNA 
FAM50B 6 protein coding 
 
Family with 
sequence 
similarity 
50 member 
B 
N protein binding - 
nucleus, 
nucleoplasm, 
intercellular 
bridge 
Plays a role in 
circadian clock 
AC007099
.1 2 antisense N/A - - - - 
 
affiliated with 
the non-coding 
RNA class 
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Gene 
symbol Chr 
Gene 
biotype 
Gene 
description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological process 
(GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
PIP4K2A 10 Protein coding 
 
Phosphatidy
linositol-5-
Phosphate 
4-Kinase 
Type 2 
Alpha 
No 
nucleotide binding, 
ATP binding, kinase 
activity, 
phosphatidylinositol 
phosphate kinase 
activity, 1-
phosphatidylinositol-
4-phosphate 5-kinase 
activity, 
phosphatidylinositol-
5-phosphate 4-kinase 
activity, ansferase 
activity, 
phosphatidylinositol-
3-phosphate 4-kinase 
activity 
phospholipid 
metabolic process, 
phosphatidylinositol 
biosynthetic process, 
regulation of 
autophagy, regulation 
of 
phosphatidylinositol 
3-kinase signaling, 
phosphorylation, 
megakaryocyte 
development, 
phosphatidylinositol 
metabolic process, 
osphatidylinositol, 
phosphorylation, 
positive regulation of 
autophagosome 
assembly 
 
nucleus, 
nucleoplasm, 
cytoplasm, 
autophagosom
e, cytosol, 
plasma 
membrane, 
membrane 
 
phosphatidylino
sitol phosphate 
kinase activity 
and 1-
phosphatidylino
sitol-5-
phosphate 4-
kinase activity 
DPT 1 Protein coding 
Dermatopon
tin No - 
 
cell adhesion, negative 
regulation of cell 
proliferation, collagen 
fibril organization 
 
extracellular 
region, 
proteinaceous 
extracellular 
matrix, 
extracellular 
space 
Seems to 
mediate 
adhesion by cell 
surface integrin 
binding 
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Gene 
symbol Chr 
Gene 
biotype 
Gene 
description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological process 
(GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
HSD11B2 16 Protein coding 
 
Hydroxyster
oid 11-Beta 
Dehydrogen
ase 2 
 
Enhanced in 
kidney and 
intestine 
 
11-beta-
hydroxysteroid 
dehydrogenase 
[NAD(P)] activity, 
steroid binding, 
oxidoreductase 
activity, NAD 
binding 
 
response to hypoxia 
regulation of blood 
volume by renal 
aldosterone, 
glucocorticoid 
biosynthetic process, 
female pregnancy, 
glucocorticoid 
metabolic process, 
response to food, 
response to insulin, 
response to drug, 
response to steroid 
hormone, response to 
glucocorticoid, 
oxidation-reduction 
process 
 
cytoplasm, 
endoplasmic 
reticulum, 
endoplasmic 
reticulum 
membrane, 
membrane, 
integral 
component of 
membrane, 
intracellular 
membrane-
bounded 
organelle 
 
oxidoreductase 
activity and 
steroid binding 
LINC0155
4 5 lincRNA 
Long 
Intergenic 
Non-Protein 
Coding 
RNA 1554 
- - - - 
affiliated with 
the non-coding 
RNA class 
 
MFSD3 
 
8 
 
Protein 
coding 
 
Major 
Facilitator 
Superfamily 
Domain 
Containing 
3  
 
No 
 
solute:proton 
symporter activity 
 
transport, proton 
transport, 
transmembrane 
transport 
 
integral 
component of 
plasma 
membrane, 
membrane 
 
solute:proton 
symporter 
activity 
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Gene 
symbol Chr 
Gene 
biotype 
Gene 
description 
Kidney 
predominant 
expression 
(HPA) 
Molecular function 
(GO) 
Biological process 
(GO) 
Cellular 
component 
(GO) 
Primary role 
(OMIM) 
SMG1P3 16 
Transcribed 
unprocessed 
pseudogene 
SMG1P3, 
Nonsense 
Mediated 
MRNA 
Decay 
Associated 
PI3K 
Related 
Kinase 
Pseudogene 
3  
- - - - pseudogene 
Position is Hg19. Abbreviations: Chr, chromosome; CpG, cytosine-phosphate-guanine; 5’UTR, 5-prime untranslated region; HTN, 
hypertension diagnosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; mRNA, messenger; DNA, deoxyribonucleic acid; 
rRNA, ribosomal RNA; ER, endoplasmic reticulum; tRNA, transfer RNA; HPA, human protein atlas; GO, gene ontology; MHC, major 
histocompatibility complex; nBAF, neuron specific chromatin remodelling complex 
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5.3.2 Correlation analysis of blood pressure-associated kidney genes and 
blood pressure GWAS 
We used kidney expression data to compare against known BP-associated genes from the most recent 
and comprehensive HTN GWAS [20]. We found an overlap for two differentially expressed kidney 
genes and the BP-associated GWAS genes in blood (Table 5.5). DPF3, is located on chromosome 14 
and is a transcription regulator that binds acetylated histones and is a component of the BAF chromatin 
remodelling complex. In humans, DPF3 is significantly upregulated in the hypertrophic hearts of 
individuals with aortic stenosis and cardiomyopathy [201]. Interestingly, we also discovered 
differential renal gene expression of the HSD11B2 gene. Mutations to HSD11B2 have been identified 
as causative for a monogenic form of HTN; in the form of apparent mineralocorticoid excess [202].  
 
Table 5.5       Correlation analysis of blood pressure-associated kidney genes and blood pressure GWAS 
ENSMBL ID Chr Position Gene β 
St. 
error 
FDR 
 
P-
Value 
Gene 
biotype 
Associated 
phenotype 
ENSG00000162604 14 73279420 DPF3 0.301 0.079 <.25 <.0001 PC HTN 
ENSG00000176387 16 67464555 HSD11B2 0.019 0.005 .998 <.001 PC DBP 
Position is Hg19. β – coefficient from linear regression models. Abbreviations: Chr, chromosome; PC, 
protein coding; HTN, hypertension 
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5.3.3 DNA methylation of hypertension-associated genes and their 
expression in the kidney 
Methylation of cytosine residues in DNA plays a role in gene regulation, affecting DNA interactions 
with chromatin proteins and specific transcription factors [11]. Therefore, we examined whether 
differences in CpG methylation of kidney DNA in proximity to HTN-associated genes correlate with 
their renal expression. This analysis was conducted in 68 TRANSLATE samples with both array-
derived renal DNA methylation data and kidney transcriptome data available. We examined the extent 
of DNA methylation in all CpG sites mapping to a cis window of 250kb. After correction for multiple 
testing, methylation of two genes (FAM50B, PC) (Figure 5.4) showed an association with its renal 
expression. The strongest association was identified for the cg23344241 probe mapping upstream of 
the PC gene (P<.0001, FDR<.35) (Table 5.6). Together, these data demonstrate an association between 
hyper/hypo methylation upstream of two of the HTN-associated renal genes and its expression in the 
kidney (Figure 5.5A/ B).  
 
Figure 5.4  Methylation of FAM50B and PC shows an association with renal expression. Venn 
diagram of genes differentially methylated and differentially expressed in the HT 
kidney. Methylation of two genes, PC and FAM50B, showed an association with its 
renal expression. Where bold indicates increased expression; *, CpG site is located in 
within an island. 
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Figure 5.5  Illustration of the relationship of methylation at various individual CpG sites with 
hypertension incidence in the TRANSLATE population.  A) Decreased methylation 
at cg23344241; cg12032489; cg08971859; cg03094226 was identified as associated 
with HTN diagnosis. Increased expression of PC was associated with decreased 
methylation at the previously mentioned sites; which suggests that DNA methylation 
influences HTN incidence through the expression of PC. B) Methylation at 
cg07898446; cg17739279; cg13289019 was identified as associated with HTN 
diagnosis. Decreased expression of FAM50B was associated with methylation at the 
previously mentioned sites; which suggests that DNA methylation influences HTN 
incidence through the reduced expression of FAM50B.  
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Table 5.6            Differentially methylated and differentially expressed genes in the hypertensive kidney 
 
ENSMBL ID 
 
Gene 
symbol 
 
Chr 
 
CpG probe 
 
Gene 
location 
Location 
of CpG 
relative 
to island 
UCSC   β 
 
P-value 
 
FDR 
 
Enhancer 
region 
 
ENSG00000173599 PC 11 cg23344241 66615704 OpenSea TSS200 1.30 <.0001 <.35  
ENSG00000173599 PC 11 cg12032489 66615704 N_Shore Body 1.30 <.0001 <.35  
ENSG00000173599 FAM50B 6 cg07898446 3849620 Island TSS1500 -2.19 <.0001 <.35  
ENSG00000145945 FAM50B 6 cg17739279 3849620 N_Shore TSS1500 -1.49 <.0001 <.35  
ENSG00000145945 PC 11 cg08971859 66615704 OpenSea TSS200 1.33 <.0001 <.35  
ENSG00000173599 PC 11 cg03094226 66615704 OpenSea Body 1.03 <.0001 <.35 TRUE 
ENSG00000173599 FAM50B 6 cg13289019 3849620 Island TSS1500 -3.15 <.0001 <.35  
Position is Hg19. β – coefficient from linear regression models. Abbreviations: Chr, chromosome; CpG, cytosine-phosphateguanine; 
TSS1500, 1500 base pair to the transcription start site; body, body of gene; N_shore, north shore to CpG island. 
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5.3.5 Reverse analysis of BP-associated methylated CpG sites and known 
GWAS BP gene loci 
We investigated the role of kidney DNA methylation in known GWAS BP loci. Therefore we 
conducted a reverse analysis of genes that are known to influence BP (GWAS), with differentially 
methylated CpG sites in the human kidney We used data obtained from the kidney methylation array 
together with the most comprehensive BP loci GWAS conducted using the blood of over one million 
individuals [20]. The BP-associated GWAS by Evangelou et al [20] identifies over 535 novel and over 
901 total gene loci that are associated with BP modulation. Of the BP-associated sites identified in the 
GWAS, two overlap with loci that are differentially methylated in the kidney and associated with SBP 
and 28 overlap with loci that are differentially methylated in the kidney and associated with DBP (Table 
5.7). A summary of the biological characterisation of the genes is available in Table 5.8. 
  
5.3.6 Differentially methylated and expressed renal genes that are 
identified in blood-based BP GWAS  
We used a less stringent kidney methylation analysis to compare against known BP-associated genes 
in the largest BP GWAS conducted in over one million individuals [20]. This analysis revealed one 
loci, DPF3 (Table 5.9), that is both differentially methylated in the kidney (P=.019), differentially 
expressed in the kidney (P=<.001), and has been identified as BP associated loci in BP GWAS 
(P=6.58E-17). 
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Table 5.7                 Reverse analysis of GWAS BP loci and loci associated with differentially methylated CpGs in the human kidney   
UCSC 
gene 
symbol 
CpG 
number Chr Position 
β 
(CpG 
site) 
P-value FDR  UCSC gene symbol Chr Position β  P-value 
TRANSLATE kidney samples  Relative blood GWAS samples 
KIAA1755 cg01202124 20 36888790 -0.388 5.58E-05 <.20  1KIAA1755 20 36849007 0.116 3.37E-11 
CMIP cg09678340 16 81506476 0.226 2.95E-05 <.20  2CMIP 16 81574197 -0.241 2.0E-09 
KDM4B cg02659867 19 5033098 0.837 2.67E-05 <.05  1KDM4B 19 5066330 -0.234 9.01E-22 
RARRES2 cg14442992 7 150039342 0.263 4.86E-05 <.05  1RARRES2 7 150050111 0.167 2.72E-10 
PKD2L1 cg25155149 10 102048137 -0.266 8.42E-05 <.05  1PKD2L1 10 102075479 0.172 1.81E-17 
PIAS1 cg06790275 15 68346669 -0.284 8.58E-05 <.05  1PIAS1 15 68454523 -0.095 3.77E-10 
OSBPL7 cg00265783 17 45891043 0.947 2.39E-05 <.05  1OSBPL7 17 45888374 -0.4132 4.60E-31 
COL15A1 cg13865810 9 101706936 2.737 3.77E-06 <.05  1COL15A1 9 101739709 0.178 1.29E-23 
FBRSL1 cg21441868 12 133125416 0.653 3.24E-05 <.05  1FBRSL1 12 133086888 0.315 2.70E-10 
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UCSC 
gene 
symbol 
CpG 
number Chr Position 
β 
(CpG 
site) 
P-value FDR  UCSC gene symbol Chr Position β  P-value 
TRANSLATE kidney samples  Relative blood GWAS samples 
FOXF1 cg20368988 16 86542943 2.040 7.73E-06 <.05  1FOXF1 16 86437811 0.192 5.40E-10 
MCPH1 cg03755955 8 6424269 -0.158 7.53E-05 <.05  1MCPH1 8 6379932 0.132 5.90E-14 
ZFP36L1 cg15558971 14 69260307 -0.423 9.93E-05 <.05  1ZFP36L1 14 69260028 0.142 4.40E-11 
SPRY2 cg22417789 13 80915465 1.342 1.59E-05 <.05  1SPRY2 13 80707408 -0.138 5.20E-11 
DPYSL2 cg00926238 8 26436304 0.447 4.01E-05 <.05  1DPYSL2 8 26445194 0.231 1.80E-10 
ATP10A cg00288824 15 26108663 1.919 8.76E-06 <.05  1ATP10A 15 26105602 -0.110 9.50E-10 
HDAC4 cg15713391 2 240033280 1.486 1.37E-05 <.05  1HDAC4 2 239864732 -0.124 3.60E-09 
BCAT1 cg22814146 12 25055518 0.427 4.10E-05 <.05  1BCAT1 12 24770878 -0.197 6.00E-12 
KLHL29 cg13874979 2 23929590 0.334 4.51E-05 <.05  1KLHL29 2 23950200 -0.152 1.40E-11 
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UCSC 
gene 
symbol 
CpG 
number Chr Position 
β 
(CpG 
site) 
P-value FDR  UCSC gene symbol Chr Position β  P-value 
TRANSLATE kidney samples  Relative blood GWAS samples 
WNT3A cg00779928 1 228225068 0.429 4.09E-05 <.05  2WNT3A 1 228191075 0.235 3.7E-09 
FOSL2 cg06911519 2 28615662 1.149 1.94E-05 <.05  2FOSL2 2 28635740 0.365 2.2E-07 
GATA2 cg14784847 3 128209252 -0.127 7.29E-05 <.05  2GATA2 3 128201889 0.861 2.6E-09 
CPEB4 cg06697488 5 173314932 0.687 3.13E-05 <.05  2CPEB4 5 173377636 -0.232 1.6E-07 
RSPO3 
Alias 
TBSD2 
cg03983331 6 127441605 2.407 5.30E-06 <.05  
3RSPO3 
Alias 
TBSD2 
6 127115454 0.850 5.9E-05 
CDK6 cg02689293 7 92464971 1.493 1.36E-05 <.05  4CDK6 7 92264410 −0.268 3.82E-08 
SLC20A2 cg03612649 8 42292332 3.221 2.30E-06 <.05  2SLC20A2 8 42324765 -0.253 1.3E-07 
EHBP1L1 cg02532488 11 65343341 0.027 6.21E-05 <.05  5EHBP1L1 11 65353906 0.909 9.9E-09 
MYH6 cg14541311 14 23877130 1.148 1.94E-05 <.05  2MYH6 14 23865885 0.261 2.9E-07 
141 | P a g e  
 
UCSC 
gene 
symbol 
CpG 
number Chr Position 
β 
(CpG 
site) 
P-value FDR  UCSC gene symbol Chr Position β  P-value 
TRANSLATE kidney samples  Relative blood GWAS samples 
AMH cg00299047 19 2252069 0.704 3.07E-05 <.05  2AMH 19 2232221 N/A 9.4E-06 
JAG1 cg20319775 20 10653482 1.336 1.60E-05 <.05  2JAG1 20 10969030 -0.432 3.9E-19 
SLC24A3 cg27382790 20 19193057 1.008 2.24E-05 <.05  2SLC24A3 20 19465907 0.326 1.2E-09 
Position is Hg19. β – coefficient from linear regression models. Abbreviations: Chr, chromosome; CpG, cytosine-phosphate-guanine; 
FDR, false discovery rate’ N/A, beta-coefficient not available; 1 GWAS data obtained from Evangelou et al (2017) [20]; 2 GWAS data 
obtained from Warren et al (2017) [30]; 3 GWAS data obtained from Franceschini et al (2013) [203]; 4 GWAS data obtained from  
Tragante et al (2014) [204]; 5 GWAS data obtained from Simino et al (2014) [205].  
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Table 5.8      Characterisation of GWAS loci that overlap with regions containing differentially methylated CpGs in the kidney   
 
UCSC gene 
symbol CpG number Chr Position 
Enhancer 
region 
UCSC 
location 
relative to 
gene 
Gene 
biotype 
Associated 
phenotype 
UCSC Gene 
name 
KIAA1755 cg01202124 20 36888790 TRUE Body 
Protein 
coding 
SBP 
Uncharacterized 
Protein 
KIAA1755 
CMIP cg09678340 16 81506476 TRUE Body 
Protein 
coding 
SBP 
 
C-Maf Inducing 
Protein 
KDM4B cg02659867 19 5033098  Body 
Protein 
coding 
DBP 
 
Lysine 
Demethylase 4B 
RARRES2 cg14442992 7 150039342  TSS1500 
Protein 
coding 
DBP 
 
Retinoic Acid 
Receptor 
Responder 2 
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UCSC gene 
symbol CpG number Chr Position 
Enhancer 
region 
UCSC 
location 
relative to 
gene 
Gene 
biotype 
Associated 
phenotype 
UCSC Gene 
name 
PKD2L1 cg25155149 10 102048137  3'UTR 
Protein 
coding 
DBP 
 
Polycystin 2 Like 
1, Transient 
Receptor 
Potential Cation 
Channel 
PIAS1 cg06790275 15 68346669  1stExon 
Protein 
coding 
DBP 
 
Protein Inhibitor 
Of Activated 
STAT 1 
OSBPL7 cg00265783 17 45891043  Body 
Protein 
coding 
DBP 
 
Oxysterol 
Binding Protein 
Like 7 
COL15A1 cg13865810 9 101706936  Body 
Protein 
coding 
DBP 
 
Collagen Type 
XV Alpha 1 
Chain 
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UCSC gene 
symbol CpG number Chr Position 
Enhancer 
region 
UCSC 
location 
relative to 
gene 
Gene 
biotype 
Associated 
phenotype 
UCSC Gene 
name 
FBRSL1 cg21441868 12 133125416  Body 
Protein 
coding 
DBP Fibrosin Like 1 
FOXF1 cg20368988 16 86542943  TSS1500 
Protein 
coding 
DBP Forkhead Box F1 
MCPH1 cg03755955 8 6424269  Body 
Protein 
coding 
DBP Microcephalin 1 
ZFP36L1 cg15558971 14 69260307  TSS1500 
Protein 
coding 
DBP 
 
ZFP36 Ring 
Finger Protein 
Like 1 
SPRY2 cg22417789 13 80915465  TSS1500 
Protein 
coding 
DBP 
 
Sprouty RTK 
Signaling 
Antagonist 2 
DPYSL2 cg00926238 8 26436304  Body 
Protein 
coding 
DBP 
 
Dihydropyrimidin
ase Like 2 
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UCSC gene 
symbol CpG number Chr Position 
Enhancer 
region 
UCSC 
location 
relative to 
gene 
Gene 
biotype 
Associated 
phenotype 
UCSC Gene 
name 
ATP10A cg00288824 15 26108663  TSS1500 
Protein 
coding 
DBP 
 
ATPase 
Phospholipid 
Transporting 10A 
(Putative) 
 
HDAC4 cg15713391 2 240033280  Body 
Protein 
coding 
DBP 
Histone 
Deacetylase 4 
BCAT1 cg22814146 12 25055518 TRUE Body 
Protein 
coding 
DBP 
 
Branched Chain 
Amino Acid 
Transaminase 1 
KLHL29 cg13874979 2 23929590 TRUE 3'UTR 
Protein 
coding 
DBP 
 
Kelch Like 
Family Member 
29 
WNT3A cg00779928 1 228225068  Body 
Protein 
coding 
DBP 
Wnt Family 
Member 3A 
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UCSC gene 
symbol CpG number Chr Position 
Enhancer 
region 
UCSC 
location 
relative to 
gene 
Gene 
biotype 
Associated 
phenotype 
UCSC Gene 
name 
FOSL2 cg06911519 2 28615662  TSS200 
Protein 
coding 
DBP 
 
FOS Like 2, AP-1 
Transcription 
Factor Subunit 
GATA2 cg14784847 3 128209252  5'UTR 
Protein 
coding 
DBP 
 
GATA Binding 
Protein 2 
CPEB4 cg06697488 5 173314932  TSS1500 
Protein 
coding 
DBP 
 
Cytoplasmic 
Polyadenylation 
Element Binding 
Protein 4 
RSPO3 
Alias TBSD2 
cg03983331 6 
 
127441605 
 
 Body 
Protein 
coding 
DBP 
R-Spondin 3 
Alias 
Thrombospondin 
Type-1 Domain-
Containing 
Protein 2 
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UCSC gene 
symbol CpG number Chr Position 
Enhancer 
region 
UCSC 
location 
relative to 
gene 
Gene 
biotype 
Associated 
phenotype 
UCSC Gene 
name 
CDK6 cg02689293 7 92464971  5'UTR 
Protein 
coding 
DBP 
 
Cyclin Dependent 
Kinase 6 
SLC20A2 cg03612649 8 42292332  Body 
Protein 
coding 
DBP 
 
Solute Carrier 
Family 20 
Member 2 
EHBP1L1 cg02532488 11 65343341  TSS200 
Protein 
coding 
DBP 
 
EH Domain 
Binding Protein 1 
Like 1 
MYH6 cg14541311 14 23877130  5'UTR 
Protein 
coding 
DBP 
Myosin Heavy 
Chain 6 
AMH cg00299047 19 2252069  3'UTR 
Protein 
coding 
DBP 
Anti-Mullerian 
Hormone 
JAG1 cg20319775 20 10653482  Body 
Protein 
coding 
DBP Jagged 1 
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UCSC gene 
symbol CpG number Chr Position 
Enhancer 
region 
UCSC 
location 
relative to 
gene 
Gene 
biotype 
Associated 
phenotype 
UCSC Gene 
name 
SLC24A3 cg27382790 20 19193057  TSS1500 
Protein 
coding 
DBP 
Solute Carrier 
Family 24 
Member 3 
Position is Hg19. Individual CpG site-associated gene loci characterisation. Abbreviations: Chr, chromosome; CpG, cytosine-
phosphateguanine; TSS1500, 1500 base pair to the transcription start site; 5’UTR, 5-prime untranslated region; body, body of gene; 
HTN, hypertension diagnosis; SBP, systolic blood pressure; DBP, diastolic blood pressure. 
 
 
 
 
Table 5.9: Differentially methylated kidney-associated CpGs that are identified in blood-based HTN GWAS  
 
UCSC gene 
name 
 
 
CpG 
number 
 
Chr Position β (CpG site)  P-value 
Differentially 
expressed 
(P-value) 
TRANSLATE 
Differentially 
expressed 
(P-value) 
GWAS 
DPF3 cg26057784 14 73362214 -3.256 .019 <.001 6.58E-171 
Position is Hg19. β – coefficient from linear regression models. Abbreviations: Chr, chromosome; CpG, cytosine-phosphate-guanine; 
FDR, false discovery rate’ N/A, beta-coefficient not available; 1 GWAS data obtained from Evangelou et al (2017) [20] 
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5.4   Discussion 
Despite the identification of numerous genes associated with BP modulation in blood, signatures of 
HTN and BP have not been identified in the human kidney. This section of my PhD thesis offers a step 
forward in understanding the genetic architecture of EH and its’ associated phenotypical traits in the 
human kidney. The 21 loci, 19 of which are novel, identified here open the vista of entirely new biology 
and highlight gene regions in tissue not previously investigated in BP studies. The clinical relevance 
of these findings are timely, as the global prevalence of individuals with SBP over the recommended 
threshold (110-115mmHg) now exceeds 3.5 billion; above which risk of cardiovascular complications 
increases in a continuous fashion [176].   
 
5.4.1   Hypertension-associated genes in the human kidney 
Our study provides new insight into HTN-related gene expression changes within the human kidney. 
Of these, some of the top locus for HTN diagnosis, SBP and DBP has been selected for discussion. 
TM2D1 encodes beta-amyloid peptide-binding protein which has been established as a causative factor 
in neuron death and cognitive impairment [206]. Vascular beta-amyloid deposition is a common 
pathology of aging and is directly toxic to smooth muscle cells, often resulting in vascular rupture and 
impairment of the vascular response to changes in systemic BP [206]. To this end, the identified 
increase in renal expression with HTN most likely represents one of the mechanisms responsible for 
increased BP, perhaps via increased beta-amyloid deposition in renal vasculature. AC007099.1 is an 
antisense long non-coding RNA (lcRNA) associated with systolic BP. While very little is known about 
this lcRNA it has been previously identified as a potential biomarker in colorectal cancer [207] and is 
now identified as a HTN-associated change to renal gene expression. Finally, HSD11B2 has long been 
associated to HTN and BP modulation. Expression of HSD11B2 is enhanced in the kidney and 
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intestine, mutations of which cause a rare monogenic juvenile HT syndrome (apparent 
mineralocorticoid excess or AME) [208]. Altered expression of this gene is expected in our study, as 
variants of the HSD11B2 gene contribute to enhanced salt-induced BP response in humans and the 
kidney is a key organ regulating salt balance. 
 
5.4.2  Correlation of BP-associated kidney genes and BP GWAS 
We used kidney expression data to compare against known BP-associated genes from the most recent 
and comprehensive HTN GWAS [20]. We found an overlap for two differentially expressed kidney 
genes and the BP-associated GWAS genes in blood (Table 5.5). Of particular interest is the 
differentially expressed renal gene DPF3, which overlaps BP-associated GWAS in peripheral blood 
and HSD11B2 which is known causative agent of a monogenic form of HTN [202]. DPF3, is located 
on chromosome 14 and is a transcription regulator that binds acetylated histones and is a component 
of the BAF chromatin remodelling complex. In humans, DPF3 is significantly upregulated in the 
hypertrophic hearts of individuals with aortic stenosis and cardiomyopathy [201]. HSD11B2 catalyses 
the glucocorticoid cortisol to the inactive metabolite cortisone in aldosterone-selective epithelial 
tissues, such as the kidney [202]. Mutations to this gene cause apparent mineralocorticoid excess 
syndrome and is recognised as a monogenic cause of HTN as discussed above. “There are possible 
limitations to this analysis, where the cause of so few overlapping loci may be due to tissue specific 
genetic expression between blood and kidney. Furthermore, the volume of samples sequenced is 
significantly less in the TRANSLATE cohort, and may be a hinderance to statistical power. However, 
given the unique nature of the human renal samples it is encouraging to see some overlap in a limited 
sample size. 
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5.4.3 The role of DNA methylation in hypertension-associated renal gene 
expression  
To identify gene transcription that functionally mediates the relationship between methylation of 
cytosine residues and BP we examined whether differences in CpG methylation of kidney DNA in 
proximity to HTN-associated genes correlate with their renal expression. Methylation of two genes 
(FAM50B, PC) showed an association with its renal expression, demonstrating an association between 
hyper/hypo methylation upstream of two of the HTN-associated renal genes and its expression in the 
kidney. Interestingly, FAM50B, which plays a role in the circadian clock, is adjacent to a differentially 
methylated region (DMR). Methylation levels of FAM50B is similar in multiple tissues and is 
unmethylated in sperm, suggesting that it is likely to be a primary maternal DMR [209]. Further, 
methylation in CpG sites located in FAM50B are positively associated with telomere length [210] and 
has been recognised as belonging to a set of 353 ‘age-predictor’ CpGs [211]. As a known risk factor 
for HTN, it is reassuring to see an epigenetic signature of chronological age. PC, among other 
functions, is involved in the synthesis of the neurotransmitter glutamate, a well-established 
endogenously produced excitatory agonist [212]. With respect to cardiovascular control, glutamate has 
been known to have an effect on BP since 1954, with intravenous glutamate inducing a pressor response 
in dogs and rabbits [213-215]. It is likely that the overexpression of PC seen in our study is contributing 
to upregulation of glutamate activity and thereby an increase in BP. The association between 
methylation and gene expression in the kidney is similar to findings conducted in peripheral blood 
leukocytes, where a functional and causal relationship connecting methylation and expression at 
TSPAN2  was identified, and TSPAN2 was recognised as a modulator of BP  [103].  
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5.4.4 Reverse analysis of BP-associated methylated renal CpG sites and 
known GWAS BP loci 
We investigated the role of DNA methylation in known GWAS BP loci and to identify the cross-tissue 
applicability of blood and kidney GWAS studies we conducted a reverse analysis of genes that are 
known to influence BP (GWAS) in blood, with differentially methylated CpG sites in the human kidney 
We used data obtained from the kidney methylation array together with the most comprehensive BP 
loci GWAS conducted using the blood of over one million individuals [20].  We identified 30 
differentially methylated kidney CpGs that are associated with known BP-associated genes in blood 
based GWAS [20]. Of the two loci associated with SBP, KIAA1755 has been identified as an 
independent low-frequency non-synonymous variant in heart rate regulation [216]. The other, CMIP, 
is associated with high-density lipoprotein cholesterol levels in individuals of European ancestry [217].  
 
Of the 28 loci associated with DBP, many have been previously implicated in HTN and BP in recent 
studies. RSPO3 is associated with the regulation of genes involved in Wnt signalling. Wnt signalling 
pathways and genetic variation to its signalling peptides have recently been associated with metabolic 
syndrome, HTN and diabetes [218]. WNT3 is also differentially methylated in the HT kidney. Studies 
investigating down-regulation of Wnt3 report impaired nitric oxide production [219] and on the other 
side of the coin SHRs treated with Wnt3a displayed a depressor response [219].  
 
Similarly, Notch signalling plays a fundamental role in vascular development [220]. This pathway is 
activated by cell surface receptors that respond to cell attached ligands. Among these is Jagged-1 
(JAG1), a protein that allows cells to signal each other. The JAG1 gene responsible for the production 
of this protein is differentially methylated in the HT renal genome.  Pathway analysis revealed that 
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HDAC4, a gene encoding a histone deacetylase previously recognised as overexpressed in the SHR 
[221], is tightly linked with the activity from JAG1. It is possible that the proinflammatory effect of 
HDAC4 is further exacerbating JAG1 dysregulation in HTN vascular development.  
 
The correlation between vascular calcification and HTN is well established in human studies [222]. 
There are rare genetic disorders that lead to exaggerated or early onset vascular calcification [223]; 
among the research in the area is identification of mutations to the SLC20A2 gene, which encodes the 
type III sodium-dependent phosphate transporter 2. Dysfunction of this gene leads to impaired 
phosphate transport and as a consequence altered phosphate homeostasis. This results in vascular and 
pericapillary calcification of the basal ganglia [224]. SLC20A2 is among the gene loci differentially 
methylated in the HTN kidney; research linking basal ganglia calcification and renal dysfunction is 
scarce, however studies of hemodialysis patients [225] and those with end-stage diabetic renal failure 
[226-228] highlight the relationship between impaired function of renal SLC20A2 and vascular 
calcification. Our findings suggest a relationship between differential methylation of SLC20A2 and 
HTN possibly via disruptions to phosphate transport mechanisms.  
 
5.4.5 Differentially methylated and expressed renal genes that are 
identified in blood-based HTN GWAS  
In humans, DPF3 is significantly upregulated in the hypertrophic hearts of individuals with aortic 
stenosis and cardiomyopathy [201]. DPF3 is particularly noteworthy as it is both differentially 
methylated and expressed in the kidney and overlaps with blood-based BP GWAS [20] indicating that 
the methylation status of DPF3 may be inherited.  
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5.4.5  Effects of coexistant cancer on the renal transcriptome 
The potential effect of coexistent cancer on the transcriptome of the TRANSLATE “healthy” renal 
tissue was comprehensively discussed by Marques et al [120], where the global expression profiles of 
three different cohorts was compared. The three groups contained either healthy tissue from 
nephrectomy due to cancer, noncancerous kidney tissue, or clear cell renal carcinoma tissue. These 
sections were analysed using hierarchical clustering analysis and RNA-sequencing. Results from this 
study showed tight clustering of global expression patterns between healthy tissue from nephrectomy 
and subjects who did not have cancer. Highlighting that it was unlikely that the transcriptome program 
in cells within neoplastically unaffected apparently healthy renal tissue were largely influenced by the 
presence of cancer in other parts of the kidney [120].  
 
5.5   Conclusion and future direction 
Our findings identify DNA methylation as a key driver of HTN-associated (causative or as a 
consequence of) transcriptional change in the human kidney. Further we report strong connections 
between HTN-associated gene expression in the kidney and findings from large scale GWAS 
previously conducted in peripheral blood.  It has been demonstrated in Chapter 5 that DNA methylation 
and renal gene expression are tightly linked in the regulation of pathways that modulate vascular 
function, cellular communication, inflammation and sodium regulation.  In particular we have 
identified a close relationship between renal DNA methylation and expression of FAM50B and PC and 
report a strong connection with this relationship to chronic BP elevation. Our findings suggest that 
further research on the connection between DNA methylation and expression of BP-associated loci is 
likely to yield additional insights into the complexity of HTN pathobiology.   
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Chapter 6.  Discussion 
 
 
 
 
 
 
“The wise person reads both books and life itself” 
~ Lin Yutang 
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Chapter 6.   Discussion  
6.1  Overview 
EH is a disease of alteration to the regulation of mechanisms that control arterial pressure. These 
include neural (primarily, adrenergic function) and catecholamine factors; the renopressor system 
(RAAS); renal excretory function including the propensity to maintain normal balance of sodium water 
and additional electrolytes; and other factors controlling hormonal, electrolytic and fluid balance [229]. 
In addition, other physiologic systems reduce arterial pressure, including histamine, kallikrein-kinin 
and prostaglandin systems [229]. Of these, the human kidney is recognised as a key organ of BP 
regulation and one of the largest contributors to the development of EH. GWAS have traditionally 
focused on DNA modulation and expression of genes that regulate BP and ultimately lead to 
hypertension, in peripheral blood samples [20, 30, 103]. Therefore, there is interest in defining the 
epigenetic and genetic mechanisms that regulate BP and drive further dysregulation in the human 
kidney. The role of epigenetics in EH has gained considerable attention as one of the factors bridging 
the gap between inherited and lifestyle risk factors, however this hypothesis has never been formally 
tested in renal tissue. Moreover the role of renal DNA methylation in gene expression remains largely 
unstudied and poorly understood.  
In this Thesis, 3 major questions have been asked and addressed: 
1. What is the role of global kidney DNA methylation in EH and is there a correlation between 
kidney and blood global DNA methylation percentage? 
2. Does renal loci specific, genome-wide DNA methylation have a role in EH diagnosis as well 
as elevated BP? 
3. What is the relationship between renal DNA methylation and renal gene expression in EH? 
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The major findings of this Thesis are: 
1. Global methylation in the kidney and in peripheral blood leukocytes does not have an 
association to EH diagnosis, but kidney global methylation does have an association with 
DBP (Chapter 3). 
2. Global methylation findings between peripheral blood findings and kidney DNA are not 
correlated (Figure 3.7, 3.8).  
3. Loci specific DNA methylation is an essential mechanism involved in the development of EH 
(Chapter 4).  
I. Several arterial pressure modulating pathways contain differentially methylated CpGs, 
such as: circadian clock; neural development; transport of monocarboxylates; peptidase 
activity; insulin signalling; transcriptional regulation; cell cycle progression; 
metabolism and RNA processing (Table 4.4, 4.5).  
II. Differentially methylated CpG islands are also found in pathways that modulate BP 
such as: MAPK leading to cellular differentiation, and possible regulation of eGFR; cell 
volume regulation, salt transport and peripheral nervous system function; circadian 
clock (Table 4.6, 4.7).  
III. Differentially methylated CpG sites identified in renal DNA replicate the findings of 
blood based genome-wide methylation studies. These include roles such as: oxidation 
of 5mC to 5hmC; members of cell cycle progression, which are also implicated in the 
SHR model; genes previously implicated in dilated cardiomyopathy; regulators of 
histone acetylation (Table 4.8).  
4. Expression of 21 renal genes (19 novel) are associated with EH and BP and there is a significant 
overlap between kidney RNA-seq findings and blood-based GWAS (Chapter 5).  
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I. Differential expression of HT renal genes involves loci that are associated with smooth 
muscle cell function; glucocorticoid conversion; salt balance (Table 5.3, 5.4, Figure 
5.1, 5.2, 5.3).  
II. Differentially expressed loci in the kidney replicate the findings of blood-based GWAS. 
These include roles such as: transcription regulation; cardiac hypertrophy; 
glucocorticoid conversion; salt balance (Table 5.5). 
5. DNA methylation is a primary epigenetic driver of HTN-associated renal gene expression 
(Chapter 5). 
I. Methylation of two genes, which regulate circadian clock and neurotransmitter uptake, 
is associated with its over/ underexpression. Where hypermethylation causes 
underexpression and hypomethylation caused overexpression. 
II. A reverse analysis of renal CpG sites and loci previously identified blood-based BP 
GWAS revealed methylation pattern similarities between the two tissues types. These 
include roles such as: heart rate regulation; cholesterol production; Wnt signalling; 
Notch pathway vascular development; inflammation; phosphate transport mechanisms.  
III. Analysis of  DPF3 in BP GWAS GWAS [20] indicates that the methylation status of 
DPF3 may be inherited.  
This PhD Thesis provides new insight in to the role of DNA methylation on the development of HTN 
and modulation of BP. This Thesis identifies novel relationships between DNA methylation and 
transcription in the human kidney that influence genes implicated in HTN; suggesting a significant role 
for renal epigenetic modification in the altered function of various genes that regulate atrial pressure. 
In addition, this Thesis uncovers previously unidentified kidney expressed genes that contribute to, and 
that are affected by, HTN. Collectively, this Thesis supports the hypothesis that HTN development and 
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BP regulation are governed by renal gene expression changes influenced by renal DNA methylation. 
The following sections will discuss the importance of these findings and their broad implications for 
our understanding of the role of the kidney in HTN pathophysiology.  
 
6.2 Global methylation and essential hypertension – 
relationships and limitations 
The research outcomes from this PhD Thesis demonstrate that global methylation in the kidney and in 
peripheral blood leukocytes are not associated with HTN diagnosis. However, it was identified that 
kidney global methylation has an association with DBP but this relationship was not conserved after 
the values were adjusted for the use of antihypertensive medication. Furthermore, for global 
methylation kidney and blood 5mC percentage is not correlated, which is indicative that blood may not 
be a good surrogate for global methylation studies of non-blood-based diseases. 
 
Many studies debate the reliability of global methylation measurement techniques. High performance 
liquid chromatography – ultraviolet (HPLC-UV) is considered the “gold-standard” assay for 
quantifying the amount of 5mC present in a hydrolysed DNA sample. However this method is limited 
by the utilisation of specialized equipment required to conduct the analyses and requirement of large 
quantities of DNA (~10µL) [230]  Liquid chromatography coupled with mass spectrometry (LC-
MS/MS) is highly sensitive and offers an alternative to HPLC-UV and requires smaller hydrolysed 
DNA quantities (50-100ng) [230]. LC-MS/MS is designed to detect levels of methylation ranging from 
0.05% to 10% and has been validated to detect differences corresponding to ~5% in global methylation 
percentage [230]. However, expertise and equipment required for LC-MS/MS is not common and for 
this reason, it is not a routine method used for global methylation analysis. The third alternative for 
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global methylation detection is the enzyme-linked immunosorbent assay (ELISA) method (used in this 
PhD). There are several commercially available ELISA kits which enable fast and simple detection of 
5mC. The major limitation of ELISA based detection is the likelihood of inter and intra-assay 
variability, and therefore can only provide estimates of DNA methylation. Furthermore, due to 
variability ELISA detection can only visualise large changes in DNA methylation (~1.5-2 fold). The 
Zymo 5mC assay is unable to discriminate between 5mc and 5hmC detection. This is of significant 
consequence as functionally, the production of 5hmC seems to promote gene expression during active 
demethylation [157]. 
 
6.3 Pathways affected by CpG methylation and differential 
expression in the hypertensive kidney 
There are several biological mechanisms that ensure BP is tightly regulated.  These include the 
autonomic nervous system, the vasculature itself, and the kidney. This PhD Thesis highlights 
differential DNA methylation and gene expression in key loci that correspond to each of these key 
biological regulators of BP.  
 
6.3.1  Pathways involved with hypertension-associated differential CpG loci 
methylation 
6.3.1.1  Renal methylation and the autonomic nervous system control of BP 
The neural control of BP operates via parasympathetic neurons that innervate the heart and three main 
classes of sympathetic efferent neurons (baroreceptive, thermosensitive and glucosensitive 
cardiovascular) which innervate blood vessels in the heart, kidneys and the adrenal medulla. 
Methylation of renal SLC17A7 was revealed via pathway analysis to have a major role in the Glutamate 
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Neurotransmitter Release Cycle. In the kidney glutamate contributes to ammonia secretion and 
regulation of acid-base balance [231]. Glutamate is also the principal excitatory neurotransmitter in the 
brain [231]. Excessive activation of glutamate receptors in the CNS induce an excitotoxicity response, 
which is associated with various forms of neurodegeneration [232]. Conversely hypo-activity of 
glutamate receptors is associated with sever cognitive disturbance, including schizophrenia [233]. A 
study by Westhoff et al [234] report a robust correlation between mean atrial pressure and glutamate 
concentration, here we report that methylation in SLC17A7  provides a potential link between BP and 
neurotransmitter status.  
 
The secretogranin family of proteins, such as the one expressed by secretogranin II (SCG2) has  a major 
role in the biology of catecholaminergic systems, such as autonomic neurons and their physiologic 
targets [235, 236]. Proteolytic cleavage of granins generates an array of bioactive peptides which, in 
aggregate, have physiological effects on cardiovascular, metabolic and endocrine systems via 
modulation of the sympathetic nervous system [235]. Studies indicate that granins have a role in the 
pathogenesis of HTN via autonomic control of BP. In particular, SCG2 derived secretoneurin peptide 
stimulates migration and proliferation of vascular smooth muscle cells [237], providing a direct link to 
vascular development and remodeling. Renal methylation of SCG2 is associated with DBP, implicating 
DNA methylation in SCG2 mediated vascular function. SNP analyses conducted by Wen et al [236] 
displayed significant association of SCG2 –associated SNPs with elevated BP and HTN diagnosis. 
DNA methylation induced variation to SCG2 expression alter the angiogenic and vasculogenic activites 
of secretonurin and may influence susceptibility to HTN via actions of the cardiovascular system. 
Similar to the actions of insulin and angiotensin II, secretoneurin activates phosphatidylinositol/ Akt 
pathways [238], which regulates BP via nitric oxide production [239].  
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6.3.1.2  Renal methylation and vasculature control of BP  
The endothelium is an integral component of the vascular wall and is a major regulator of BP [3], acting 
as a door that either blocks or allows access to the inflamed organ. CD95 (FAS/ apoptosis antigen 1) 
belongs to the tumor necrosis factor receptor superfamily [240]. Recent data reveals that CD95 
promotes anti-apoptotic signals, promotes inflammation and contributes to carcinogenesis [240]. CD95 
is overexpressed at the surface of endothelial cells covering blood vessels of patients affected by 
inflammatory disorders [240] and can simulate production of nitric oxide thereby controlling BP [241]. 
DCP2 is a component of mRNA decay machinery acting as an mRNA decapping enzyme. Renal 
differential methylation of DCP2 is identified in pathway analysis to be implicated in expression of 
CD95-associated endothelial dysfunction, offering a complex biological role for DCP2 in the context 
of endothelial survival and function. It is likely that methylation of DCP2 is operating via interactions 
with tristetraprolin, which can induce reduced nitric oxide-mediated vasorelaxation [242]. 
 
6.3.1.3  Renal methylation and kidney-based mechanisms of BP control 
The transaldolase enzyme is involved in the reversible section of the pentose phosphate pathway. 
Transaldolase deficiency (OMIM 606003), like HTN, is a multisystem disorder, characterised by 
abnormal polyol concentrations in body fluids, hepatosplenomegaly, hepatic fibrosis, coagulopathy, 
thrombocytopenia and dysmorphic features [243]. Differential methylation of the TALDO1 gene, 
which codes for transaldolase, is associated with DBP in the human kidney. A study by Loeffen et al 
[243] found that transaldolase deficiency was linked to renal low molecular weight, proteinuria and 
hypercalciuria. In addition renal tubular dysfunction was present and chronic renal failure had 
developed in aging patients [243]. It is therefore likely that differential methylation in TALDO1 is 
influencing renal function directly.  
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The RAAS is a key player of BP control and regulation of electrolyte and body fluid homeostasis [244]. 
It has been demonstrated that the JAK-STAT pathway mediates angiotensin II-triggered gene 
transcription, in turn acting as an amplifying system that contributes to further intrarenal RAAS 
activation [244]. There is mounting evidence that JAK is implicated in the development of RAAS-
associated diseases and, in consequence, JAK is now acknowledge as a key target for clinical and 
biochemical studies associated with the RAAS system. Additionally, the interactions between JAK and 
angiotensin II are important in the context of HTN. The RAAS and inflammatory cytokines synergise 
to raise BP [245], with angiotensin II systemically and locally increasing levels of interleukin 6 and 
interferon γ [245]; leading to activation of the JAK-signal transducers and activators of transcription 
(STAT) pathway. The activated JAK-STAT pathway is a potent stimulus to protein expression of 
angiotensinogen [244]. Pathway analysis reveals that differential methylation of TALDO1 is associated 
with JAK-STAT signalling after interleukin 12, potentially contributing to the local synthesis of 
angiotensin II and the progression of HTN.  
 
VDR is differentially methylated in the kidney and the main activity of vitamin D is mediated by the 
vitamin D receptor (VDR). Inadequate vitamin D status is linked to many non-skeletal chronic diseases 
including CVD and HTN. Vitamin D can downregulate RAAS, and cellular treatment with active 
vitamin D has been demonstrated to directly reduce promotor activity on the renin gene [246]. 
Futhermore, in the VDR knockout mouse, renin expression and plasma angiotensin II concentration 
are dramatically increased and result in increased BP [246]. In human studies, individuals with 
insufficient vitamin D have higher plasma concentration of renin [247], angiotensin II [247, 248] and 
renal plasma flow response to infused angiotensin II was blunted [248].  The mechanisms by which 
vitamin D influences renin gene transcription were found by Yuan et al [249], who identified that 
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calcitriol is not involved in the vitamin D response element pathway but rather bind to the cyclic 
adenosine monophosphate (c-AMP)  response element. c-AMP is a primary intracellular signal in renin 
expression, in this manner, the c-AMP response element in the promotor region of renin is bound to 
CREB and triggers gene transcription [249].  
 
6.3.2  Pathways involved in differential gene expression in the hypertensive 
kidney 
6.3.2.1  Renal gene expression and vasculature control of BP 
Redox signalling is implicated in the pathogenesis and progression of HTN via different physiological 
and pathological processes in the vasculature. Dysregulation of vasomotor function and structural 
remodelling of blood vessels contribute to HTN as high BP is partially determined by peripheral 
vascular resistance [250].  In this Thesis differential expression of TXNRD1 is associated with HTN. 
TXNRD1 codes for a protein called Thioredoxin Reductase 1, which pays a key role in redox 
homeostasis [250]. Reactive oxygen species increase vascular tone by influencing the regulatory role 
of the endothelium and directly effecting the contractility of vascular smooth muscle cells [250]. It is 
likely that altered expression of TXNRD1 is contributing to HTN status via aberrant redox signalling 
pathways leading to excessive production of reactive oxygen species, and thereby altered vascular 
function.  
 
Phosphoinositides are acidic phospholipids of cell membranes which are found primarily in the 
cytoplasmic leaflet and serve as membrane recognition sites as well as act as membrane delimited 
second messengers modulating the activities of some membrane proteins [251]. Renal differential 
expression of PIP4K2A was recognised in the kidney to be involved in receptor tyrosine kinase 
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signalling. Receptor tyrosine kinases contribute to vascular remodelling via close interaction with many 
downstream targets, where over activation of receptor tyrosine kinases is responsible for several 
pathological conditions including CVD [252]. Receptor tyrosine kinases are key players in vascular 
biology, and are activated by ligand-dependent and independent mechanisms such as trans-activation 
of G protein coupled receptors, mineralocorticoid receptors and reactive oxygen species.  
 
6.3.2.2  Renal gene expression and kidney-based mechanisms of BP control 
The renal HSD11B2 gene encodes the beta-hydroxysteroid dehydrogenase type 2 enzyme, which 
inactivates 11- hydroxysteroid in the kidney. This activity protects the nonselective mineralocorticoid 
receptor from occupying glucocorticoids. It is via this mechanism that loss of function to the HSD11B2 
gene results in overstimulation of the mineralocorticoid receptor to cause salt-sensitive HTN [253]. 
Differential expression of HSD11B2 is identified in this thesis and associated with DBP. This is 
consistent with essential HTN studies by Williams et al [253] and monogenic studies of HSD11B2 
[254]. 
 
Mitochondria are the primary cellular energy producers, and are present in abundance, in the heart, 
kidney and brain. As well as their role in the maintenance of cellular respiration, these membrane bound 
organelles also modulate functions of cellular proliferation, apoptosis, generation of reactive oxygen 
species and cellular calcium homeostasis [255]. Therefore, any damage to the structure or function of 
the mitochondria will compromise the overall function of the cell. Futhermore, mitochondrial 
abnormalities and dysfunction have been identified in experimental models of HTN [255]. One of the 
renal genes responsible for mitochondrial cristae formation is C19orf70, which was differentially 
expressed in the HT population. This is in line with several studies of experimental HTN which report 
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renal mitochondrial injury [256-258]. Here we demonstrate that altered expression of C19orf70 is a 
key signature of mitochondrial function in the HT kidney.  
 
6.4 DNA methylation is associated with altered expression of 
renal genes  
6.4.1 Alterations in renal DNA methylation increase expression of 
Pyruvate Carboxylase (PC)  
Disruption to pyruvate metabolism may arrive from mutations to many of the genes coding for enzymes 
that regulate it [259]. PC encodes pyruvate carboxylase which uses carbon dioxide and adenosine 
triphosphate to produce oxaloacetate and adenosine diphosphate [260]. The result of disruptions to this 
process are highly variable but may include lactic acidosis, developmental delay and elevate proline 
and alanine [260]. The oxaloacetate produced by PC is a critical intermediate in metabolism, which 
links carbohydrate metabolism, lipid, amino acid and nucleotide metabolism [261]. Pyruvate utility 
also includes provision of carbon to several major biosynthetic pathways that intersect the citric acid 
cycle. Together oxaloacetate and citrate support the major biosynthetic pathways of gluconeogenesis 
and lipogenesis [259]. Expression of PC is ubiquitous in the human body, with higher expression in 
the liver, kidney adipose and heart [259]. The brain is reliant upon glucose and pyruvate metabolism 
to generate cellular energy. Therefore, perturbations to glucose and pyruvate metabolism have striking 
neurological consequences [259]. Here we report disruptions to the expression of PC in the renal 
transcriptome are associated with HTN. This finding is supported by previous works by demonstrating 
that  disruptions to the citric acid cycle has been implicated in resistance forms of HTN, where 
increased levels of oxaloacetate was associated with resistant HTN cases [262]. Furthermore, PC, 
among other functions, is involved in the synthesis of the neurotransmitter glutamate, a well-
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established endogenously produced excitatory agonist [212]. With respect to cardiovascular control, 
glutamate has been known to have an effect on BP since 1954, with intravenous glutamate inducing a 
pressor response in dogs and rabbits [213-215]. It is likely that the overexpression of PC seen in our 
study is contributing to upregulation of glutamate activity and thereby an increase in BP. 
 
6.4.2 Alterations in renal DNA methylation decrease expression of Family 
With Sequence Similarity 50 Member B (FAM50B)  
Current management strategies for HTN gives small consideration to the biological rhythms inherit to 
the disease process. However, studies indicate that the absence of nocturnal BP “dipping” and an 
increased morning surge of BP increases is associated with overall CVD risk [263]. A study by Cuspidi 
et al [264] demonstrated that chronic absence of nocturnal BP dipping is associated with increased left 
ventricular mass, a thicker interventricular septum and increased diameter of the left atrium. There is 
also growing evidence linking the early morning rise in BP to cardiovascular risk [265]. FAM50B is a 
key regulatory gene of the circadian clock, which may have corresponding implications for the RAAS. 
RAAS displays peak plasma concentrations of renin activity, ACE and aldosterone just before morning 
wake times [266]. It is likely that altered RAAS activation is an end product of the circadian variations 
under regulation by FAM50B.  Interestingly FAM50B, is adjacent to a differentially methylated region 
(DMR). Methylation levels of FAM50B is similar in multiple tissues and is unmethylated in sperm, 
suggesting that it is likely to be a primary maternal DMR [209]. Further, methylation in CpG sites 
located in FAM50B are positively associated with telomere length [210] and has been recognised as 
belonging to a set of 353 ‘age-predictor’ CpGs [211]. As a known risk factor for HTN, it is not 
surprising to see an epigenetic signature of chronological age.  
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6.5 Double PHD finger (DPF3) is a candidate of methylation 
inheritance 
Analysis of  DPF3 in our renal methylation and expression findings coupled with data from BP GWAS 
[20] indicates that the methylation status of DPF3 may be inherited. In humans, DPF3 is significantly 
upregulated in the hypertrophic hearts of individuals with aortic stenosis and cardiomyopathy [201]. 
During development Dpf3 is expressed in the heart and somites of mice, chicken and zebrafish [267], 
where knockdown studies in zebrafish resulted in reduced cardiac contractibility. DPF3 is associated 
with the BAF chromatin remodeling complex and binds methylated and acetylated lysine residues of 
histone 3 and 4 [267]. Our analysis of DPF3 adds a complex layer to the BAF complex and indicates 
that DPF3 has a role to play in the recruitment of chromatin remodelling complexed to acetylated 
histones.  
 
6.6  Summary and future directions 
The kidney has a key regulatory role during the onset of HTN and periods of sustained elevated BP. 
Futhermore, epigenetic modification to the kidney in the form of DNA methylation is a complex and 
interactive link to expression of genes that modulate BP. Lessons from previous methylation studies 
suggest a role for DNA methylation in the multisystem and polygenic nature of HTN. Locus specific 
targeting of the epigenome is critical to enhance our understanding of modifiers such as DNA 
methylation on BP; however, for effective analysis a deeper understanding the interaction between 
HTN-associated systems is required. In addition, a more comprehensive understanding of the 
relationship between the renal epigenome and transcription changes during HTN onset is necessary 
and could shape the future of therapeutic advancement. Some of the renal genes mentioned in this 
thesis, where the RNA or protein products are clinically measurable (DPF3 and FAM50B) may become 
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attractive targets for the development of new diagnostics, for example to detect early renal signatures 
of HTN onset. Further studies on the altered expression of these genes in context to HTN onset and 
severity would be beneficial, particularly in a larger cohort with blood and renal samples available with 
the possibility of extending investigations onto sorted cell subsets. Indeed, pharmacological and 
lifestyle therapies informed by genomics are already available for patients with HTN. However, due to 
the multifaceted nature of the disease and the development of resistant forms of HTN, more targeted 
interventions are needed. Further omics-based investigation of the kidney could help facilitate the 
advancement of the current treatment strategies for HTN, from management of its modifiable risk 
factors into individualised preventative protection strategies. 
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